0001558370-24-01157910-Q GLYCOMIMETICS INC 20240808202408081600351600351600351

focused on improving the lives of people living with cancer and inflammatory diseases by leveraging the inhibition of carbohydrate interactions that occur on the surface of cells. The Company has been developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. As a result, the Company intends to conduct a strategic review of its business, in an effort to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan and the Companyâ€™s GMI-1687 to ensure their continued advancement. In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately 80%. â€‹2. Going Concernâ€‹The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2023, the Company incurred a net loss of $36.9 million and had net cash flows used in operating activities of $34.9 million. The Company incurred a net loss of $20.8 million and had net cash flows used in operating activities of $19.4 million during the six months ended June 30, 2024. At June 30, 2024, the Company had $22.4 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings, although the Company may, at its discretion, sell equity securities under the terms of its existing at-the-market sales agreement (see Note 7), subject to certain conditions and limitations. Management believes that given the Companyâ€™s current cash position and forecasted negative cash flows from operating activities over the next twelve months, despite the adoption of a streamlined operating plan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these unaudited financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement. The Company expects that its current cash resources will only be sufficient to fund the Companyâ€™s operations into the second quarter of 2025.The Companyâ€™s ability to fund its operations is dependent upon managementâ€™s plans, which include reducing operating expenses and potentially entering into collaborations, strategic alliances and marketing, distribution or licensing arrangements in order to raise additional capital. There can be no assurances that any strategic transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital or enter into a strategic transaction, the Company will need to eliminate some or all of its operations and may seek to liquidate.The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.â€‹3. Significant Accounting Policiesâ€‹There have been no material changes to the significant accounting policies previously disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the SEC) on March 27, 2024 (the Form 10-K).â€‹7 Table of ContentsBasis of Accounting â€‹The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). â€‹Unaudited Financial Statements â€‹The accompanying balance sheet as of June 30, 2024, statements of operations and comprehensive loss and stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Companyâ€™s financial position as of June 30, 2024 and its results of operations and changes in its stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. â€‹Use of Estimatesâ€‹The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. â€‹â€‹Fair Value Measurements â€‹The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of June 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $18.8 million and $38.8 million as of June 30, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company didÂ not transfer any assets measured at fair value on a recurring basis between levels during theÂ three and six months ended June 30, 2024 and 2023.â€‹Concentration of Credit Risk â€‹Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. â€‹Revenue Recognition â€‹The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers (Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, 8 Table of Contentssuch as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidatesâ€™ rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Companyâ€™s license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.Licensing of Intellectual Property: If the license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.Manufacturing and Supply:Â The obligations under the Companyâ€™s agreements may include clinical and/or commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The 9 Table of ContentsCompany recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.â€‹Accruals for Clinical Trial Expenses â€‹â€‹Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses have historically been a significant component of research and development expenses, and the Company previously outsourced a significant portion of its clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, estimated project duration and other pass-through costs. As a result of the Company ceasing its clinical activities, the costs of closing down clinical sites are also included in the accruals. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)Â the Companyâ€™s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Companyâ€™s historical clinical accrual estimates have not been materially different from the actual costs. â€‹Stock-Based Compensation â€‹Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensationâ€”Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company accounts for forfeitures as they occur.â€‹The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. â€‹A discussion of managementâ€™s methodology for developing some of the assumptions used in the valuation model follows: â€‹Expected Dividend Yieldâ€”The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. â€‹Expected Volatilityâ€”Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Companyâ€™s publicly traded common stock. â€‹Risk-Free Interest Rateâ€”This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. â€‹Expected Termâ€”This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. â€‹10 Table of ContentsNet Loss Per Common Share â€‹Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Companyâ€™s stock options and restricted stock units (RSUs).â€‹The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive:

â€‹â€‹Six Months Ended JuneÂ 30,Â	â€‹2024Â	â€‹2023Â
Stock options and RSUs	16,047,875Â	11,469,764Â

â€‹Comprehensive LossComprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Companyâ€™s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. â€‹Recently Issued Accounting Standards â€‹Accounting Standards Not Yet AdoptedThere have been no new accounting pronouncements that have significance, or potential significance, to the Companyâ€™s unaudited financial statements as of and for the six months ended June 30, 2024.â€‹4. Prepaid Expenses and Other Current Assetsâ€‹The following is a summary of the Companyâ€™s prepaid expenses and other current assets:

â€‹â€‹JuneÂ 30,Â	â€‹DecemberÂ 31,Â
Prepaid research and development expensesâ€‹	$ 805,610â€‹
Other prepaid expensesâ€‹	589,133â€‹
Other receivablesâ€‹	76,710â€‹
Prepaid expenses and other current assetsâ€‹	$ 1,471,453â€‹

2024Â	2023Â
$ 1,420,642â€‹	401,442â€‹
175,820â€‹	$ 1,997,904â€‹

â€‹5. Accrued Expensesâ€‹The following is a summary of the Companyâ€™s accrued expenses: â€‹â€‹JuneÂ 30,Â â€‹December 31,â€‹â€‹2024â€‹2023Accrued research and development expensesâ€‹ $ 1,916,629â€‹ $ 1,824,689Accrued bonusesâ€‹ â€”â€‹ 2,561,913Accrued consulting and other professional feesâ€‹ 441,652â€‹ 439,192Accrued employee benefitsâ€‹ 545,549â€‹ 399,763Other accrued expensesâ€‹ 52,948â€‹ â€”Accrued expensesâ€‹ $ 2,956,778â€‹ $ 5,225,557â€‹â€‹11 Table of Contents6. Operating LeasesAt the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one single component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives

received.â€‹The Company leases office and research space in Rockville, Maryland under an operating lease that is subject to annual rent increases (the Lease). The Company paid a security deposit of $52,320 to be held until the expiration or termination of the Companyâ€™s obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately 30,000 square feet, would be extended from November 1, 2023 to January 31, 2025. The Companyâ€™s lease of the remaining premises, consisting of approximately 12,000 square feet, expired on October 31, 2023. There were no additional operating leases entered into during the six months ended June 30, 2024.â€‹The components of lease expense and related cash flows were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended JuneÂ 30,Â â€‹Six Months Ended JuneÂ 30,Â â€‹ â€‹2024Â Â Â 2023Â Â Â 2024Â Â Â 2023â€‹Operating lease cost $ 188,310â€‹$ 247,359â€‹$ 376,620â€‹$ 479,349â€‹Variable lease costâ€‹ 138,819â€‹â€‹ 133,022â€‹â€‹ 238,706â€‹â€‹ 316,296â€‹Total operating lease cost$ 327,129â€‹$ 380,381â€‹$ 615,326â€‹$ 795,645â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash paid for amounts included in the measurement of lease liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating cash outflows for operating leases$ 196,314â€‹$ 280,518â€‹$ 392,628â€‹$ 560,210â€‹â€‹Maturities of lease liability due under these lease agreements as of June 30, 2024 were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating Leaseâ€‹Â Â Â Â ObligationJuly 1, 2024 - December 31, 2024â€‹$ 396,5552025â€‹â€‹ 67,401Thereafterâ€‹â€‹ â€”Totalâ€‹â€‹ 463,956Present value adjustmentâ€‹â€‹ (15,181)Present value of lease paymentsâ€‹$ 448,775â€‹12 Table of ContentsSupplemental information related to leases were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â â€‹DecemberÂ 31,Â Operating Leasesâ€‹2024â€‹2023 Weighted-average remaining lease term (in years)â€‹ â€‹0.6â€‹ â€‹1.1 Weighted-average incremental borrowing rateâ€‹â€‹10.0%â€‹â€‹10.0%â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹2024Â Â Â 2023Right-of-use assets obtained in exchange for operating lease obligations$ -â€‹$ 872,892â€‹â€‹â€‹â€‹7. Stockholdersâ€™ Equity â€‹Common Stockâ€‹During the three months ended June 30, 2024, the Companyâ€™s board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from 100,000,000 to 150,000,000 shares with a par value of $0.001 per share.â€‹At-The-Market Sales Facilityâ€‹In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the 2022 Sales Agreement) with Cowen and Company, LLC. Under the 2022 Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the six months ended June 30, 2023, the Company issued and sold 9,822,930 shares of common stock under the 2022 Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no shares issued under the 2022 Sales Agreement during the six months ended June 30, 2024. As of June 30, 2024, approximately $66.0 million remained available to be sold under the terms of the 2022 Sales Agreement.â€‹8. Stock-based Compensation â€‹2013 Equity Incentive Plan â€‹The Companyâ€™s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of SectionÂ 422 of the Internal Revenue Code (the Code) to the Companyâ€™s employees and its parent and subsidiary corporationsâ€™ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Companyâ€™s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.â€‹Authorized Shares â€‹The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000Â shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that 13 Table of Contentsmay be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000 shares. As of June 30, 2024, the total number of shares reserved for issuance under the 2013 Plan was 14,257,627 shares, of which 94,036 shares were available for future grants.â€‹Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. â€‹A summary of the Companyâ€™s stock option activity under the 2013 Plan for the six months ended June 30, 2024 is as follows: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

headcount reduction, which costs are expected to be substantially recognized in the third quarter of 2024, with related cash payments expected to be paid out by the end of 2024. These charges will consist primarily of one-time severance payments upon termination and continued benefits for a specified period of time.â€‹â€‹â€‹18 Table of Contents ITEMÂ 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSâ€‹Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of SectionÂ 27A of the Securities Act of 1933, as amended, and SectionÂ 21E of the Securities Exchange Act of 1934, as amended. The words or phrases â€œwould be,â€ â€œwill allow,â€ â€œintends to,â€ â€œwill likely result,â€ â€œare expected to,â€ â€œwill continue,â€ â€œis anticipated,â€ â€œestimate,â€ â€œproject,â€ or similar expressions, or the negative of such words or phrases, are intended to identify â€œforward-looking statements.â€ We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K, particularly in Part I â€” Item 1A, â€œRisk Factors,â€ and our other filings with the Securities and Exchange Commission. Statements made herein are as of the date of the filing of this Form 10-Q with the Securities and Exchange Commission and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. â€‹The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December 31, 2023, which are included in our Annual Report on Form 10-K filed with the SEC on March 27, 2024. â€‹OverviewWe are a late clinical-stage biotechnology company focused on improving the lives of people living with cancer and inflammatory diseases by leveraging the inhibition of carbohydrate interactions that occur on the surface of cells. We have been developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. We have focused our efforts on drug candidates for diseases that we believe will qualify for orphan drug designation.â€‹Our lead glycomimetic drug candidate, uproleselan, is a specific E-selectin antagonist that we are developing to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. In 2021, we completed enrollment of 388 patients across nine countries in a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory (R/R) AML, the design of which was based on guidance received from the FDA. â€‹On May 6, 2024, we reported topline results from the trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat (ITT) population versus chemotherapy alone. Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the trial. On June 4, 2024, we announced comprehensive results of the Phase 3 trial, which are summarized below.â€‹The trial evaluated uproleselan in combination with MEC (mitoxantrone, etoposide and cytarabine) or FAI (fludarabine, cytarabine and idarubicin) in patients with R/R AML. Patients received either uproleselan or placebo for 8 days over 1 cycle of induction and, if applicable, up to 3 cycles of consolidation. The primary endpoint was overall survival (OS), which was not censored for transplant. Secondary endpoints included incidence of severe oral mucositis, complete remission (CR) rate and CR with partial hematologic recovery (CRh). Patients were randomized 1:1 between treatment and placebo arms. There were 59 sites that enrolled at least one patient. Median follow up was over three years at the time of primary analysis.â€‹19 Table of ContentsOverall Survivalâ—Primary Endpoint: median overall survival (mOS) in the ITT population (n=388) was 13.0 months for the uproleselan arm, compared to 12.3 months for the placebo arm (hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.69-1.15); this difference was not statistically significant.â—Disease Statusâ—¾Primary Refractory:Â mOS for primary refractory patients in the uproleselan arm (n=62) was 31.2 months, compared to 10.1 months (HR 0.58; 95% CI 0.37-0.91) for the placebo arm (n=66). This benefit was irrespective of backbone chemotherapy.â—Median duration of response (DoR) for complete remission (CR) was not reached for primary refractory patients in the uproleselan arm compared to a median DoR of 12.7 months for the placebo arm.â—¾Early Relapse:Â mOS for early relapse patients in the uproleselan arm (n=28) was 3.7 months, compared to 6.4 months (HR 1.50; 95% CI 0.69-3.27) for the placebo arm (n=22).â—¾Late Relapse:Â mOS for late relapse patients in the uproleselan arm (n=104) was 15.4 months, compared to 18.2 months (HR 1.10; 95% CI 0.77-1.57) for the placebo arm (n=106).â—¾Backbone Chemotherapy:â—¾FAI:Â mOS for patients treated with uproleselan plus FAI (n=98) was 30.2 months compared to 12.8 months (HR 0.73; 95% CI 0.50-1.06) for patients treated with FAI alone (n=96) in the ITT population.â—¾MEC:Â mOS for patients treated with uproleselan plus MEC (n=96) was 8.7 months compared to 12.3 months (HR 1.06; 95% CI 0.75-1.51) for patients treated with MEC alone (n=98) in the ITT population.â—¾Transplantation Status:â—¾For patients who received hematopoietic stem cell transplantation (HSCT) after study treatment, mOS was not reached for patients in the uproleselan arm (n=101). In contrast, for HSCT patients in the placebo arm, mOS for patients receiving FAI (n=53) was 26.3 months and for patients receiving MEC (n=46) was 24.4 months.Secondary Endpointsâ€‹â—¾7.2% of patients in each arm (n=388) experienced induction emergent severe oral mucositis.â—¾36.1% of patients in the uproleselan arm (n=194) experienced CR at the end of induction (EOI) as determined by an independent endpoint review committee (IERC), compared to 33.5% of patients in the placebo arm (n=194).â—¾46.4% of patients in the uproleselan arm experienced CR/CRh at EOI as determined by IERC, compared to 41.2% of patients in the placebo arm.â—¾Post-treatment HSCT rate was 52.1% in the uproleselan arm and 51.0% in the placebo arm.â—¾Subsequent AML therapy in non-responders was 40.0% in the uproleselan arm (n=80) and 46.2% in the placebo arm (n=78).Safetyâ€‹â—¾Adverse events were consistent with the known safety profile for backbone chemotherapy regimens.â—¾35.9% of patients in the uproleselan arm experienced serious treatment-emergent adverse events (TEAEs) compared to 34.2% in the placebo arm.â—¾85.9% of patients in the uproleselan arm experienced grade 3 or higher TEAEs compared to 87.6% in the placebo arm.â€‹Following the announcement of the data from the Phase 3 trial, we requested and held a meeting with the FDA to discuss whether any of the results summarized above could serve as a basis for a submission for regulatory approval. Based on the feedback received, we have concluded that the regulatory path forward for uproleselan in this patient population would require an additional clinical trial, the conduct of which would require capital resources beyond those that are currently available to us. We are evaluating strategic alternatives to provide for the continued advancement of uproleselan.â€‹20 Table of ContentsWe have also entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, to conduct a Phase 2/3 randomized, controlled clinical trial testing the addition of uproleselan to a standard chemotherapy regimen. Enrollment of 267 patients in the Phase 2 portion was completed in December 2021. There will be a planned interim analysis that will evaluate event-free survival and whether the pre-specified threshold for continuing to Phase 3 has been met. The trial could provide support for regulatory filings, if the results of the planned interim analysis are sufficiently positive. Notwithstanding the results of our Phase 3 pivotal trial of uproleselan, the Phase 2/3 trial is ongoing with limited funding from us.â€‹In addition to uproleselan, we designed an innovative antagonist of E-selectin, GMI-1687, that could be a subcutaneously administered treatment. Initially developed as a potential life-cycle extension to uproleselan, we believe that GMI-1687 could be developed to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. In 2022, we filed an IND for GMI-1687 as a potential treatment for vaso-occlusive event (VOE), a common complication of sickle cell disease, and in December 2023, we completed enrollment of 40 subjects in a Phase 1a trial of GMI-1687 in healthy adult volunteers. As described below, we have entered into a collaboration with Apollomics for the development of GMI-1687, as well as uproleselan, in Greater China. We are not otherwise actively developing GMI-1687.â€‹We have financed our operations primarily through private placements of our securities, up-front and milestone payments under our license and collaboration agreements and the net proceeds from public offerings of common stock, including sales of common stock under at-the-market sales facilities with Cowen and Company LLC, or Cowen. We have no approved drugs currently available for sale, and substantially all of our revenue to date has been revenue from up-front and milestone payments under license and collaboration agreements.â€‹Since inception, we have incurred significant operating losses. We had an accumulated deficit of $478.3 million as of June 30, 2024 and continue to incur operating losses. â€‹In July 2024, following the announcement of the data from our Phase 3 pivotal trial and our discussions with the FDA, we also announced that we would initiate a review of strategic alternatives focused on maximizing stockholder value, which could include, but are not limited to, a merger, sale, divestiture of assets, licensing, or other strategic transaction. We expect to devote substantial time and resources to exploring strategic alternatives that our board of directors believes will maximize stockholder value. Despite devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. We have not set a timetable for completion of this strategic review process, and our board of directors has not approved a definitive course of action. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value, or that we will make any cash distributions to our stockholders. In connection with the evaluation of strategic alternatives and in order maximize capital preservation, we have implemented a plan to reduce our workforce by approximately 80%. This workforce reduction plan was approved in July 2024 and is substantially complete as of the date of this report.â€‹Based on our revised operating plan, we expect that our current cash and cash equivalents will fund our operations into the second quarter of 2025; however, we have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. To fund any further operations, we would need to further reduce our expenses or raise additional capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings, through collaborations or partnerships with other companies, or through the sale of rights to our drug candidates. We may not be able to raise additional capital on terms acceptable to us, or at all. If we are unable to raise additional capital and are unable to enter into a strategic transaction, we will need to further reduce the scope of or eliminate some or all of our operations or liquidate our company.â€‹Our Agreements with ApollomicsIn January 2020, we entered into an exclusive collaboration and license agreement with Apollomics (Hong Kong) Limited, or Apollomics, for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China. Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. We will also collaborate with Apollomics 21 Table of Contentsto advance the preclinical and clinical development of GMI-1687. We received an upfront cash payment of $9.0 million and in September 2020 received a $1.0 million development milestone payment. There were no milestone payments from Apollomics during the six months ended June 30, 2024 or 2023. Subject to the terms of the agreement, we will be eligible to receive potential further milestone payments totaling approximately $179.0 million, as well as tiered royalties ranging from the high single digits to 15%, as a percentage of net sales. Apollomics will be responsible for all costs related to development, regulatory approvals, and commercialization activities for uproleselan and GMI-1687 in Greater China, and we and Apollomics expect to enter into clinical and commercial supply agreements with respect to our provision of uproleselan and GMI-1687 to Apollomics. We retain all rights for both compounds in the rest of the world. In September 2020, the China National Medical Products Administration, or NMPA,Â Center for Drug Evaluation, or CDE, granted IND approval for uproleselan (also known as APL-106), enabling the initiation of a Phase 1 pharmacokinetics and tolerability study and a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML. In January 2021, APL-106 was granted Breakthrough Therapy Designation from the China NMPA CDE for the treatment of relapsed/refractory AML. In January 2024, Apollomics announced the completion of enrollment in the Phase 3 bridging study. A total of 140 adult patients across 20 sites in Greater China with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy were randomized to receive either uproleselan combined with chemotherapy or placebo plus chemotherapy. The primary endpoint for the Phase 3 bridging study is overall survival. Secondary outcome measures include the rate and duration of remission and whether uproleselan can reduce the rate of oral mucositis, a chemotherapy-related side effect.â€‹In June 2020, we entered into a clinical supply agreement with Apollomics under which we will manufacture and supply uproleselan product to Apollomics at agreed upon prices. Apollomics has the option to begin manufacture after appropriate material transfer requirements are met. During the year ended December 31, 2021, we recognized $1.1 million in revenue from the sale of clinical supplies to Apollomics under the clinical supply agreement. There were no sales of clinical supplies to Apollomics during the six months ended June 30, 2024 or 2023.â€‹Critical Accounting Policies and Significant Judgments and Estimates â€‹Our managementâ€™s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may materially differ from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.â€‹We define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. For a description of our critical accounting policies and estimates, please see the disclosures in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023. There have not been any material changes to our critical accounting policies and estimates since December 31, 2023.â€‹Components of Operating Results â€‹Revenue To date, we have not generated any revenue from the sale of our drug candidates and do not expect to generate any revenue from the sale of drugs in the near future. Substantially all of our historical revenue consisted of upfront and milestone payments under license and collaboration agreements.22 Table of ContentsResearch and Development Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to CROs and other consultants and other outside expenses. Other preclinical research and platform programs include activities related to exploratory efforts, target validation, lead optimization for our earlier programs and our proprietary glycomimetics platform. Our research and development expenses have related primarily to the development of uproleselan and our other drug candidates. We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis because we are organized and record expense by functional department and our employees may allocate time to more than one development project. Accordingly, we only allocate a portion of our research and development expenses by functional area and by drug candidate. â€‹Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. â€‹Research and development activities are central to our business model. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. It is difficult to determine with certainty the duration and completion costs of preclinical studies and clinical trials of our drug candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our drug candidates.Should we resume development of our product candidates, the duration, costs and timing of clinical trials and development of our drug candidates would depend on a variety of factors that include: â—per patient trial costs; â—the number of patients that participate in the trials; â—the number of sites included in the trials; â—the countries in which the trial is conducted; â—the length of time required to enroll eligible patients; â—the number of doses that patients receive; â—the drop-out or discontinuation rates of patients; â—potential additional safety monitoring or other studies requested by regulatory agencies; â—the duration of patient follow-up; and â—the safety and efficacy profile of the drug candidate. In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidateâ€™s commercial potential. General and Administrative â€‹General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. 23 Table of ContentsOther significant costs include facility costs not otherwise included in

research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services. â€‹Interest Income Interest income consists of interest income earned on our cash and cash equivalents. â€‹Results of Operations for the Three and Six Months Ended June 30, 2024 and 2023â€‹The following tables set forth our results of operations for the three and six months ended June 30, 2024 and 2023: â€‹â€‹â€‹

transaction is completed. Any such expenses will decrease the remaining cash available for use in our business. In addition, potential counterparties in a strategic transaction involving our company may place minimal or no value on our assets and our public listing. Further, should we resume the development of our product candidates, the development and any potential commercialization of our product candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving our company may choose not to spend additional resources and continue development of our product candidates and may attribute little or no value, in such a transaction, to those product candidates.In addition, any strategic business combination or other transactions that we may consummate in the future could have a variety of negative consequences and we may implement a course of action or consummate a transaction that yields unexpected results that adversely affects our business and decreases the remaining cash available for use in our business or the execution of our strategic plan. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to third parties in a potential transaction with us on reasonable terms. Any failure of such potential transaction to achieve the anticipated results could significantly impair our ability to enter into any future strategic transactions and may significantly diminish or delay any future distributions to our stockholders. If we are not successful in setting forth a new strategic path for our company, or if our plans are not executed in a timely fashion, this may cause reputational harm with our stockholders and the value of our securities may be adversely impacted. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to our future could cause our stock price to fluctuate significantly. Even if we are successful in completing a strategic transaction, we may fail to realize all of the anticipated benefits of the transaction and may be exposed to other operational and financial risks.Although there can be no assurance that a strategic transaction will result from the process we have undertaken to identify and evaluate strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of our management, and the diversion of managementâ€™s attention may disrupt our business.Our ability to realize the anticipated benefits of any potential business combination or any other result from our strategic assessment are highly uncertain. Any anticipated benefits will depend on a number of factors, including our ability to integrate with any future business partner and our ability to generate future stockholder value. The expected benefits may not be achieved within the anticipated time frame, or at all.The negotiation and consummation of any such transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including:â—increased near-term and long-term expenditures;â—exposure to unknown liabilities;â—higher than expected acquisition or integration costs;â—incurrence of substantial debt or dilutive issuances of equity securities to fund future operations;â—write-downs of assets or goodwill or incurrence of non-recurring, impairment or other charges;â—increased amortization expenses;â—difficulty and cost in combining the operations and personnel of any acquired business with our operations and personnel;â—impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership;â—inability to retain key employees of our company or any acquired business; and30 Table of Contentsâ—possibility of future litigation.If a strategic transaction is not consummated, our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.There can be no assurance that a strategic transaction will be completed. If a strategic transaction is not completed, our board of directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up.Our ability to consummate a strategic transaction depends on our ability to retain our employees required to consummate such transaction.Our ability to consummate a strategic transaction depends upon our ability to retain our employees required to consummate such a transaction, the loss of whose services may adversely impact the ability to consummate such transaction. In connection with the evaluation of strategic alternatives and in order to extend our resources, in July 2024 we implemented a reduction in our workforce by approximately 80%. Our cash conservation activities may yield unintended consequences, such as attrition beyond our reduction in workforce and reduced employee morale, which may cause remaining employees to seek alternative employment. Our ability to successfully complete a strategic transaction depends in large part on our ability to retain our remaining personnel. If we are unable to successfully retain our remaining personnel, we are at risk of a disruption to our exploration and consummation of a strategic alternative as well as our business operations.Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected, and could disrupt our business. As part of our reduction in force announced in July 2024, we incurred personnel-related restructuring charges of approximately $3.6 million in connection with one-time employee termination cash expenditures, including severance and other benefits. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, our restructuring plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees.Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Due to our limited resources, we may not be able to effectively manage our operations or recruit and retain qualified personnel, which may result in weaknesses in our infrastructure and operations, risks that we may not be able to comply with legal and regulatory requirements, and loss of employees and reduced productivity among remaining employees. For example, the workforce reduction may negatively impact our clinical, regulatory, technical operations, our cybersecurity program, and commercial functions, should we 31 Table of Contentschoose to continue to pursue them, which would have a negative impact on our ability to successfully develop, and ultimately, commercialize our product candidates. Our future financial performance and, should we resume development, our ability to develop our product candidates or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be.We may become involved in litigation, including securities class action litigation, that could divert managementâ€™s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC. We may be exposed to such litigation, even if no wrongdoing occurred. Litigation is usually expensive and diverts managementâ€™s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.If we cannot comply with Nasdaqâ€™s continued listing standards, our common stock could be delisted, which would harm our business and could have an adverse impact on the liquidity and trading price of our common stock and our ability to raise additional capital. Risks Related to an Investment in Our Common StockIf we fail to comply or regain compliance with Nasdaqâ€™s continued listing standards, our common stock may be delisted and the price of our common stock, our ability to access the capital markets and our financial condition could be negatively impacted.Our common stock is currently listed on the Nasdaq Global Market. To maintain the listing of our common stock on the Nasdaq Global Market, we are required to meet certain listing requirements, including, among others, either: (i) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $5 million and stockholdersâ€™ equity of at least $10 million; or (ii) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors, affiliates and 10% or more stockholders) of at least $15 million and a total market value of listed securities of at least $50 million. In June 2024, we received a written notice, or the Notice, from the Listing Qualifications Department of The Nasdaq Stock Market, or Nasdaq, that we are not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Pursuant to Nasdaq listing rules, we have been provided an initial compliance period of 180 calendar days from receipt of the Notice, or until December 18, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for our common stock would need to close at $1.00 per share or more for a minimum of 10 consecutive business days during this 180-day grace period, among other requirements. While we may be able to qualify for additional time to attempt to regain compliance, there can be no assurance that we will qualify for additional time to regain compliance, or that we will regain compliance with or without such additional time. If necessary to regain compliance with Nasdaq listing standards, we may, subject to approval of our board of directors and stockholders, implement a reverse stock split. However, there can be no assurance that a reverse stock split, or any other alternatives we may consider to regain compliance with the minimum bid price requirement, would be approved or would result in a sustained higher stock price that would allow us to meet the Nasdaq stock price listing requirements.If we are not able to regain compliance within the compliance period allotted by Nasdaq, our common stock could be delisted, which would have a further material adverse effect on the market price of our common stock and on stockholder liquidity. We intend to actively monitor the bid price of our common stock and will consider available options to regain compliance with the listing requirement; however, there can be no assurance that we will be able to regain compliance with the listing requirement or will otherwise be in compliance with other Nasdaq listing criteria. If Nasdaq delists our common stock for failure to meet its listing standards, and our common stock is not eligible for 32 Table of Contentsquotation or listing on another market or exchange, we and our stockholders could face significant negative consequences, including:â—trading of our common stock being conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board, which could result in limited availability of market quotations for our common stock and increased difficulty of disposing of shares of common stock;â—a determination that the common stock is a â€œpenny stock,â€ which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of our common stock;â—a limited amount of analyst coverage; andâ—a decreased ability to issue additional securities or obtain additional financing in the future.â€‹ITEMÂ 2.
Â Â Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSâ€‹None.â€‹ITEMÂ 5. Â Â Â Â Â Â OTHER INFORMATIONâ€‹Trading Plansâ€‹During the three months ended June 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any contracts, instructions or written plans for the purchase or sale of our securities.â€‹Retention Agreements and Enhanced Severance Benefitsâ€‹On August 7, 2024, the Company entered into retention agreements (the â€œRetention Agreementsâ€) with certain employees who remain with the Company following the reduction in headcount described in the Companyâ€™s Current Report on Form 8-K filed with the SEC on July 30, 2024. Among the employees with whom the Company entered into Retention Agreements were Harout Semerjian, the Companyâ€™s Chief Executive Officer, and Brian Hahn, the Companyâ€™s Chief Financial Officer (the â€œNamed Executive Officersâ€). â€‹Under the Retention Agreements, in the event that a Named Executive Officer does not resign and remains employed by the Company through December 31, 2024 (or such earlier date as established by the Company), he will be eligible to receive, as a retention bonus, an amount equal to the officerâ€™s target bonus for the year ending December 31, 2024 (the â€œRetention Bonusâ€). If and to the extent that the officer receives a Retention Bonus, he will not otherwise be eligible to receive a bonus for the year ending December 31, 2024. However, if the officer remains employed by the Company subsequent to December 31, 2024, then he will be eligible to receive a prorated target bonus for the year ending December 31, 2025 based on the number of months the officer is employed in 2025.â€‹In addition to the potential Retention Bonuses, the Named Executive Officers will be eligible to receive severance benefits under the Retention Agreements that are in addition to the benefits provided in the officersâ€™ current employment agreements, which have been previously filed as Exhibits 10.8 and 10.9 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 (the "Employment Agreements") and summarized in the Companyâ€™s definitive proxy statement filed with the SEC on April 1, 2024.â€‹In the event that a Named Executive Officer is terminated by the Company without Cause or terminates his employment for Good Reason (each as defined in the respective Employment Agreement) prior to December 31, 2024, the officer will be entitled to receive, in addition to the severance amounts set forth in Section 9.2 of the officerâ€™s Employment Agreement, an enhanced severance amount equal to the Retention Bonus described above (but only to the extent the Retention Bonus has not otherwise been paid). â€‹33 Table of ContentsFurthermore, in the event that the Company consummates a transaction or series of transactions that results in a Change in Control (as defined in the Employment Agreements) within 12 months following the date on which a Named Executive Officer is terminated by the Company without Cause or terminates his employment for Good Reason (and provided the Company executes a definitive agreement within 3 months following such termination date), then such termination will be considered to be a â€œChange in Control Terminationâ€ under Section 9.3 of the Employment Agreements, notwithstanding that the termination in question will have occurred prior to the Change in Control. â€‹In the case of such a Change of Control, the Named Executive Officer will be entitled to receive the severance payments described in Section 9.3 of his respective Employment Agreement in connection with a â€œChange in Control Terminationâ€ in lieu of the severance payments described in Section 9.2 of the Employment Agreement, with the â€œTarget Bonusâ€ referenced in Section 9.3 of such agreements being the target bonus for the year ending December 31, 2024 (the â€œCIC Bonus Severanceâ€), regardless of the date of such Change in Control. The payment of any Retention Bonus described above will not impact eligibility for receipt of CIC Bonus Severance under Section 9.3 of the Employment Agreements. Any incremental severance amounts payable in connection with a Change in Control under Section 9.3 of the Employment Agreements, as modified by the Retention Agreements, will be payable upon the closing of the Change in Control.â€‹The foregoing description of the terms of the Retention Agreements is a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the Retention Agreements, which will be filed as exhibits to the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ending September 30, 2024. â€‹â€‹34 Table of Contentsâ€‹ITEMÂ 6.
Â Â Â Â Â Â EXHIBITSâ€‹â€‹â€‹ExhibitNo.â€‹Documentâ€‹â€‹â€‹3.1â€‹Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrantâ€™s Current Report on FormÂ 8-K (File No.Â 001-36177), filed with the Commission on January 15, 2014).â€‹â€‹â€‹3.2â€‹Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrantâ€™s Current Report on FormÂ 8-K (File No.Â 001-36177), filed with the Commission on JanuaryÂ 15, 2014).â€‹â€‹â€‹3.3â€‹Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrantâ€™s Current Report on FormÂ 8-K (File No.Â 001-36177), filed with the Commission on MayÂ 1, 2024).â€‹â€‹â€‹3.4â€‹Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrantâ€™s Current Report on FormÂ 8-K (File No.Â 001-36177), filed with the Commission on MayÂ 1, 2024).â€‹â€‹â€‹4.1â€‹Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to ExhibitÂ 4.2 to Amendment No. 2 to the Registrantâ€™s Registration Statement on Form S-1 (File No.Â 333-191567), filed with the Commission on October 31, 2013).â€‹â€‹â€‹31.1*â€‹Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.â€‹â€‹â€‹31.2*â€‹Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.â€‹â€‹â€‹32.1**â€‹Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.â€‹â€‹â€‹101.INSâ€‹XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document)â€‹â€‹â€‹101.SCHâ€‹Inline XBRL Taxonomy Extension Schema Documentâ€‹â€‹â€‹101.CALâ€‹Inline XBRL Taxonomy Extension Calculation Linkbase Documentâ€‹â€‹â€‹101.DEFâ€‹Inline XBRL Taxonomy Extension Definition Linkbase Documentâ€‹â€‹â€‹101.LABâ€‹Inline XBRL Taxonomy Extension Label Linkbase Document â€‹â€‹â€‹101.PREâ€‹Inline XBRL Taxonomy Extension Presentation Linkbase Documentâ€‹â€‹â€‹104â€‹Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*Â Â Â Â Â Filed herewith. â€‹**Â Â Â These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.â€‹â€‹â€‹35 Table of Contentsâ€‹SIGNATURESâ€‹Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹â€‹â€‹â€‹â€‹â€‹â€‹GLYCOMIMETICS, INC.â€‹â€‹â€‹â€‹Date: August 8, 2024â€‹By:/s/ Brian M. Hahnâ€‹â€‹â€‹Brian M. Hahnâ€‹â€‹â€‹Senior Vice President and Chief Financial Officer â€‹â€‹â€‹(On behalf of the Registrant and as Principal Financial Officer)â€‹â€‹â€‹36 EX-31.1 2 glyc-20240630xex31d1.htm EX-31.1 Exhibit 31.1â€‹CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 â€‹I, Harout Semerjian, certify that: â€‹1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2024 of GlycoMimetics, Inc. (the â€œregistrantâ€);â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; â€‹4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: â€‹(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; â€‹(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and â€‹(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and â€‹5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): â€‹(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and â€‹(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. â€‹Date: August 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Harout Semerjianâ€‹â€‹Harout Semerjianâ€‹â€‹Chief Executive Officerâ€‹â€‹(principal executive officer)â€‹ EX-31.2 3 glyc-20240630xex31d2.htm EX-31.2 Exhibit 31.2â€‹CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 â€‹I, Brian M. Hahn, certify that: â€‹1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2024 of GlycoMimetics, Inc. (the â€œregistrantâ€);â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; â€‹4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: â€‹(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; â€‹(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and â€‹(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and â€‹5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): â€‹(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and â€‹(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. â€‹Date: August 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Brian M. Hahnâ€‹â€‹Brian M. Hahnâ€‹â€‹Senior Vice President and Chief Financial Officer â€‹â€‹(principal financial officer)â€‹ EX-32.1 4 glyc-20240630xex32d1.htm EX-32.1 Exhibit 32.1â€‹CERTIFICATIONS OFPRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 â€‹Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the â€œExchange Actâ€) and SectionÂ 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Harout Semerjian, Chief Executive Officer of GlycoMimetics, Inc. (the â€œCompanyâ€), and Brian M. Hahn, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: â€‹1.The Companyâ€™s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Exchange Act; and â€‹2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. â€‹IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8th day of August 2024. â€‹â€‹â€‹â€‹â€‹/s/ Harout Semerjian â€‹/s/ Brian M. HahnHarout Semerjianâ€‹Brian M. HahnChief Executive Officerâ€‹Senior Vice President and Chief Financial Officer *This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of GlycoMimetics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Periodic Report), irrespective of any general incorporation language contained in such filing. EX-101.SCH 5 glyc-20240630.xsd EX-101.SCH 995200100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Operating Leases - Components of lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Operating Leases - Maturities of lease liability (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Operating leases - Maturities of lease liability (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Description of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Significant Accounting Policies - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Significant Accounting Policies - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Stock-based Compensation - Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Stock-based Compensation - Inducement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99940806 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940807 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 99940808 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of the Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Operating Leases - Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 glyc-20240630_cal.xml EX-101.CAL EX-101.DEF 7 glyc-20240630_def.xml EX-101.DEF EX-101.LAB 8 glyc-20240630_lab.xml EX-101.LAB Document and Entity Information Document Type Document Type Document Quarterly Report Document Transition Report Document Period End Date Document Period End Date Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Amendment Flag Amendment Flag Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Prepaid Expense, Noncurrent Prepaid research and development expenses Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Other Assets Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities & stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Operating Lease, Liability, Current Lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liabilities, net of current portion Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock; $0.001 par value; 150,000,000 shares authorized at June 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at June 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Operations and Comprehensive Loss Operating Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development expense General And Administrative Expense General and administrative expense Operating Expenses Total costs and expenses Operating Income (Loss) Loss from operations Interest Income (Expense), Nonoperating, Net Interest income The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent. Net Income Loss And Comprehensive Income Net Of Tax Net loss Net loss and comprehensive loss Earnings Per Share, Basic Basic net loss per common share (in dollars per share) Earnings Per Share, Diluted Diluted net loss per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Basic weighted-average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted weighted-average number of common shares outstanding (in shares) Statements of Stockholders' Equity Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital Retained Earnings [Member] Accumulated Deficit Statement [Line Items] Statement Shares, Outstanding Balance, shares Balance, shares Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs, shares Stock Issued During Period, Value, Issued for Services Issuance of common stock for services Stock Issued During Period, Shares, Issued for Services Issuance of common stock for services, shares Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Common stock issued under stock plans Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Common stock issued under stock plans, shares The value of share options and warrants and vesting of stock units exercised during the current period. Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting Exercise of options and vesting of restricted stock units Number of share options and warrants and vesting of stock units exercised during the current period. Stock Issued During Period Shares Stock Options And Warrants And Restricted Stock Units Vesting Exercise of options and vesting of restricted stock units, shares Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation Operating Lease Right Of Use Asset Amortization Non-cash lease expense Issuance of Stock and Warrants for Services or Claims Issuance of common stock for services Share-based

Compensation Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (decrease) in prepaid research and development expenses. Increase Decrease In Prepaid Research And Development Expenses Prepaid research and development expenses Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses The increase (decrease) during the reporting period in the operating lease liabilities. Increase Decrease In Operating Lease Liabilities Lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash flows used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Description of the Business Nature of Operations [Text Block] Description of the Business No definition available. Going Concern Substantial Doubt about Going Concern [Text Block] Going Concern Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Significant Accounting Policies Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Operating Leases Lessee, Operating Leases [Text Block] Operating Leases Stockholders' Equity Equity [Text Block] Stockholders' Equity Stock-based Compensation Share-Based Payment Arrangement [Text Block] Stock-based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes n/a License and Collaboration Agreements The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones. Research And License Agreement Text Block License and Collaboration Agreements Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Accounting Disclosure of accounting policy for unaudited interim financial statements. Unaudited Interim Financial Statements Policy Text Block Unaudited Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Disclosure of accounting policy for Accruals for Clinical Trial Expenses. Accruals For Clinical Trial Expenses [Policy Text Block] Accruals for Clinical Trial Expenses Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Earnings Per Share, Policy [Policy Text Block] Net Loss Per Common Share Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Standards Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities outstanding Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Summary of Prepaid Expenses and Other Current Assets Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses Lease, Cost [Table Text Block] Components of lease expense and related cash flows Lessee, Operating Lease, Liability, Maturity [Table Text Block] Maturities of lease liabilities due Tabular disclosure of supplemental information related to leases. Lease Quantitative Disclosure [Table Text Block] Schedule of supplemental information related to leases Plan Name [Axis] Plan Name [Domain] Pertaining to the 2013 Equity Incentive Plan. Equity Incentive Plan 2013 [Member] 2013 Equity Incentive Plan Represents information relating to inducement plan. Equity Inducement Plan [Member] Inducement Plan Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Company's Stock Option Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of RSU Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Weighted-Average Fair Value of Options Granted Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Stock-Based Compensation Expense Restructuring Cost [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Restructuring Cost and Reserve [Line Items] The percent of workforce reduction for conservation of cash resources. Conservation of Cash Resources, Workforce Reduction, Percent Workforce reduction, percent Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Assets, Fair Value Disclosure Assets measured at fair value levels 2 or 3 Financial and Nonfinancial Liabilities, Fair Value Disclosure Liabilities measured at fair value levels 2 or 3 Money Market Funds, at Carrying Value Carrying value of cash held in money market fund Defined Contribution Plan [Table] Range [Axis] Range [Domain] Maximum [Member] Maximum Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure Share-based Compensation Arrangement By Share-based Payment Award Expiration Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Information related to stock options and restricted stock units. Employee Stock Options And Restricted Stock Units [Member] Stock options and restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities Prepaid Expense, Current Prepaid research and development expenses Other Prepaid Expense, Current Other prepaid expenses Other Receivables, Net, Current Other receivables Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Expense Current Accrued research and development expenses Accrued Bonuses, Current Accrued bonuses Accrued Professional Fees, Current Accrued consulting and other professional fees Accrued Employee Benefits, Current Accrued employee benefits Other Accrued Liabilities, Current Other accrued expenses Lessee, Lease, Description [Table] Geographical [Axis] Geographical [Domain] Pertaining to Rockville, Maryland. Rockville Maryland [Member] Rockville, Maryland Pertaining to first portion of the Rockville, Maryland lease. First Portion Square Feet Rockville, Maryland [Member] First portion of Rockville, Maryland lease Pertaining to second portion of the Rockville, Maryland lease. Second Portion Square Feet Rockville, Maryland [Member] Second portion of Rockville, Maryland lease Lessee, Lease, Description [Line Items] Lessee, Lease, Description Lessee, Operating Lease, Description [Abstract] Operating leases Lease, Practical Expedient, Lessor Single Lease Component [true false] Security Deposit Square feet leased. Square Feet Leased Square feet leased Lessee, Operating Lease, Existence of Option to Extend [true false] Represents the number of additional operating leases entered into during the period. Lessee Operating Lease Number Of New Leases Number of additional operating leases entered during the period Lease, Cost [Abstract] Components of lease expense Operating Lease, Cost Operating lease cost Variable Lease, Cost Variable lease cost Lease, Cost Total operating lease cost Cash Flow, Operating Activities, Lessee [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Operating Lease, Payments Operating cash outflows for operating leases Operating Lease Liabilities, Payments Due [Abstract] Maturities of lease liability due Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year July 1, 2024 - December 31, 2024 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2025 Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due After Year Two Thereafter Lessee, Operating Lease, Liability, Payments, Due Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value adjustment Operating Lease, Liability Present value of lease payments Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Lessee, Operating Lease, Remaining Lease Term Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average incremental borrowing rate Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease obligations Sale of Stock [Axis] Sale of Stock [Domain] Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in March 2022. At Market Offering 2022 [Member] 2022 Sales Agreement Equity offerings Shares Issued, Price Per Share Price per share Sale of Stock, Consideration Received on Transaction Aggregate net proceeds from stock sale Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period. Common Stock Value Available For Sale Under Agreement Common stock available for sale under agreement Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Upon first anniversary of start date Share-Based Payment Arrangement, Tranche Two [Member] Each month after the first anniversary Represents a stock option award with vesting based on achievement of performance conditions. Stock Options Vesting Based On Performance [Member] Stock options vesting based on performance RSU [Member] RSU Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member] Employees Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award Incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Percent of shares subject to option grant that will vest Vesting percentage Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments Number of monthly installments Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period After Termination Of Employment Period from date of termination that any vested options shall expire Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense related to unvested options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Period for unrecognized compensation expense related to unvested options yet has not been recognized Share-based compensation arrangement by share-based payment award options exercises in period total intrinsic value Intrinsic value of options exercised Proceeds from Stock Options Exercised Cash proceeds from exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised Shares issued from exercise of stock options Options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Fair value of shares vested Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement. Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense Maximum fair value of option excluded from the unrecognized compensation expense n/a Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract Authorized shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Common stock authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for future grants Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options. Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options Maximum number of shares that may be issued pursuant to exercise of incentive stock options Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increase in number of shares of common stock Total number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee. Percentage Of Total Number Of Common Stock Stock Issued Or Outstanding Immediately Preceding Fiscal Year Or Lesser Number As Determined By Board Of Directors Or Compensation Committee Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Newly hired recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires. Share-based Payment Arrangement, Newly Hired Employee [Member] Newly hired employees Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] OUTSTANDING OPTIONS Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of period Outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] WEIGHTED-AVERAGE EXERCISE PRICE Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of period Outstanding at beginning of period Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] VESTED AND EXPECTED TO VEST Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] ADDITIONAL DISCLOSURES Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Outstanding options exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average exercise price exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average contractual term outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average contractual term (years) exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value (in thousands) outstanding at end of period Aggregate intrinsic value (in thousands) outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Restricted Stock Units information Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation expense related to unvested service RSUs Unrecognized compensation expense related to unvested options Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] NUMBER OF SHARES Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested at end of period Unvested at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] WEIGHTED-AVERAGE GRANT DATE FAIR VALUE Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested at end of period Unvested at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited Share-Based Payment Arrangement, Nonemployee [Member] Non-employee Represents the information pertaining to other awards. Other Awards [Member] Other Awards Title of Individual [Axis] Title of Individual [Domain] Director [Member] Director Share-based Compensation Arrangement by Share-based Payment Award, Shares

Issued in Period Common stock shares issued Pertaining to the 2013 Equity Incentive and Inducement Plan. Equity Incentive Plan 2013 And Equity Inducement Plan [Member] 2013 Equity Incentive and Inducement Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average fair value of the options granted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted-average assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development [Member] Research and development expense General and Administrative Expense [Member] General and administrative expense Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Total stock-based compensation expense Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Apollomic. Apollomic [Member] Apollomics, Inc. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Research And License Agreements Research and License Agreements Amount of up-front payment received under terms of the agreement. Up Front Payment Received Up-front payment received The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events. Development And Regulatory Approval Milestones Clinical And Regulatory Events Milestones based on achievement of certain clinical and regulatory events The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products. Achievement of Specified Net Sales Thresholds for all Licensed Products Milestone payment upon achievement of specified net sales thresholds for all licensed products The entitled royalty payments to be received based on a tiered percentage of annual net sales. Tiered Percentage Of Annual Net Sales Tiered percentage of annual net sales Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event Restructuring and Related Cost, Number of Positions Eliminated Reduction in workforce under corporate restructuring Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Percentage of reduction in workforce under corporate restructuring Restructuring Charges Total charges in headcount reduction under corporate restructuring EX-101.PRE 9 glyc-20240630_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 07, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Jun. 30, 2024 Â Entity File Number 001-36177 Â Entity Registrant Name GlycoMimetics, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 06-1686563 Â Entity Address, Address Line One 9708 Medical Center Drive Â Entity Address, City or Town Rockville Â Entity Address, State or Province MD Â Entity Address, Postal Zip Code 20850 Â City Area Code 240 Â Local Phone Number 243-1201 Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol GLYC Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 64,483,958 Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Entity Central Index Key 0001253689 Â Current Fiscal Year End Date --12-31 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 22,386,052 $ 41,792,830 Prepaid expenses and other current assets 1,471,453 1,997,904 Total current assets 23,857,505 43,790,734 Prepaid research and development expenses Â 603,737 Operating lease right-of-use asset 424,209 767,828 Other assets 137,105 154,176 Total assets 24,418,819 45,316,475 Current liabilities: Â Â Accounts payable 950,763 868,115 Accrued expenses 2,956,778 5,225,557 Lease liabilities 448,775 741,558 Total current liabilities 4,356,316 6,835,230 Lease liabilities, net of current portion Â 66,844 Total liabilities 4,356,316 6,902,074 Stockholders' equity: Â Â Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023 Common stock; $0.001 par value; 150,000,000 shares authorized at June 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at June 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023 64,484 64,394 Additional paid-in capital 497,315,304 494,835,219 Accumulated deficit (477,317,285) (456,485,212) Total stockholders' equity 20,062,503 38,414,401 Total liabilities and stockholders' equity $ 24,418,819 $ 45,316,475 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Balance Sheets Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 150,000,000 100,000,000 Common stock, shares issued 64,483,958 64,393,744 Common stock, shares outstanding 64,483,958 64,393,744 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Operations and Comprehensive Loss - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Costs and expenses: Â Â Â Â Research and development expense $ 6,285,734 $ 4,072,708 $ 12,311,195 $ 9,491,414 General and administrative expense 4,071,960 4,857,237 9,161,526 10,379,549 Total costs and expenses 10,357,694 8,929,945 21,472,721 19,870,963 Loss from operations (10,357,694) (8,929,945) (21,472,721) (19,870,963) Interest income 262,288 671,033 640,648 1,252,701 Net loss and comprehensive loss $ (10,095,406) $ (8,258,912) $ (20,832,073) $ (18,618,262) Basic net loss per common share (in dollars per share) $ (0.16) $ (0.13) $ (0.32) $ (0.30) Diluted net loss per common share (in dollars per share) $ (0.16) $ (0.13) $ (0.32) $ (0.30) Basic weighted-average number of common shares outstanding (in shares) 64,483,848 64,276,184 64,470,541 62,313,155 Diluted weighted-average number of common shares outstanding (in shares) 64,483,848 64,276,184 64,470,541 62,313,155 X - DefinitionThe portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent. + ReferencesNo definition available. + Details Name: glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting

operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Stockholders' Equity - USD ($) Common Stock Additional Paid-In Capital Accumulated Deficit Total Balance at Dec. 31, 2022 $ 54,378 $ 462,461,251 $ (419,585,792) $ 42,929,837 Balance, shares at Dec. 31, 2022 54,377,798 Â Â Â Issuance of common stock, net of issuance costs $ 9,823 28,697,188 Â 28,707,011 Issuance of common stock, net of issuance costs, shares 9,822,930 Â Â Â Common stock issued under stock plans $ 44 33,724 Â 33,768 Common stock issued under stock plans, shares 44,496 Â Â Â Stock-based compensation Â 870,180 Â 870,180 Net Income (Loss) Â Â (10,359,350) (10,359,350) Balance at Mar. 31, 2023 $ 64,245 492,062,343 (429,945,142) 62,181,446 Balance, shares at Mar. 31, 2023 64,245,224 Â Â Â Balance at Dec. 31, 2022 $ 54,378 462,461,251 (419,585,792) 42,929,837 Balance, shares at Dec. 31, 2022 54,377,798 Â Â Â Balance at Jun. 30, 2023 $ 64,313 492,940,477 (438,204,054) 54,800,736 Balance, shares at Jun. 30, 2023 64,313,333 Â Â Â Balance at Mar. 31, 2023 $ 64,245 492,062,343 (429,945,142) 62,181,446 Balance, shares at Mar. 31, 2023 64,245,224 Â Â Â Common stock issued under stock plans $ 68 20,046 Â 20,114 Common stock issued under stock plans, shares 68,109 Â Â Â Stock-based compensation Â 858,088 Â 858,088 Net Income (Loss) Â Â (8,258,912) (8,258,912) Balance at Jun. 30, 2023 $ 64,313 492,940,477 (438,204,054) 54,800,736 Balance, shares at Jun. 30, 2023 64,313,333 Â Â Â Balance at Dec. 31, 2023 $ 64,394 494,835,219 (456,485,212) 38,414,401 Balance, shares at Dec. 31, 2023 64,393,744 Â Â Â Issuance of common stock for services $ 15 35,985 Â 36,000 Issuance of common stock for services, shares 15,256 Â Â Â Common stock issued under stock plans $ 42 4,856 Â 4,898 Common stock issued under stock plans, shares 41,835 Â Â Â Stock-based compensation Â 1,192,080 Â 1,192,080 Net Income (Loss) Â Â (10,736,667) (10,736,667) Balance at Mar. 31, 2024 $ 64,451 496,068,140 (467,221,879) 28,910,712 Balance, shares at Mar. 31, 2024 64,450,835 Â Â Â Balance at Dec. 31, 2023 $ 64,394 494,835,219 (456,485,212) 38,414,401 Balance, shares at Dec. 31, 2023 64,393,744 Â Â Â Balance at Jun. 30, 2024 $ 64,484 497,315,304 (477,317,285) 20,062,503 Balance, shares at Jun. 30, 2024 64,483,958 Â Â Â Balance at Mar. 31, 2024 $ 64,451 496,068,140 (467,221,879) 28,910,712 Balance, shares at Mar. 31, 2024 64,450,835 Â Â Â Issuance of common stock for services $ 13 39,362 Â 39,375 Issuance of common stock for services, shares 13,127 Â Â Â Exercise of options and vesting of restricted stock units $ 20 480 Â 500 Exercise of options and vesting of restricted stock units, shares 19,996 Â Â Â Stock-based compensation Â 1,207,322 Â 1,207,322 Net Income (Loss) Â Â (10,095,406) (10,095,406) Balance at Jun. 30, 2024 $ 64,484 $ 497,315,304 $ (477,317,285) $ 20,062,503 Balance, shares at Jun. 30, 2024 64,483,958 Â Â Â X - DefinitionNumber of share options and warrants and vesting of stock units exercised during the current period. + ReferencesNo definition available. + Details Name: glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting Namespace Prefix: glyc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of share options and warrants and vesting of stock units exercised during the current period. + ReferencesNo definition available. + Details Name: glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Statements of Cash Flows - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Operating activities Â Â Â Net loss $ (20,832,073) $ (18,618,262) Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Depreciation 27,043 87,257 Â Non-cash lease expense 343,619 441,566 Â Issuance of common stock for services 75,375 Â Â Stock-based compensation 2,399,402 1,728,268 Â Changes in assets and liabilities: Â Â Â Prepaid expenses and other current assets 526,451 512,324 Â Prepaid research and development expenses 603,737 Â Â Accounts payable 82,648 (728,704) Â Accrued expenses (2,268,779) (1,481,734) Â Lease liabilities (359,627) (522,428) Â Net cash used in operating activities (19,402,204) (18,581,713) $ (34,900,000) Investing activities Â Â Â Purchases of property and equipment (9,972) (12,727) Â Net cash used in investing activities (9,972) (12,727) Â Financing activities Â Â Â Proceeds from issuance of common stock, net of issuance costs Â 28,707,011 Â Proceeds from exercise of stock options 5,398 53,882 Â Net cash provided by financing activities 5,398 28,760,893 Â Net change in cash and cash equivalents (19,406,778) 10,166,453 Â Cash and cash equivalents, beginning of period 41,792,830 47,870,619 47,870,619 Cash and cash equivalents, end of period $ 22,386,052 $ 58,037,072 $ 41,792,830 X - DefinitionThe increase (decrease) during the reporting period in the operating lease liabilities. + ReferencesNo definition available. + Details Name: glyc_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in prepaid research and development expenses. + ReferencesNo definition available. + Details Name: glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of the Business 6 Months Ended Jun. 30, 2024 Description of the Business Â Description of the Business 1. Description of the Businessâ€‹GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is focused on improving the lives of people living with cancer and inflammatory diseases by leveraging the inhibition of carbohydrate interactions that occur on the surface of cells. The Company has been developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. As a result, the Company intends to conduct a strategic review of its business, in an effort to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan and the Companyâ€™s GMI-1687 to ensure their continued advancement. In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately 80%. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Going Concern 6 Months Ended Jun. 30, 2024 Going Concern Â Going Concern 2. Going Concernâ€‹The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2023, the Company incurred a net loss of $36.9 million and had net cash flows used in operating activities of $34.9 million. The Company incurred a net loss of $20.8 million and had net cash flows used in operating activities of $19.4 million during the six months ended June 30, 2024. At June 30, 2024, the Company had $22.4 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings, although the Company may, at its discretion, sell equity securities under the terms of its existing at-the-market sales agreement (see Note 7), subject to certain conditions and limitations. Management believes that given the Companyâ€™s current cash position and forecasted negative cash flows from operating activities over the next twelve months, despite the adoption of a streamlined operating plan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these unaudited financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement. The Company expects that its current cash resources will only be sufficient to fund the Companyâ€™s operations into the second quarter of 2025.The Companyâ€™s ability to fund its operations is dependent upon managementâ€™s plans, which include reducing operating expenses and potentially entering into collaborations, strategic alliances and marketing, distribution or licensing arrangements in order to raise additional capital. There can be no assurances that any strategic transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital or enter into a strategic transaction, the Company will need to eliminate some or all of its operations and may seek to liquidate.The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.â€‹ X - ReferencesNo definition available. + Details Name: glyc_GoingConcernAbstract Namespace Prefix: glyc_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Significant Accounting Policies 3. Significant Accounting Policiesâ€‹There have been no material changes to the significant accounting policies previously disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the SEC) on March 27, 2024 (the Form 10-K).â€‹Basis of Accounting â€‹The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). â€‹Unaudited Financial Statements â€‹The accompanying balance sheet as of June 30, 2024, statements of operations and comprehensive loss and stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Companyâ€™s financial position as of June 30, 2024 and its results of operations and changes in its stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. â€‹Use of Estimatesâ€‹The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

â€‹â€‹Fair Value Measurements â€‹The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of June 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $18.8 million and $38.8 million as of June 30, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company didÂ not transfer any assets measured at fair value on a recurring basis between levels during theÂ three and six months ended June 30, 2024 and 2023.â€‹Concentration of Credit Risk â€‹Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. â€‹Revenue Recognition â€‹The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers (Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidatesâ€™ rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Companyâ€™s license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.Licensing of Intellectual Property: If the license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.Manufacturing and Supply:Â The obligations under the Companyâ€™s agreements may include clinical and/or commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs.â€‹Accruals for Clinical Trial Expenses â€‹â€‹Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses have historically been a significant component of research and development expenses, and the Company previously outsourced a significant portion of its clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, estimated project duration and other pass-through costs. As a result of the Company ceasing its clinical activities, the costs of closing down clinical sites are also included in the accruals. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)Â the Companyâ€™s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Companyâ€™s historical clinical accrual estimates have not been materially different from the actual costs. â€‹Stock-Based Compensation â€‹Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensationâ€”Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company accounts for forfeitures as they occur.â€‹The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. â€‹A discussion of managementâ€™s methodology for developing some of the assumptions used in the valuation model follows: â€‹Expected Dividend Yieldâ€”The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. â€‹Expected Volatilityâ€”Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Companyâ€™s publicly traded common stock. â€‹Risk-Free Interest Rateâ€”This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. â€‹Expected Termâ€”This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. â€‹Net Loss Per Common Share â€‹Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Companyâ€™s stock options and restricted stock units (RSUs).â€‹The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Â Â Â Â Stock options and RSUs 16,047,875Â 11,469,764Â â€‹Comprehensive LossComprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Companyâ€™s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. â€‹Recently Issued Accounting Standards â€‹Accounting Standards Not Yet AdoptedThere have been no new accounting pronouncements that have significance, or potential significance, to the Companyâ€™s unaudited financial statements as of and for the six months ended June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets 6 Months Ended Jun. 30, 2024 Prepaid Expenses and Other Current Assets Â Prepaid Expenses and Other Current Assets 4. Prepaid Expenses and Other Current Assetsâ€‹The following is a summary of the Companyâ€™s prepaid expenses and other current assets: â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity Â Stockholders' Equity 7. Stockholdersâ€™ Equity â€‹Common Stockâ€‹During the three months ended June 30, 2024, the Companyâ€™s board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from 100,000,000 to 150,000,000 shares with a par value of $0.001 per share.â€‹At-The-Market Sales Facilityâ€‹In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the 2022 Sales Agreement) with Cowen and Company, LLC. Under the 2022 Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the six months ended June 30, 2023, the Company issued and sold 9,822,930 shares of common stock under the 2022 Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no shares issued under the 2022 Sales Agreement during the six months ended June 30, 2024. As of June 30, 2024, approximately $66.0 million remained available to be sold under the terms of the 2022 Sales Agreement.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation 6 Months Ended Jun. 30, 2024 Stock-based Compensation Â Stock-based Compensation 8. Stock-based Compensation â€‹2013 Equity Incentive Plan â€‹The Companyâ€™s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of SectionÂ 422 of the Internal Revenue Code (the Code) to the Companyâ€™s employees and its parent and subsidiary corporationsâ€™ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Companyâ€™s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.â€‹Authorized Shares â€‹The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000Â shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000 shares. As of June 30, 2024, the total number of shares reserved for issuance under the 2013 Plan was 14,257,627 shares, of which 94,036 shares were available for future grants.â€‹Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. â€‹A summary of the Companyâ€™s stock option activity under the 2013 Plan for the six months ended June 30, 2024 is as follows: â€‹â€‹â€‹

benefit for the six months ended June 30, 2024 or 2023. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License and Collaboration Agreements 6 Months Ended Jun. 30, 2024 License and Collaboration Agreements Â License and Collaboration Agreements 10. License and Collaboration Agreementsâ€‹Apollomicsâ€‹In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Companyâ€™s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:â—an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; andâ—a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. In 2020, the Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize any revenue under the clinical supplies agreement during the six months ended June 30, 2024 and 2023.The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $9.0 million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $75.0 million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $105.0 million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to 15%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. The Company did not recognize any milestone revenue under the Agreement for the six months ended June 30, 2024 or 2023.The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event. X - DefinitionThe entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones. + ReferencesNo definition available. + Details Name: glyc_ResearchAndLicenseAgreementTextBlock Namespace Prefix: glyc_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definitionn/a + ReferencesNo definition available. + Details Name: glyc_ResearchAndLicenseAgreementsAbstract Namespace Prefix: glyc_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events Â Subsequent Events 11. Subsequent EventsIn July 2024, the Companyâ€™s Board of Directors approved a streamlined operating plan that includes the exploration of strategic alternatives focused on maximizing shareholder value. The Company concluded, following feedback from the U.S. Food and Drug Administration, that the regulatory path forward for its lead product candidate uproleselan for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision was not related to any safety or medical issues or negative regulatory feedback related to the Companyâ€™s programs. In connection with the streamlined operating plan approved by the Board, the Company has undertaken a corporate restructuring that includes a reduction in the Companyâ€™s workforce by 26 employees, or approximately 80% of its headcount. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction, which costs are expected to be substantially recognized in the third quarter of 2024, with related cash payments expected to be paid out by the end of 2024. These charges will consist primarily of one-time severance payments upon termination and continued benefits for a specified period of time. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (10,095,406) $ (10,736,667) $ (8,258,912) $ (10,359,350) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag

Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Basis of Accounting Basis of Accounting â€‹The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Unaudited Financial Statements Unaudited Financial Statements â€‹The accompanying balance sheet as of June 30, 2024, statements of operations and comprehensive loss and stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Companyâ€™s financial position as of June 30, 2024 and its results of operations and changes in its stockholdersâ€™ equity for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. Use of Estimates â€‹Use of Estimatesâ€‹The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. Fair Value Measurements Fair Value Measurements â€‹The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of June 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $18.8 million and $38.8 million as of June 30, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company didÂ not transfer any assets measured at fair value on a recurring basis between levels during theÂ three and six months ended June 30, 2024 and 2023. Concentration of Credit Risk Concentration of Credit Risk â€‹Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. Revenue Recognition Revenue Recognition â€‹The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers (Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidatesâ€™ rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Companyâ€™s license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success.Licensing of Intellectual Property: If the license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition.Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment.Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.Manufacturing and Supply:Â The obligations under the Companyâ€™s agreements may include clinical and/or commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs. Accruals for Clinical Trial Expenses Accruals for Clinical Trial Expenses â€‹â€‹Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses have historically been a significant component of research and development expenses, and the Company previously outsourced a significant portion of its clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, estimated project duration and other pass-through costs. As a result of the Company ceasing its clinical activities, the costs of closing down clinical sites are also included in the accruals. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv)Â the Companyâ€™s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Companyâ€™s historical clinical accrual estimates have not been materially different from the actual costs. Stock-Based Compensation Stock-Based Compensation â€‹Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensationâ€”Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company accounts for forfeitures as they occur.â€‹The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. â€‹A discussion of managementâ€™s methodology for developing some of the assumptions used in the valuation model follows: â€‹Expected Dividend Yieldâ€”The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. â€‹Expected Volatilityâ€”Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Companyâ€™s publicly traded common stock. â€‹Risk-Free Interest Rateâ€”This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. â€‹Expected Termâ€”This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. Net Loss Per Common Share Net Loss Per Common Share â€‹Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Companyâ€™s stock options and restricted stock units (RSUs).â€‹The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Â Â Â Â Stock options and RSUs 16,047,875Â 11,469,764Â Comprehensive Loss Comprehensive LossComprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Companyâ€™s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. Recently Issued Accounting Standards Recently Issued Accounting Standards â€‹Accounting Standards Not Yet AdoptedThere have been no new accounting pronouncements that have significance, or potential significance, to the Companyâ€™s unaudited financial statements as of and for the six months ended June 30, 2024. X - DefinitionDisclosure of accounting policy for Accruals for Clinical Trial Expenses. + ReferencesNo definition available. + Details Name: glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock Namespace Prefix: glyc_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for unaudited interim financial statements. + ReferencesNo definition available. + Details Name: glyc_UnauditedInterimFinancialStatementsPolicyTextBlock Namespace Prefix: glyc_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Significant Accounting Policies Â Schedule of potentially dilutive securities outstanding â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Â Â Â Â Stock options and RSUs 16,047,875Â 11,469,764Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets (Tables) 6 Months Ended Jun. 30, 2024 Prepaid Expenses and Other Current Assets Â Summary of Prepaid Expenses and Other Current Assets The following is a summary of the Companyâ€™s prepaid expenses and other current assets: â€‹â€‹â€‹â€‹â€‹â€‹â€‹

disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Going Concern (Details) - USD ($) 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Going Concern Â Â Â Â Â Net loss $ 10,095,406 $ 8,258,912 $ 20,832,073 $ 18,618,262 $ 36,900,000 Net cash flows used in operating activities Â Â 19,402,204 $ 18,581,713 34,900,000 Cash and cash equivalents $ 22,386,052 Â $ 22,386,052 Â $ 41,792,830 X - ReferencesNo definition available. + Details Name: glyc_GoingConcernAbstract Namespace Prefix: glyc_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent. + ReferencesNo definition available. + Details Name: glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies - Fair Value Measurements (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Level 1 Â Â Fair Value Measurements Â Â Carrying value of cash held in money market fund $ 18.8 $ 38.8 Level 2 Â Â Fair Value Measurements Â Â Assets measured at fair value levels 2 or 3 0.0 0.0 Liabilities measured at fair value levels 2 or 3 0.0 0.0 Level 3 Â Â Fair Value Measurements Â Â Assets measured at fair value levels 2 or 3 0.0 0.0 Liabilities measured at fair value levels 2 or 3 $ 0.0 $ 0.0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesNo definition available. + Details Name: us-gaap_MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies - Stock-Based Compensation (Details) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Defined Contribution Plan Disclosure Â Â Expected term 6 years 3 months 6 years 3 months Maximum Â Â Defined Contribution Plan Disclosure Â Â Expiration period 10 years Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies - Potentially Dilutive Securities (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Stock options and restricted stock units Â Â Anti-dilutive securities 16,047,875 11,469,764 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Prepaid Expenses and Other Current Assets Â Â Prepaid research and development expenses $ 805,610 $ 1,420,642 Other prepaid expenses 589,133 401,442 Other receivables 76,710 175,820 Prepaid expenses and other current assets $ 1,471,453 $ 1,997,904 X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Accrued Expenses Â Â Accrued research and development expenses $ 1,916,629 $ 1,824,689 Accrued bonuses Â 2,561,913 Accrued consulting and other professional fees 441,652 439,192 Accrued employee benefits 545,549 399,763 Other accrued expenses 52,948 Â Accrued expenses $ 2,956,778 $ 5,225,557 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: glyc_AccruedResearchAndDevelopmentExpenseCurrent Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Operating Leases (Details) 6 Months Ended Jun. 30, 2024 lease Apr. 30, 2023 ftÂ² May 31, 2016 USD ($) Operating leases Â Â Â Lease, Practical Expedient, Lessor Single Lease Component [true false] true Â Â Lessee, Operating Lease, Existence of Option to Extend [true false] true Â Â Number of additional operating leases entered during the period | lease 0 Â Â Rockville, Maryland Â Â Â Operating leases Â Â Â Security Deposit | $ Â Â $ 52,320 First portion of Rockville, Maryland lease Â Â Â Operating leases Â Â Â Square feet leased Â 30,000 Â Second portion of Rockville, Maryland lease Â Â Â Operating leases Â Â Â Square feet leased Â 12,000 Â X - DefinitionRepresents the number of additional operating leases entered into during the period. + ReferencesNo definition available. + Details Name: glyc_LesseeOperatingLeaseNumberOfNewLeases Namespace Prefix: glyc_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionSquare feet leased. + ReferencesNo definition available. + Details Name: glyc_SquareFeetLeased Namespace Prefix: glyc_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -SubTopic 30 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A + Details Name: us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=glyc_FirstPortionSquareFeetRockvilleMarylandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=glyc_SecondPortionSquareFeetRockvilleMarylandMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Operating Leases - Components of lease expense (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Components of lease expense Â Â Â Â Operating lease cost $ 188,310 $ 247,359 $ 376,620 $ 479,349 Variable lease cost 138,819 133,022 238,706 316,296 Total operating lease cost 327,129 380,381 615,326 795,645 Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Operating cash outflows for operating leases $ 196,314 $ 280,518 $ 392,628 $ 560,210 X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Operating Leases - Maturities of lease liability (Details) Jun. 30, 2024 USD ($) Maturities of lease liability due Â July 1, 2024 - December 31, 2024 $ 396,555 2025 67,401 Thereafter Total 463,956 Present value adjustment (15,181) Present value of lease payments $ 448,775 Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Operating Lease, Liability, Noncurrent X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Operating Leases - Supplemental Information (Details) - USD ($) 6 Months Ended Jun. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Operating Leases Â Â Â Weighted-average remaining lease term (in years) Â 7 months 6 days 1 year 1 month 6 days Weighted-average incremental borrowing rate Â 10.00% 10.00% Right-of-use assets obtained in exchange for operating lease obligations $ 872,892 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 Dec. 31, 2023 Apr. 28, 2022 Equity offerings Â Â Â Â Â Common stock, shares authorized 150,000,000 Â 100,000,000 100,000,000 Â Common stock, par value $ 0.001 Â Â $ 0.001 Â 2022 Sales Agreement Â Â Â Â Â Equity offerings Â Â Â Â Â Issuance of common stock, net of issuance costs, shares 0 9,822,930 Â Â Â Price per share Â $ 3.01 Â Â Â Aggregate net proceeds from stock sale Â $ 28.7 Â Â Â Common stock available for sale under agreement $ 66.0 Â Â Â $ 100.0 X - DefinitionAmount of common stock remaining available to be sold under the terms of the agreement at the end of the period. + ReferencesNo definition available. + Details Name: glyc_CommonStockValueAvailableForSaleUnderAgreement Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-

gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Incentive Plans (Details) - 2013 Equity Incentive Plan - USD ($) 1 Months Ended 6 Months Ended May 31, 2022 Jan. 31, 2022 Jan. 31, 2014 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Incentive plans Â Â Â Â Â Â Â Period from date of termination that any vested options shall expire Â Â 90 days Â Â Â Expiration period Â Â 10 years Â Â Â Unrecognized compensation expense related to unvested options Â Â Â $ 10,012,044 Â Â Period for unrecognized compensation expense related to unvested options yet has not been recognized Â Â Â 3 years 2 months 12 days Â Â Intrinsic value of options exercised Â Â Â $ 4,091 $ 54,083 Â Cash proceeds from exercise of stock options Â Â Â $ 5,398 53,882 Â Shares issued from exercise of stock options Â Â Â 3,250 Â Â Fair value of shares vested Â Â Â Â $ 2,182,608 $ 1,090,699 Â Authorized shares Â Â Â Â Â Â Common stock authorized Â Â 1,000,000 14,257,627 Â Â Shares available for future grants Â Â Â 94,036 Â Â Maximum number of shares that may be issued pursuant to exercise of incentive stock options Â Â 20,000,000 Â Â Â Increase in number of shares of common stock 2,619,622 Â Â Â Â Â Â Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee Â Â Â Â Â Â 4.00% Stock options vesting based on performance Â Â Â Â Â Â Incentive plans Â Â Â Â Â Â Â Maximum fair value of option excluded from the unrecognized compensation expense Â Â Â $ 825,353 Â Â Stock options vesting based on performance | Employees Â Â Â Â Â Â Incentive plans Â Â Â Â Â Â Maximum fair value of option excluded from the unrecognized compensation expense Â $ 681,766 Â Â Â Â RSU | Employees Â Â Â Â Â Â Incentive plans Â Â Â Â Â Â Period for unrecognized compensation expense related to unvested options yet has not been recognized Â Â Â 7 months 6 days Â Â Upon first anniversary of start date Â Â Â Â Â Â Incentive plans Â Â Â Â Â Â Percent of shares subject to option grant that will vest Â Â 25.00% Â Â Â Each month after the first anniversary Â Â Â Â Â Â Incentive plans Â Â Â Â Â Â Percent of shares subject to option grant that will vest Â Â 0.0208% Â Â Â X - DefinitionTotal number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee. + ReferencesNo definition available. + Details Name: glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee Namespace Prefix: glyc_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Definitionn/a + ReferencesNo definition available. + Details Name: glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract Namespace Prefix: glyc_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement. + ReferencesNo definition available. + Details Name: glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options. + ReferencesNo definition available. + Details Name: glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions Namespace Prefix: glyc_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment Namespace Prefix: glyc_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Company's Stock Option Activity (Details) - 2013 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 6 Months Ended 12 Months Ended Jan. 31, 2022 Jun. 30, 2024 Dec. 31, 2023 OUTSTANDING OPTIONS Â Â Â Outstanding at beginning of period Â 8,273,800 Â Options granted Â 5,756,875 Â Options exercised Â (3,250) Â Options forfeited Â (747,095) Â Outstanding at end of period Â 13,280,330 8,273,800 WEIGHTED-AVERAGE EXERCISE PRICE Â Â Â Outstanding at beginning of period Â $ 5.29 Â Options granted Â 1.85 Â Options exercised Â 1.66 Â Options forfeited Â 7.39 Â Outstanding at end of period Â $ 3.68 $ 5.29 VESTED AND EXPECTED TO VEST Â Â Â Outstanding options Â 10,771,055 Â Weighted-Average Exercise Price Â $ 4.47 Â Weighted-Average Remaining Contractual Term Â 7 years 2 months 12 days Â ADDITIONAL DISCLOSURES Â Â Â Outstanding options exercisable at end of period Â 5,572,477 Â Weighted-average exercise price exercisable at end of period Â $ 6.11 Â Weighted-average contractual term outstanding Â 7 years 8 months 12 days 6 years 3 months 18 days Weighted-average contractual term (years) exercisable Â 4 years 10 months 24 days Â Aggregate intrinsic value (in thousands) outstanding at end of period Â $ 50 Â Employees | Stock options vesting based on performance Â Â Â OUTSTANDING OPTIONS Â Â Â Options granted 2,509,275 Â Â Newly hired employees | Stock options vesting based on performance Â Â Â OUTSTANDING OPTIONS Â Â Â Options granted Â 584,200 Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Summary of RSU Activity (Details) - 2013 Equity Incentive Plan 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Restricted Stock Units information Â Period for unrecognized compensation expense related to unvested options yet has not been recognized 3 years 2 months 12 days RSU Â NUMBER OF SHARES Â Unvested at beginning of period | shares 117,157 Vested | shares (58,581) Forfeited | shares (9,581) Unvested at end of period | shares 48,995 WEIGHTED-AVERAGE GRANT DATE FAIR VALUE Â Unvested at beginning of period | $ / shares $ 3.81 Vested | $ / shares 3.81 Forfeited | $ / shares 3.81 Unvested at end of period | $ / shares $ 3.81 RSU | Employees Â Restricted Stock Units information Â Vesting period 4 years Unrecognized compensation expense related to unvested service RSUs | $ $ 103,762 Period for unrecognized compensation expense related to unvested options yet has not been recognized 7 months 6 days X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details) - shares 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Non-employee | Other Awards | Director Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Common stock shares issued 0 13,127 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=glyc_OtherAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Inducement Plan (Details) - Inducement Plan 1 Months Ended 6 Months Ended Jan. 31, 2020 installment Jun. 30, 2024 USD ($) shares Jun. 30, 2023 USD ($) shares Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Period from date of termination that any vested options shall expire 90 days Â Â Expiration period 10 years Â Â Unrecognized compensation expense related to unvested options | $ Â $ 1,419,532 Â Period for unrecognized compensation expense related to unvested options yet has not been recognized Â 2 years 3 months 18 days Â Fair value of shares vested | $ Â $ 474,192 $ 312,314 Options granted Â 130,000 Â Options exercised Â 0 0 Upon first anniversary of start date Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Vesting percentage 0.25% Â Â Each month after the first anniversary Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Number of monthly installments | installment 36 Â Â Increase in number of shares of common stock Â 3,000,000 Â Common Stock Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Â Â Shares available for future grants Â 271,358 Â X - DefinitionNumber of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesNo definition available. + Details Name: glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments Namespace Prefix: glyc_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPeriod from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment Namespace Prefix: glyc_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) - Inducement Plan - $ / shares 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 OUTSTANDING OPTIONS Â Â Outstanding at beginning of period 2,590,400 Â Options granted 130,000 Â Options forfeited (1,850) Â Outstanding at end of period 2,718,550 2,590,400 WEIGHTED-AVERAGE EXERCISE PRICE Â Â Outstanding at beginning of period $ 1.97 Â Options granted 3.20 Â Options forfeited 3.85 Â Outstanding at end of period $ 2.02 $ 1.97 VESTED AND EXPECTED TO VEST Â Â Outstanding options 2,134,350 Â Weighted-Average Exercise Price $ 2.04 Â Weighted-Average Remaining Contractual Term 7 years 7 months 6 days Â ADDITIONAL DISCLOSURES Â Â Outstanding options exercisable at end of period 1,177,896 Â Weighted-average exercise price exercisable at end of period $ 1.98 Â Weighted-average contractual term outstanding 7 years 6 months 8 years Weighted-average contractual term (years) exercisable 7 years 2 months 12 days Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Weighted-Average assumptions (Details) - $ / shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Weighted-average assumptions Â Â Expected term 6 years 3 months 6 years 3 months Expected volatility 101.79% 81.26% Risk-free interest rate 4.17% 3.54% Expected dividend yield 0.00% 0.00% 2013 Equity Incentive and Inducement Plan Â Â Share-based Compensation Arrangement by Share-based Payment Award Â Â Weighted-average fair value of the options granted $ 1.49 $ 2.00 X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013AndEquityInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Stock-based compensation expense Â Â Â Â Total stock-based compensation expense $ 1,207,322 $ 858,088 $ 2,399,402 $ 1,728,268 Research and development expense Â Â Â Â Stock-based compensation expense Â Â Â Â Total stock-based compensation expense 335,445 229,422 683,687 467,353 General and administrative expense Â Â Â Â Stock-based compensation expense Â Â Â Â Total stock-based compensation expense $ 871,877 $ 628,666 $ 1,715,715 $ 1,260,915 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License and Collaboration Agreements (Details) - Apollomics, Inc. $ in Millions 12 Months Ended Dec. 31, 2020 USD ($) Research and License Agreements Â Up-front payment received $ 9.0 Milestones based on achievement of certain clinical and regulatory events 75.0 Milestone payment upon achievement of specified net sales thresholds for all licensed products $ 105.0 Maximum Â Research and License Agreements Â Tiered percentage of annual net sales 15.00% X - DefinitionThe amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products. + ReferencesNo definition available. + Details Name: glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: glyc_ArrangementsAndNonarrangementTransactionsLineItems Namespace Prefix: glyc_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events. + ReferencesNo definition available. + Details Name: glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe entitled royalty payments to be received based on a tiered percentage of annual net sales. + ReferencesNo definition available. + Details Name: glyc_TieredPercentageOfAnnualNetSales Namespace Prefix: glyc_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of up-front payment received under terms of the agreement. + ReferencesNo definition available. + Details Name: glyc_UpFrontPaymentReceived Namespace Prefix: glyc_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=glyc_ApollomicMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) - Subsequent Event $ in Millions 1 Months Ended Jul. 31, 2024 USD ($) employee Subsequent Event Â Reduction in workforce under corporate restructuring | employee 26 Percentage of reduction in workforce under corporate restructuring 80.00% Total charges in headcount reduction under corporate restructuring | $ $ 3.6 X - DefinitionThe number of positions eliminated during the period as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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

H+S(/TW0.)OY_8$^!CSQEWH=/!D\#OKP2/?6?DP7%LL"NX[_9JB"D#AH6 M+*'5;P20?<<+^D[0S;/?X-D-QC\%/_8<;S1RQI-=2A %36A\/U3]U?BQT_?@ MI!H\"0GY.OAXNQ)^+V#$=P.#7%&;+-MZJBH1ZD M;"S41@>WWAXC*-D:Q7:K1SA@CZ7\)X_T1WW'FYAWY)X%GN\$^(8>M/&U>7LO MWM0HZ5_'T ?CON-7K]<;C#=@M4UE'X0 M_1[[\BY8 =\VT*=MQ!PJ?\BYKVMW+.)L_KONRY_OYNY3ZR_$21DSP"%#& MSD+OU_5=;U0O#MQ!_WE-E@9=/-5NI(!C8:]>V/C8?.NX,X31?PULP8(XU2ME M%(5J;=\E:A7UZV+F[S.M7I/HS;?E:Y$K"X)2AU?L#Y?=*Y=" M"*/Z'U0)ZRO#<>,QTU(NC\<4?TK MKYP).!M#"Z(#;I3(5.+C#\KY;9;C$8QDC6?00W_L#!NO"G@P1 WP7^.*?Y MD\:5:^IW^K&H:XRIT$U XI96X\'8Z8W'3 =N_76_^ MGS1^F)&+([)9^?H+839'FYC<:U=7J%RY3\\..>KGY>7 #WETKEY1=D4/WNY]V_ %!+ P04 M" -@ A9.$(-*LX" S!@ &0 'AL+W=O99=IIJ(4TRF\38K9M-;$M*&KQUX%NMA=O.4=GU-!DF3X$[MN:PI!-+9I!%+O$?ZWMPZ7J4]2RDU&B^M 8?5-+D8GL_'(3\F_)"X]GMS")4L MK'T,B^MRFF1!$"HL*# ('E9XB4H%(I;Q:\>9]$<&X/[\B?U+K)UK60B(EU;] ME"75T^0L@1(KT2JZL^NON*OG)/55OGX"^LN=SA*H&@]6;T#LP(M33>*S>X> M]@!GV1N ? ?(H^[NH*CR2I"839Q=@P09S!8F1=2(9G'2A$>Y)\>[DG$TNS:% MU0@/8N-DA(SAGA:[-#S#IV_@3Z%&VNH]O#9E%B^Q*>LI)>3/\F9YP<)O[5F M *L"/(L'Q_@&_7EC2+?Z#_+Z]#CU]&A(W0K3&;OWPU/LT\' MM(U[;>-#[/_4=AC]<0#[!/!0(UQ:W0BSA5*68"QQTQ36E1!")#;0.+N2L9LL M?\IHL)($W-= C/5R [I[3 R/"?P4V#]%0/ X&KPXIQ:^(PWY E9"M:+K-<7- M+DR!/7W5*@5"V]80V HD>3!L.=P_Z!RC@$[A/7+Z$0"'5C'3L+UU\Q+3*-/XK'L(%WABCHN2ERQ635L/00%BPMBI8\WJJW#8R4?46V/J1;F. 3]LJ:=X' 1 M]-?=!-3=Y&M?4+K7R!K=,MH5ZPW7UO5T'^T=\:(S@N?TSDYOMA%M*XT%AQ=!L\.$D ==95+<@VT1;6%ABDXG3FET=74C@_EJ$ _K_B=D? M4$L#!!0 (V "%DK7.C:G0< +43 9 >&PO=V]R:W-H965T9&&9'4MITXMY-7.^;M0*17%Y]K8<#VI8FPNYO-0M5*J68>8:9?%DXWPM(R[]=AX:KV3)AVHS7RT69_-::CNOY>)[' S<E4O1:*L^ M>!%274N_?Z.,VUU/EI/NQD]Z6T6Z,;'Y:N16?53QY^:#Q]6\UU+]6MF@G15> M;;XGM\N+-Z#X=Z?].XX=L:QE4&^=^567L;J>O)J(4FUD,O$GM_M!M?&\)'V% M,X' BEV6/3F?B"*%Z.KV,#RHM<6A]&!5XLG#JS: ROV.QMB+_\KH[RY M\FXG/$E#&_W@4/DTG-.6DO(Q>CS5.!=O?M0%$%9"VE(@,B/7SDO&ZWKE0+\ M,5S-(RR1_+QHM;[)6E=/:#T3[YV-51#?VE*5A^?G\+!W<]6Y^6;UK,+ _)3L3 M)XNI6"U6I\ H.^G#/F%])_]RV%GKZ>-;J8 N0B,+=3U!A03E[]7DYINOEF>+MRV=\/NU]/GU.^S_V^7FMR\5, !7-XINO7JT6)Y?BMH&$JW4QW'IG*2 (3JP4 M%-2-M'N!0\JK4F@;G9"B.-+EDQGM;,ACNA\;. (8I1"KL;VC'YS=BO_CS_$4 M3M7P;2TKADRS5W[]_]V*Y.E^R=KXX>W6> MH_G0JNU=\[)1*>]"96&TJ?:&6E,A4E A'_I.*U,> SGQMM)63L4GJ7?23D4? M/Y]^+PN9\HE/RGL=G=\?S\3/J+F, A)0A\[_'M?#-&V]M 3C@.(%\OKZ[/SU M)8P(}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

:P:$2.4##K#ULE\&3ESC*[)K^V#<]A'E 76S ["+*W;T;3Z-,IV_^) M[%D1DJ$(R=DB+.@6712'&V2'&W3*=,#=%A.BU\4[Z(+VEJ=4/F+TTW\FZY*07] M7PE;HHPN9R3+=&.DVZ!N?"?
>:Z2^]LN*)B\8ET#G6TV]UF_&PO=V]R:W-H965TRSA4@3OE6,5K 02&[+DH@_]\#X M?NIXSO.#![HIE'G@IDE--K $]5@OA)ZY'4M.2Z@DY142L)XZ=][M+#;UMN G
MA;WLC9%QLN+\R4R^YE,'&T' (%.&@>C;#F; F"'2,GZWG$[W20/LCY_9/UOO MVLN*2)AQ]HOFJI@Z8P?EL"9;IA[X_@NT?B+#EW$F[17MVUKLH&PK%2];L%90 MTJJYDT.;0P_@A2< ?
@OP+P4$+2"P1AMEUM:<*)(F@N^1,-6:S0QL-A:MW=#* MK.)2"?V6:IQ*%P)0JQ/TZ:# "PD2D2I'/U0! LVV0D"ET)V4H"3Z@);-2B.^ M1I?#KN:@"&7R6A,\+N?HZNUUXBJWM3'S
S5J5]XU*_X3*;]OJ!@7X/?*Q'P[M9^?A<\@TW+/PX"7H2Y,!M/$,I=!0QY;: M=)I=.L91[.'$W??]'9=YH8_CT._J7D@/.^GA6>G-6M6M@7,Z&YZH)R :3[P@ M>*?TN"S$7GA*9M3)C"Z0*2 #NB,K-
JPP.OKT*!X=!7E-%V]F2A>V\:XXDJW63LL]$$(PA3H]VO.U?/$]-KN:$W_ E!+ P04 M " -@ A9Y+==5M " "W" &0 'AL+W=OP,;W')]S[6LSWG#Q* L A9[JBLF)4RC57+FNS JHJ;SD#3] MDG-
14Z6[8NG*1@!=6%!=N7@T"MV:ELQ)Q_;;G4C'?*6JDL&=0')5UU0\WT#% M-Q/'JF#BQ@Q:0TU6E[OGF,VS]$,.7\4K:)]TL6'DH&PE%:^W M8*V@+EG[ID_;/.P!O. $ &\!^%R OP7XUFBKS-
JZI8JF8\$W2)AHS68:-C<6 MK=V4S*SB3 D]6FJ<2J^S3*Q@@3X^Z7TA0:+W:-8N*.(Y.AJ]N 5%RTJ^U7$/ MLUMT\?KMV%5:AV%SL^V<-^V<^,2<7U?L$OFC=PB/<- #GP[#;R'3<,_"_9=P
M5[OO4H"[%&#+YY^9@CY#+4/0SV J[4HV-(.)HTM)@EB#D[YY86C#WWV_A/9 M"[-^9]8?8N_,&F8JL@)1MM#;?JW+N=%J1 ,9*&E#BVU.1[6J9=X88B3L;O> M-]@3%^,@C/_$O=_>=-
J#L[3/.5N=4#A(\+?KU)*1/1N8A-JQWV^#=#;(638R MSJ0^;$JVM(O 50$"-8+G(,T922N40[]+2'34*8T&E7ZW&:4[O0,; M.SJ6B9,@/E Y.-L_UFW<>8G/R_J B[BH'!"PB@Z]'$<1S FA$0'Z7;WKA5S
MI7^C8EDRB2K(-7)T&>F$B?::;#N*-_:FF7.E[RW;+/2?!0@3H,=SSM6N8RZO M[E\E_0U02P,$% @ #8 (6=H,Q\+V P ?!0 !D !X;"]W;W)K&ULK9AM;]LV$,>_"J$50PL$T8,?F]D&$JO%-C1;D*#;
MBV$O&.EL$Y%$E:3L!-B'[Y%29"N3F7EA7L02Q?OS[B?>4>1LQ\6#W H\IAG MA9Q[&ZY*"]^7R09R*LJY"04^67&14X6W8NW+4@!-C5&>^5$0C/V*4R5L"-(+**KB#CN[D7>L\-
MVR]4;K!7\Q*NH8[4%_+&X%W?]N2 MLAP*R7A!!*SFWF5X$8/VL_MD$C\'<4PE+GOW)4K69>U./I+"B5:9N^>YG M: (R#B8\D^8_V=5])Y%'DDHJGC?&Z$'.BOJ7/C8@#@RBX(A!U!A$+PS"Z1&#
M06,P>#E">,1@V!@,#9DZ%,,AIHHN9H+OB-"]44U?&)C&&L-GA7[O=TK@4X9V M:O%["8(J5JS)%T!\DKR/05&6R0\S7Z&^[N4GC=95K14=T1J3:UZHC22?BA32 MKKV/?
K7.1<_.7456P5^KXIP,@C,2!=&09-K!']^6=I'+4K0B (}2/_X03J8_M]>C$=IUK^D0&H98)Q^3K74S>O_M@B7'0OH"!D1\V\^@),?+(/>ZTP[%?0E>%" MEC2!N8>I+T%LP5M@E..@+\JE2['8D5B'W+
E-[2I+\R$/2,W0M>.A&;DTV,) M*8-"G>%DEI(+34BNE2+'8DUH$W;>%-W[S63%V2=2+*[%Q@?CF7&TD7.%SJ1:[4NOBB_;X(GO"?JNH MP*\1O74V 'N7";O(R0"C?ZW#@P#_NFMQ[&K0+IG]?B.T?
I3K4L8Q)_]WRCK= MC#A5BUVI=Q-L=>DB2*E1]&PO=V]R:W-H965TPS9LW?C-F&&8'I;^8G'.+G@I9FKF76UM-?=]D.2^8N5$5 M+^')5NF"69CJG6\JS=FF-BJDCX.
^@43I;>8U6MW>C%3>RM%R>\'T,ONB8/KK M+9?],/="[WGAH]CEUBWXBUG%=OR>VT_5G8:9W[%L\,%+(U2)-_.O7?A=)TZ M? WX+/C\'(V14 *@U!,?9>X';$)<\LXZ!P>V1+
[F4C@BV\6_+Z74NG>'Q M^G]MUH[:'E@AB^5_$=L;#[W4@]M^);MI?VH#K_S5D_L^#(E37U%AP:;8]E M>V-5T1K##@I1-G?VU,;AR !XQ@UP:X#[!M$K!J0U()=ZBX]#Z%(/<6MU2_<;
M[77@5LRRQ4RK](.#6QN4$>_MH9XB=*=DWNKX:D .[OX]^*:65'NT)\W,M[/Q^9GK<_ ; MQB=^Q2=!'U1I(!#\C'.!H
M9#_+R\W)F)S,YWW]W=Y/@D&Z$T%J/O(*WYGTCZ6Z(8O&R5R5FJ*97SN01DS M7#]R;_'3#R$-?AV+\S7)5M1Z!S[T3O:9"-3QHZEHF&A-8O[M/CPNPC0E83#S'X^#/(3A*"'QY!2V&L)
(0BGNL:V'L"B9D.B%[41RW$F.STK^ MS+1@#Y)_0W%#$A\K)FD:][J0LQV DP+BG> C#)$T"VE,\A)&0X@D=5TP[Q?2L MXK^591*I"U--AWO 28C[PD=@:4#2L"=\"*-A3'!?^!"63&(:Q>"DTYX
M,).CBHD-@JX'L4+M7>D192;W4-UA@&S.40'AV&L.'8I]*4L2SHB0P@INIF-1 M2JY9FZY)MKHFV?I*9"?92[OLI1?6ILSE$3K1+;2>ILYE[S";L12EPYHUH22, M>@=Y",-I$(=I[R /862"*>[!UD-83 -
\5"B;4/A';57!]:[N9PV\DW!"F^]I MM]JUS._J3K&W?AM.E^'(^@I:[*8C?]%O^O,/3.]$:2!P6W 5W"3PUNFFYVTF M5E5U4_>@++2(]3"'WP2N'0">;Y6RSQ/GH/OQ6/P*4$L#!!0 (V "%DT M+5MYT (,H'
9 >&PO=V]R:W-H965TH-)*GC L]<3:(^:7KZG0#&=47,@=AOJRDRBB:KE[M.E= EV50QEW?\R(WHTPXR;@_9%?/]1R2%AIE5@<;@HR)ZI\^U>MP M%!!')P+\.L
ON2NCDG)*D29C)7=$V=E&S3;*5,MH \>$W90Y*O.5F3A,ON2@ M*#*Q)G=@DM/DG-Q3+!1#9CIR1;@=)IS1!>,,]^1L"D@9UV_'+AI_J^*FM==5 MY>6?\/I4B LR\'K$]_R
?)M/R=GK9S*NP6]R\)L<_%)W<$*W&WA90!MJ)1FT M2]JK<*ESFL+$,6==@]J"D[QYU8^\=QW @P9XT*5N%H+O2;]>AW,RA12R!2@R MJ,?:>"O%]%2'T-VV;#$91&(9C=]M"$C0D02>)
<0O;W*JH\,@MB@.OWVX6-F9A M1G7#9BZL4)0;9:=L>T;0CKV(FJ@HFXHB92W\40OEB"(!J,P:E^#N+&+.^UF M%EX@V5)> *'+W^:*FQ]';03Q"X+S?M@?GMB%84,P_>"YL+D=&\Y=!O(\,79
M"X)A')\X>Z,&9-0)\JST],C=X<[VR!PI@N6Q@+=,4)$RRLE,:E86\Y\W3VA? MA@4'Z9KT68JTFM=V&MVCTFQ?N7NJUDQHL^@K M@^-=Q&9[5?5R5!V4>5FM%Q)-[2^;&_/8@K(3S/>5E'CHV
>@>;Z3OU!+ P04 M " -@&NQA0C " Y"0 &0 'AL+W=O&Z,LZ@I'+(*V#X M9K*2@!-#*@L7-_S K>D.7/"F5F[%>&,UZK(&=P*(NNRI.+Y"@]^
MG3LC9[=PEZ>9T@MN.*MH"DM0]]6MP)G;LB1Y"4SFG!$!ZE[S.;[(FUO#/[D ML)5[8Z(S67'^J"?7R=SQ=$!00*PT \6_ #2R@*#01AO&WX71:EQJX/]ZQ?S>Y M8RXK*F'!BX<\4=G<.7-(
FM:%^J.;W] D\^IYHMY(P$$@0&W#"3Q]&@?>U2YWW)(O>B>Q MN4FKW*2//7PP5QR2 =V@A"E@4=)E3TM9:"] E&2DYR19Z!"=A[=7@_'*ML? M[I24]AX$)*'/?'
L<]1.,3!YD9'DZ:0YT/&UU#/#U.QYS%8E<.5EP@G=843RET M2=A+?]R$ENS(*&Z$99OBV :$-\N:<[6;: ?M:RG\!U:! + P04 M" -@ A9]>X"\0(${ "[% &0 'AL+W=O:^:,#X^WGLYXMM[,6)LC>>
CT+4MSOK02(8H'V^9Q AGF(UI M+I_L*5:YX(OY) (56"O%@4^P!;$2_',Y)W=4'8D@YP3FB,&^Z6U=A\B5PMT MC;\)G'CK&JFNO%+ZIFX^[Y:6HUH$*<1"(;#\.<(&TE219#N^UE"KB:F$[>LS
M/=*=EYUYQ1PV-/V'[$2RM.86VL$>EZGX0D]_0MVAJ>+%-.7Z/SI5=6>^A>*2 M"YK58MF"C.35+_Y6)Z(ED)Q^@5<+O$O!Y!W!N!:,KQ5,;L'D6L&T%DRO%?BU MP-
>YKY*E,QU@@5<+1D^(J=J2IBZT75HM$TQR]69M!9-/B=2)U5;0^"VAZ0X8 M_PV%7TLBQJ./ 0A,4OX)_8Y>M@'Z^.$3^H!LQ!,@".2HY><"'XG"^7U$TE3
M^9+PA2UD@Q36CNO@CU5P[YW@/GJBN4@X"O,=[+IZ6W:DZ8UW[LVC-PC\]\Q' M:.S<(<_Q)CWMV5PO'_?(@V'Y$V92[KX;/1R6!Q W\K[HT;!\7!<%:_?J+ZSM_ M]'EC$A:8A(4F89$A6,?
32>/I9(B^VM LD],Y5X/^[CR<<2D2RLB_ER.PLK@" M3C50+5/'E3MUJK^%?6S[-QCZ5OJZPCJ]8<.K:T:&&MC)_+3) /2&$!>8H2-. M2^C+> 6:M3KDC!S'O3,("D[#0)"PR!.OX.FM\G?
WO)6MFTE.3L, D+#0)BPS! M.I[&T_G@V/U,^[GGG<_OJ@7##;Y5JM,PB)#L(Y5]XU5]X-6/3,B;2B 51[T63 (N'7T5;!Y MRZWQZ'*="4Q&#$W"(D.PCE6N\V/?YPR:M3[(E>^ !>AQ5# : ^PXVC.:50,,
M<;E]N[!!L&WFEC3U$]CHS5"D$S?9D EFZK"O+YGE)QOE$!FO/*U7]02P,$% M @ #8 (66PDP+-@" T$< !D !X;"]W;W)K&ULQ9SO;Z,X&L?
_%2NW.NU*NQ,P"4EZ;:29\N/FI)&]J;KWV@$GX09PUC9M ML[H__FP@ 5/J-M='_ -B2H#G8\SC6V^=KA^8OR'V%,]T7.1E^)FLI?R<#6= MBF1/"R(^L0,MU9$MXP61ZB/?
3<6!4Y+6044^Q8[C3PN2E9U=;WOCJ^O627S MK*1W'(FJ* @_?J$Y>[J9N)/3CN_9;B_UCNGZ^D!V])[*A\,=5Y^F9TJ:%;04 M&2L11]N;R6?W*O:P#JC/^#VC3Z*WC?2E;!C[H3]\36\FCJX1S6DB-
8*H/X_T MEN:Y]JEZ_-%")^1LP?V\)?AO@OS=@T08LZF0U=[=.34 D65]S]H2X M/EO1]$:=WSI:920KM13O)5=',Q4GU_>2)3]^T\E,T2TKE,(%]J37R&_I:)K34
M0D%W.2D%^CF@DF2Y^$4=PX[KH?"/*I/'P7GJX,-]@'[^Z9?KJ505U,5,D[8R M7YK*X%E(?&B/JRWQ4W5CSG<'G^[.%VP%?B-'Y+F_JLO% M>*0ZM_;H?Y#RDRT\>'>X.QN[&6^$5SK'^Z-A,?V\(
FYVOW+)GP MSCKU:I[W"J\3V4&++<4Q;#6 V#M!-^I4XD(3>3%2;+2A_I)/U7__B^L[?QC(+ M"0L@82$D+(*$Q4 P0Q^SLSYF-OKZCO*,I6C+68%2(BEB6R0I5RUFTYS)/9&(ME$?T2(54;1T[Z-
T"B3W)L%!+H-'*H=;2F!JLB$O5 D+[!?G.NA("1^5 V0U(DA8 M# 0SY."?Y>!;[]A#R6G"=F7VIVHLDO[2+45:INJ<7A.=$LB&:I*LU49DXZU MN$NE PD+(&%A _-KF'X,>E3:]-
=2\]P468(>25[50YV3AN@SY4DFQA5CI5ZJ&$A8 M D+ER^:H)FS<@?-S\N3YC-GZ9EGQ4#U,K*\.F=Y9+X7<=U-:$ MHIEI[HG-U^[DM>,"\DBRG&QR6C]I;BM9<8IVG)1RO(4 -2Y!:0$H+6QI?5FL
M9H[G#S4!ZE1"T4Q-=%ZE:_?SOI'GK*@*5%;%AO+>D*"VN0MR1!MZ&DD>*BXJ M)1/M.?0'E-EY1N7MH26H[PE*"UI:/_W8&6_0)U.4%H,13/UU)F=KMWM_%HF MG!*EBZQ\J2FUE?
2ZFE&!^"^3X+LK'P\>L6[M];@X]Z#6)2@M J7%4#13'YW% MZ=IMME-[2E((E!*F\D]5<[F6',WC/!4GY1FBBH9 M%YJCCQA&K*YI)B4=G>RSWX6+VSE04Q64%H+2(E!:W-
)6O<;$^>1T\P>FACO3 MU+6[IO?]7JY^=M;":U:^-)-^]<(NU2N.2@/4/ 6E!:"T$)06@=)B*)HIH=-58NMENYI^YR:[AV3=.CQN!)7J4G MBU=W4&].&XX)S5Z%2X4&2@M
:6%+ZSMW2SSWYH/)F@BTU!B*9DJH,WRQW?!] M?V^%_HW"XI"S(QWW"NT%72P44\8E!:"TB)06@Q%,^74N\K_DYX+U(QN:?W>P5^Z"W_@_P6@I8:@M B4 M%D/13 EU?C6V^]7?[Q_>[))
S6E06@!*"T%I$2@MAJ*9.ND\;#S_<)<$ZCN# MT@)06@A*BT!I,13-U$96G36.[-_W_6E]IK];%X@,UOD%IX1L)6)S65OJO+JT$ MK4\,13,%UYG=V&YV/QR4H+89%_H'(Z5JH+@@_-
BLP2):M>%W,Z3]E>5Z[0*." O6<06E!2S,G<_!\,#4/6F8$ M2HNA:.;/7CLOV;-[R2%)]DT'C,A6TF9*\T7O-*8+_A268#2 E!:"$J+0&DQ M%,V43^^Y^R,/U= & &I06@M!"4%H'28BB:J9/.(/:LQB)H?
V0OZF)!@3K) M+_&D:H)^RJE,TK&LY[SZ^? M^5R_=&6P_XM[%;@C^T/W*FI>+M/AFW?=?"-\EZF'\YQN55'.I\5\@GCS^ICF M@V2'^NTE&R8E*^K-/24IY?H$=7S+F#QJT 6<7^*S_@]02P,$% @
#8 (M63PR.D=7!@ PR8 !D !X;"]W;W)K&ULM5I= M<]HX%/TK&K:SF\PT8,M@DRYAAF"W9:<-#)!V7Q50P%/;HI: ,K,_?B5C_!%! MI^(EL8SNN;['TM6YLGI[$OZ@:XP9^.5[7UHK!G;?&BUZ&*-?
42;9(,#_LLK M"7W$>#-@FQ&@9&?E>"VJ:V?*1&S3ZO>C>).SWR)9Y;H G(:!;WT?AX1%[M9/_0T!NG&U-WM6;B1JO?VZ 5GF'VO)F$O-5*4):NCP/JD@"$^,6A,=_ V(8F M#*(>WUR\IYEX($)Y(>2':
(R6#PU-/!'V\((",3_[? 0>YY XL_Q,P9M)#Z% M8?;ZA/XQ"IX'\X(H'A+ON[MDZX=&MP&6^!5M/38E^\\X#J@C\!;$H)%?L(_[M:@VPV%)&- -B8/X'O!L?_Z%=,1,: XU0;P-@
%@R@^8:!$1L818.W/+1C@W;$ MS#&4B <;,=3OA60/0M&;HXF+B,S(FH?O!N*]SUC(?W6Y'>O/&%G\N!/,+<&0 M'PX412]D+NHB8+#7Q1$G\KY0TPW@_-R*^Z-@ M@0/Q-
L'$0P+H>6:#FW>WX!UH ;I&(:; #6X;>'V\997Q>N,$*(9>\,H- M$@KV"#0Y=4#=A'*69= M+H]@G0A,+"*[?A=:1E?3>JU=EB9%3G,T=1*:.G*:HLQ$P2I$:NH2U"T1I!NPJQE&<=R4.Q;S4"
[X^R3X>^GR]-T9??H\=^R[P3=G.OCD .=? M9SH6R MG.0E%GKQ\$4+I]Q%777ICM-S^2<>";:LXJU6YS3.7ZG0HU^G)K$;QK#XI4[1 MN:\^BTI%?
8R638QF4]>%%Y#'\-4TT.YIB]1N,BD0\;3(2#I*$D*3G>/ .T MI]38O2 UGH$R8R@C@>I60.5930L"*"(SK-Z$WF_S0[12G:5%@UGGKH=4Z)K M)TY@^VUZKU%9P+2R@/+*8K!:A7B%& 8N9]8-
J+L .^1M,;AQ \!.GZMNL\/W MLAR@M 2)'T\3<>.6!,P7_Q=\33(K3#E G:CA\? M22!8BSYD!]6Z4NZH-G5*:QA5:'F2TQH&FBH^LD&E-8Q2-%L56I[!M,Z!EWT: MD.S)P?)F/NQH][#XV6^\ UF[(YRA6-
Y>55CQ* MT6Q5:'G"TZ('RHN>2^>RTHI'*9JM"BU_X""M>(PS%<_YN2Q'J'W>H**@Z;9A MZ1NY*J]'7EJ94S\^#E?1Z2G*M> V8,<#0,G=Y(36(#J7U$J['X]W?47ABHL<
MX.%7;JHU+1Y*>#PQ=6PPLHG.$+T0QH@?:XQ6N)0=.^_OQ+"3@WA(#FWUO\? M4$L#!!0 (V "%EG,.#7 P0 L/ 9 >&PO=V]R:W-H965TGZKX0VWB>>>;%8T]WP\6S7!"BX"5+F>QY"Q66%[OX
MXP7)L#SG2\+T7\,S,JST5,Q)N10$)[E0EOIA$#3]#%/F];OYVDCTNWRE4LK(M2(!<91D6VR%)^:;G(6^_,*;SA3(+?K^[Q(,R(6JZ' D]\PNA4&:$20-T,0P#
(Y#O>*1D(P_&8$QYXOS93.Z2GA<81B0EL3(06'_6Y)*DJ4'2/+[O M0+U"IQ$\'._1KW/CM3%/6))+GGZCB5KTO+8'"9GA5:K&?'-+=@8U#%[,4YG_ MPF:W-_ @7DG%LYVP9I!19K_X9>>(
X'Z,8%P)Q#FO*VBG.455KC?%7P#PNS6 M:&:0FYI+:W*4F:A,E-#_4BVG^A/%X^EY^KQ)(M;$Z__^&VH&?S@8UPO&=1=Z?T0$Y0EH?K!B@L1\SNC?FG\\ MF /DQ8R)/GTI-
K8IKC>OM:UZS)=FBX2MKAP++/(%Q!4^$F*.Z!ZNRVLBFWT&D?8'%P8R)FUWZ*[F]N'Z.IL\!B-!S<1 MW(P'7Q_@:O 0P?7@;@R/@$^G424C] ()C,*2>/@?T[F\&BKI6_CV@4-KYT>C
M6UX=R%GGRYP^H=VBH/!UZLM[+E+[F%FGV!0_R4&96%&[LKL2N\3C!J_$I&R M+"-G5357A58=9]1EU%9F%'K'=X;R%GNWTJZK-WH=/$V)\X&MY*@
M&Z!N7PER=]+X,N]VGKC2O5,^7.ANE0BS0^]_XUSM)T9!T?_V M?P!02P,$% @ #8 (6?X&L"O @ "@< ! D !X;"]W;W)K&ULK551;YLP$/XK)R9-F[06 DD[=00I23>MT[I%C;8]:W)
M5L%FMDD::3]^9T-8TI$\]07L\WT?=Y_OCG@KU:/.$0T\E8708R\WIKKQ?9WF M6#)]*2L4=+*2]F2&MFKMZTHARQRH+/PP"*[\DG'A);&SS542RJH47.!<@:[+ MDJG=% NY'7L#;V]XX.O<6(.?
Q!5;XP+-CVJN:.=W+!DO46@N!2A6CW=QE8R^P 6&!J;$,C%X;G&%16"(*XW?+Z76?M,## M]9[]D\N=>P\R7+&Z,]R^QG;?%R J2RT>*V]0T\2&MM M9-F"*8*2B^;-GEH=#@#$TP\(6T#X'# \
8A:0.02;2)S:=TRPY)8R2THZTUL M=N&T<6C*A@M[BPNCZ)03SB0+(]/"'RM$!C-94G%HYO2]@#NM:R92L+F"1)\2[K(.JUE/P[.$7VIQ"5'P#L@ M';$,SL/OV>*X(,^^%$X47<)D>,;GN#
[)L4%EE4A=XCP![Z;'!5,MDQEFK9[MQ?MT.\MK)\"-KEB*8X]:7-.-H)>\?C6X"C[T)?U"9$<2##L)AHX].E6'MC3Z MZG"B%!-KI,%A8+F#0[\YVSFS4ZI/G>%+JO-"9$?JC#IU1F<+A!0I20MMF[7M
M(N#4GL^;H4F[X1HY+CO%-TD0^YO#7/[W&$2#\+KS:H+T#\9*B6KMIJV&5-," M-+W66;N!/G%S[)E]2H.^F&PO=V]R:W-H965T?!F046 M9,K2WY.EW(R!8.@- C.#087#,+2('RK0:Z3*/"?2Q1+,4
M4_0^(A(G]?CP^MW0E= 6I>C&9;V3HM[@0KT^^L*HW CT0)=DV6(_-=OW#/8N M,*A !$<0D\ H^ NF-RCT?T*!%W@HH4+B-%4.MK7M'Z1R)>5IJ0YZFD?H ;,L/
M2&PP)Z)%+7J[6FA4:_@=5@$0:OGP4@ HH;8 N.<;X8-^?+_' MO*WO)D65G?8JU51V)[8X)B\'YBI!^(XXXQ]\'O>SVVP;8I%EL0:J#L5ZHY) M?3PC/&%+-JO-"9$?JC#IU1F<+A!0I20MMF[7M
M(N#4GL^;H4F[X1HY+CO%-TD0^YO#7/[W&$2#\+KS:H+T#\9*B6KMIJV&5-;"

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!="TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 104 219 1 false 28 0 false 8 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://glyc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Balance Sheets Sheet http://glyc.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Balance Sheets (Parenthetical) Sheet http://glyc.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Statements of Operations and Comprehensive Loss Sheet http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 995200300 - Statement - Statements of Stockholders' Equity Sheet http://glyc.com/role/StatementStatementsOfStockholdersEquity Statements of Stockholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Statements of Cash Flows Sheet http://glyc.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Description of the Business Sheet http://glyc.com/role/DisclosureDescriptionOfBusiness Description of the Business Notes 7 false false R8.htm 995210201 - Disclosure - Going Concern Sheet http://glyc.com/role/DisclosureGoingConcern Going Concern Notes 8 false false R9.htm 995210301 - Disclosure - Significant Accounting Policies Sheet http://glyc.com/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 995210401 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 995210501 - Disclosure - Accrued Expenses Sheet http://glyc.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 995210601 - Disclosure - Operating Leases Sheet http://glyc.com/role/DisclosureOperatingLeases Operating Leases Notes 12 false false R13.htm 995210701 - Disclosure - Stockholders' Equity Sheet http://glyc.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 995210801 - Disclosure - Stock-based Compensation Sheet http://glyc.com/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 14 false false R15.htm 995210901 - Disclosure - Income Taxes Sheet http://glyc.com/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 995211001 - Disclosure - License and Collaboration Agreements Sheet http://glyc.com/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 16 false false R17.htm 995211101 - Disclosure - Subsequent Events Sheet http://glyc.com/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 99920202 - Disclosure - Significant Accounting Policies (Policies) Sheet http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://glyc.com/role/DisclosureSignificantAccountingPolicies 20 false false R21.htm 99930303 - Disclosure - Significant Accounting Policies (Tables) Sheet http://glyc.com/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://glyc.com/role/DisclosureSignificantAccountingPolicies 21 false false R22.htm 99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 22 false false R23.htm 99930503 - Disclosure - Accrued Expenses (Tables) Sheet http://glyc.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://glyc.com/role/DisclosureAccruedExpenses 23 false false R24.htm 99930603 - Disclosure - Operating Leases (Tables) Sheet http://glyc.com/role/DisclosureOperatingLeasesTables Operating Leases (Tables) Tables http://glyc.com/role/DisclosureOperatingLeases 24 false false R25.htm 99930703 - Disclosure - Stock-based Compensation (Tables) Sheet http://glyc.com/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://glyc.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 99940101 - Disclosure - Description of the Business (Details) Sheet http://glyc.com/role/DisclosureDescriptionOfBusinessDetails Description of the Business (Details) Details http://glyc.com/role/DisclosureDescriptionOfBusiness 26 false false R27.htm 99940201 - Disclosure - Going Concern (Details) Sheet http://glyc.com/role/DisclosureGoingConcernDetails Going Concern (Details) Details http://glyc.com/role/DisclosureGoingConcern 27 false false R28.htm 99940301 - Disclosure - Significant Accounting Policies - Fair Value Measurements (Details) Sheet http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails Significant Accounting Policies - Fair Value Measurements (Details) Details 28 false false R29.htm 99940302 - Disclosure - Significant Accounting Policies - Stock-Based Compensation (Details) Sheet http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails Significant Accounting Policies - Stock-Based Compensation (Details) Details 29 false false R30.htm 99940303 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities (Details) Sheet http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails Significant Accounting Policies - Potentially Dilutive Securities (Details) Details 30 false false R31.htm 99940401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Details 31 false false R32.htm 99940501 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 32 false false R33.htm 99940601 - Disclosure - Operating Leases (Details) Sheet http://glyc.com/role/DisclosureOperatingLeasesDetails Operating Leases (Details) Details http://glyc.com/role/DisclosureOperatingLeasesTables 33 false false R34.htm 99940602 - Disclosure - Operating Leases - Components of lease expense (Details) Sheet http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails Operating Leases - Components of lease expense (Details) Details 34 false false R35.htm 99940603 - Disclosure - Operating Leases - Maturities of lease liability (Details) Sheet http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails Operating Leases - Maturities of lease liability (Details) Details 35 false false R36.htm 99940604 - Disclosure - Operating Leases - Supplemental Information (Details) Sheet http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails Operating Leases - Supplemental Information (Details) Details 36 false false R37.htm 99940701 - Disclosure - Stockholders' Equity (Details) Sheet http://glyc.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://glyc.com/role/DisclosureStockholdersEquity 37 false false R38.htm 99940801 - Disclosure - Stock-based Compensation - Incentive Plans (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails Stock-based Compensation - Incentive Plans (Details) Details 38 false false R39.htm 99940802 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails Stock-based Compensation - Company's Stock Option Activity (Details) Details 39 false false R40.htm 99940803 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails Stock-based Compensation - Summary of RSU Activity (Details) Details 40 false false R41.htm 99940804 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details) Details 41 false false R42.htm 99940805 - Disclosure - Stock-based Compensation - Inducement Plan (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails Stock-based Compensation - Inducement Plan (Details) Details 42 false false R43.htm 99940806 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) Details 43 false false R44.htm 99940807 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails Stock-based Compensation - Weighted-Average assumptions (Details) Details 44 false false R45.htm 99940808 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) Sheet http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-Based Compensation Expense (Details) Details 45 false false R46.htm 99941001 - Disclosure - License and Collaboration Agreements (Details) Sheet http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails License and Collaboration Agreements (Details) Details http://glyc.com/role/DisclosureLicenseAndCollaborationAgreements 46 false false R47.htm 99941101 - Disclosure - Subsequent Events (Details) Sheet http://glyc.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://glyc.com/role/DisclosureSubsequentEvents 47 false false All Reports Book All Reports glyc-20240630.xsd glyc-20240630_cal.xml glyc-20240630_def.xml glyc-20240630_lab.xml glyc-20240630_pre.xml glyc-20240630x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "glyc-20240630x10q.htm": { "nsprefix": "glyc", "nsuri": "http://glyc.com/20240630", "dts": { "schema": { "local": ["glyc-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["glyc-20240630_cal.xml"] }, "definitionLink": { "local": ["glyc-20240630_def.xml"] }, "labelLink": { "local": ["glyc-20240630_lab.xml"] }, "presentationLink": { "local": ["glyc-20240630_pre.xml"] }, "inline": { "local": ["glyc-20240630x10q.htm"] } }, "keyStandard": 195, "keyCustom": 24, "axisStandard": 14, "axisCustom": 0, "memberStandard": 16, "memberCustom": 12, "hidden": { "total": 29, "http://fasb.org/us-gaap/2024": 22, "http://glyc.com/20240630": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 104, "entityCount": 1, "segmentCount": 28, "elementCount": 437, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 393, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://glyc.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://glyc.com/role/StatementBalanceSheets", "longName": "995200100 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2",

"firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://glyc.com/role/StatementBalanceSheetsParenthetical", "longName": "995200105 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_16u2gG0xy02P-ESWgleWBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_16u2gG0xy02P-ESWgleWBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Statements of Operations and Comprehensive Loss", "shortName": "Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://glyc.com/role/StatementStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Statements of Stockholders' Equity", "shortName": "Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aLY4KKjG00mhgDc076Ll7w", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O9kHvcx1SEKvdw5QORYCrA", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R6": { "role": "http://glyc.com/role/StatementStatementsOfCashFlows", "longName": "995200400 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://glyc.com/role/DisclosureDescriptionOfBusiness", "longName": "995210101 - Disclosure - Description of the Business", "shortName": "Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://glyc.com/role/DisclosureGoingConcern", "longName": "995210201 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPolicies", "longName": "995210301 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210401 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://glyc.com/role/DisclosureAccruedExpenses", "longName": "995210501 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://glyc.com/role/DisclosureOperatingLeases", "longName": "995210601 - Disclosure - Operating Leases", "shortName": "Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://glyc.com/role/DisclosureStockholdersEquity", "longName": "995210701 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://glyc.com/role/DisclosureStockBasedCompensation", "longName": "995210801 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://glyc.com/role/DisclosureIncomeTaxes", "longName": "995210901 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://glyc.com/role/DisclosureLicenseAndCollaborationAgreements", "longName": "995211001 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "glyc:ResearchAndLicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "glyc:ResearchAndLicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://glyc.com/role/DisclosureSubsequentEvents", "longName": "995211101 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPoliciesTables", "longName": "99930303 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://glyc.com/role/DisclosureAccruedExpensesTables", "longName": "99930503 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://glyc.com/role/DisclosureOperatingLeasesTables", "longName": "99930603 - Disclosure - Operating Leases (Tables)", "shortName": "Operating Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationTables", "longName": "99930703 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails", "longName": "99940101 - Disclosure - Description of the Business (Details)", "shortName": "Description of the Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kVFT2Dc8G0C0RDsICgzv0w", "name": "glyc:ConservationOfCashResourcesWorkforceReductionPercent", "unitRef": "Unit_Standard_pure_R8jv4XExgEC-nyBfLEUIGQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kVFT2Dc8G0C0RDsICgzv0w", "name": "glyc:ConservationOfCashResourcesWorkforceReductionPercent", "unitRef": "Unit_Standard_pure_R8jv4XExgEC-nyBfLEUIGQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://glyc.com/role/DisclosureGoingConcernDetails", "longName": "99940201 - Disclosure - Going Concern (Details)", "shortName": "Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_caA14xuW50C8pVJqCJsICQ", "name": "glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R28": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails", "longName": "99940301 - Disclosure - Significant Accounting Policies - Fair Value Measurements (Details)", "shortName": "Significant Accounting Policies - Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_sYkZnYhe4k27nfv1DKyjGQ", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_sYkZnYhe4k27nfv1DKyjGQ", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails", "longName": "99940302 - Disclosure - Significant Accounting Policies - Stock-Based Compensation (Details)", "shortName": "Significant Accounting Policies - Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_RangeAxis_srt_MaximumMember_cDlyHOs-PEKeVYaO5FC3pA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R30": { "role": "http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails", "longName": "99940303 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities (Details)", "shortName": "Significant Accounting Policies - Potentially Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_9mn_4uDdw0ST1uxOhWGP", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_9mn_4uDdw0ST1uxOhWGP", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails", "longName": "99940501 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "glyc:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "glyc:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://glyc.com/role/DisclosureOperatingLeasesDetails", "longName": "99940601 - Disclosure - Operating Leases (Details)", "shortName": "Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails", "longName": "99940602 - Disclosure - Operating Leases - Components of lease expense (Details)", "shortName": "Operating Leases - Components of lease expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails", "longName": "99940603 - Disclosure - Operating Leases - Maturities of lease liability (Details)", "shortName": "Operating Leases - Maturities of lease liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails", "longName": "99940604 - Disclosure - Operating Leases - Supplemental Information (Details)", "shortName": "Operating Leases - Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "glyc:LeaseQuantitativeDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "glyc:LeaseQuantitativeDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://glyc.com/role/DisclosureStockholdersEquityDetails", "longName": "99940701 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_zTJwOa0ABkqddt1WOHqGKQ", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2024_d8xMwTWbEkiaD8EcuwWajA", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R38": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "longName": "99940801 - Disclosure - Stock-based Compensation - Incentive Plans (Details)", "shortName": "Stock-based Compensation - Incentive Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2014_To_1_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_sMxtugCat0GP4FcdTXEtFg", "name": "glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2014_To_1_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_sMxtugCat0GP4FcdTXEtFg", "name": "glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "longName": "99940802 - Disclosure - Stock-based

Compensation - Company's Stock Option Activity (Details)", "shortName": "Stock-based Compensation - Company's Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_Y3mbP-NAzUSnOSUu2m0L5w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_YwFicLWgjkK3K9LfPPX86w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R40": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "longName": "99940803 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)", "shortName": "Stock-based Compensation - Summary of RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_YUVTONtB4U--O3CikEOu4A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_YUVTONtB4U--O3CikEOu4A", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "longName": "99940804 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)", "shortName": "Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENJFS4lxn0Sb6rK3qL4Wfg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENJFS4lxn0Sb6rK3qL4Wfg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "longName": "99940805 - Disclosure - Stock-based Compensation - Inducement Plan (Details)", "shortName": "Stock-based Compensation - Inducement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_lajDaR2qPUSUDuXVhCsbXA", "name": "glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_lajDaR2qPUSUDuXVhCsbXA", "name": "glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "longName": "99940806 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)", "shortName": "Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_EP32NdWy10uEf6juzMzvng", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_KxnnxZ38u0upXGCb5utEAg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_fcPAh5Gl00Kvt6yml3jfxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R44": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "longName": "99940807 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details)", "shortName": "Stock-based Compensation - Weighted-Average assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_j5reU2Fa7UmQOw_5WNn_cQ", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Unit_Standard_pure_R8jv4XExgEC-nyBfLEUIGQ", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "unique": true } }, "R45": { "role": "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "longName": "99940808 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_AbnxODhh0UWhdTHOwgOOGg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails", "longName": "99941001 - Disclosure - License and Collaboration Agreements (Details)", "shortName": "License and Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_2aZAAZCEtkacVJQaIi0-Cg", "name": "glyc:UpFrontPaymentReceived", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "glyc:ResearchAndLicenseAgreementTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_glyc_ApollomicMember_2aZAAZCEtkacVJQaIi0-Cg", "name": "glyc:UpFrontPaymentReceived", "unitRef": "Unit_Standard_USD_LRRRm9z2u06X-Wxq4QUFlw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "glyc:ResearchAndLicenseAgreementTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://glyc.com/role/DisclosureSubsequentEventsDetails", "longName": "99941101 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kVFT2Dc8G0C0RDsICgzv0w", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "Unit_Standard_employee_RARwaXSsYk6xlLePZ3hj0w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kVFT2Dc8G0C0RDsICgzv0w", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "Unit_Standard_employee_RARwaXSsYk6xlLePZ3hj0w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "glyc-20240630x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://glyc.com/role/DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r23", "r25", "r28", "r652"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r23", "r492"] }, "glyc_AccrualsForClinicalTrialExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glyc.com/20240630", "localname": "AccrualsForClinicalTrialExpensesPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Accruals for Clinical Trial Expenses.", "label": "Accruals For Clinical Trial Expenses [Policy Text Block]", "terseLabel": "Accruals for Clinical Trial Expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r25"] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued employee benefits", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r25"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails", "http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r25"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued consulting and other professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r25"] }, "glyc_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "glyc_AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "AchievementOfSpecifiedNetSalesThresholdsForAllLicensedProducts", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of revenue to be received upon the achievement of specified net sales thresholds for all licensed products.", "label": "Achievement of Specified Net Sales Thresholds for all Licensed Products", "terseLabel": "Milestone payment upon achievement of specified net sales thresholds for all licensed products" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional

402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r550"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r33", "r492", "r702"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r377", "r607", "r608", "r609", "r610", "r654", "r703"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r563"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r563"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r563"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r563"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r19", "r20", "r187"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r596"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r522", "r532", "r542", "r574"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r525", "r535", "r545", "r577"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r597"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r563"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r570"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r526", "r536", "r546", "r570", "r578", "r582", "r590"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r588"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r219", "r228"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r111"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r10"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r10"] }, "glyc_ApollomicMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "ApollomicMember", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Apollomic.", "label": "Apollomic [Member]", "terseLabel": "Apollomics, Inc." } } }, "auth_ref": [] }, "glyc_ArrangementsAndNonarrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://glyc.com/20240630", "localname": "ArrangementsAndNonarrangementTransactionsLineItems", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research And License Agreements", "terseLabel": "Research and License Agreements" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r53", "r57", "r73", "r86", "r114", "r116", "r117", "r118", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r253", "r257", "r281", "r353", "r403", "r468", "r469", "r492", "r513", "r621", "r622", "r662"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r69", "r75", "r86", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r253", "r257", "r281", "r492", "r621", "r622", "r662"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured at fair value levels 2 or 3", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r270", "r271", "r485"] }, "glyc_AtMarketOffering2022Member": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "AtMarketOffering2022Member", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in March 2022.", "label": "At Market Offering 2022 [Member]", "terseLabel": "2022 Sales Agreement" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r585"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r586"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r581"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r581"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r581"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r581"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r581"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r581"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r584"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r583"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r582"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r582"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Accounting", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [

"http://glyc.com/role/DisclosureSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r44"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureGoingConcernDetails", "http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r9", "r71", "r460"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r9", "r41", "r84"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r41"] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r561"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r558"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r556"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r562"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r562"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r503", "r504", "r505", "r507", "r508", "r509", "r510", "r607", "r608", "r610", "r654", "r700", "r703"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails", "http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r32"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails", "http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r32", "r391"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r32"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r4", "r32", "r391", "r409", "r703", "r704"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.001 par value; 150,000,000 shares authorized at June 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at June 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r32", "r355", "r492"] }, "glyc_CommonStockValueAvailableForSaleUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "CommonStockValueAvailableForSaleUnderAgreement", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.", "label": "Common Stock Value Available For Sale Under Agreement", "terseLabel": "Common stock available for sale under agreement" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r567"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r566"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r568"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r565"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "verboseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r21", "r61"] }, "glyc_ConservationOfCashResourcesWorkforceReductionPercent": { "xbrltype": "percentItemType", "nsuri": "http://glyc.com/20240630", "localname": "ConservationOfCashResourcesWorkforceReductionPercent", "presentation": ["http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"], "lang": { "en-us": { "role": { "documentation": "The percent of workforce reduction for conservation of cash resources.", "label": "Conservation of Cash Resources, Workforce Reduction, Percent", "terseLabel": "Workforce reduction, percent" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r88", "r89", "r151", "r156", "r307", "r316", "r351", "r462", "r464"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Summary of Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r183"] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTable", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": ["r183"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r15"] }, "glyc_DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "DevelopmentAndRegulatoryApprovalMilestonesClinicalAndRegulatoryEvents", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of development and regulatory specific approval milestones based on achievement of certain clinical and regulatory events.", "label": "Development And Regulatory Approval Milestones Clinical And Regulatory Events", "terseLabel": "Milestones based on achievement of certain clinical and regulatory events" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "auth_ref": ["r616", "r701"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref":

["r185", "r189", "r220", "r221", "r223", "r479"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-based Compensation" } } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r517"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r549"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r560"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per common share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r81", "r95", "r96", "r97", "r98", "r99", "r100", "r104", "r106", "r108", "r109", "r110", "r113", "r248", "r251", "r267", "r268", "r349", "r361", "r465"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per common share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r81", "r95", "r96", "r97", "r98", "r99", "r100", "r106", "r108", "r109", "r110", "r113", "r248", "r251", "r267", "r268", "r349", "r361", "r465"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r10", "r11", "r112"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock-based compensation expense", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for unrecognized compensation expense related to unvested options yet has not been recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r222"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation expense related to unvested service RSUs", "verboseLabel": "Unrecognized compensation expense related to unvested options", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r651"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expense related to unvested options", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r651"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "EmployeeStockOptionsAndRestrictedStockUnitsMember", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to stock options and restricted stock units.", "label": "Employee Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock options and restricted stock units" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r515"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r515"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r515"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r599"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r515"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r515"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r515"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r515"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r554"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r595"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r595"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r595"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r4", "r67", "r78", "r79", "r80", "r90", "r91", "r92", "r94", "r99", "r101", "r103", "r115", "r123", "r124", "r127", "r167", "r239", "r240", "r245", "r246", "r247", "r249", "r250", "r251", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r291", "r306", "r360", "r366", "r367", "r368", "r377", "r429"] }, "glyc_EquityIncentivePlan2013AndEquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "EquityIncentivePlan2013AndEquityInducementPlanMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Pertaining to the 2013 Equity Incentive and Inducement Plan.", "label": "Equity Incentive Plan 2013 And Equity Inducement Plan [Member]", "terseLabel": "2013 Equity Incentive and Inducement Plan" } } }, "auth_ref": [] }, "glyc_EquityIncentivePlan2013Member": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "EquityIncentivePlan2013Member", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Pertaining to the 2013 Equity Incentive Plan.", "label": "Equity Incentive Plan 2013 [Member]", "terseLabel": "2013 Equity Incentive Plan" } } }, "auth_ref": [] }, "glyc_EquityInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "EquityInducementPlanMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to inducement plan.", "label": "Equity Inducement Plan [Member]", "terseLabel": "Inducement Plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r564"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r522", "r532", "r542", "r574"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r519", "r529", "r539", "r571"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r570"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r270", "r271", "r278", "r485"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r270", "r271", "r278", "r485"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r152", "r177", "r178", "r179", "r180", "r181", "r182", "r269", "r271", "r272", "r273", "r274", "r277", "r278", "r280", "r311", "r312", "r313", "r471", "r472", "r475", "r476", "r477", "r485", "r487"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r152", "r177", "r182", "r271", "r278", "r311", "r475", "r476", "r477", "r485"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r152", "r177", "r182", "r271", "r272", "r278", "r312", "r471", "r472", "r475", "r476", "r477", "r485"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r152", "r177", "r178", "r179", "r180", "r181", "r182", "r271", "r272", "r273", "r274", "r278", "r313", "r471", "r472", "r475", "r476", "r477", "r485", "r487"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r152", "r177", "r178", "r179", "r180", "r181", "r182", "r269", "r271", "r272", "r273", "r274", "r277", "r278", "r280", "r311", "r312", "r313", "r471", "r472", "r475", "r476", "r477", "r485", "r487"] }, "glyc_FirstPortionSquareFeetRockvilleMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "FirstPortionSquareFeetRockvilleMarylandMember", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Pertaining to first portion of the Rockville, Maryland lease.", "label": "First Portion Square Feet Rockville, Maryland [Member]", "terseLabel": "First portion of Rockville, Maryland lease" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r526", "r536", "r546", "r578"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r559"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General And Administrative Expense", "terseLabel": "General and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r39", "r413"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r39"] }, "glyc_GoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glyc.com/20240630", "localname": "GoingConcernAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Going Concern" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": ["r186", "r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": ["r186", "r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r128", "r129", "r132", "r275", "r276", "r279", "r363", "r365", "r414", "r457", "r486", "r672"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r129", "r132", "r275", "r276", "r279", "r363", "r365", "r414", "r457", "r486", "r672"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://glyc.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r87", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r242", "r243", "r244", "r375", "r482"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit",

"presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "glyc_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses and assets classified as other." } } }, "auth_ref": ["r2"] }, "glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in prepaid research and development expenses.", "label": "Increase Decrease In Prepaid Research And Development Expenses", "negatedLabel": "Prepaid research and development expenses" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r526", "r536", "r546", "r570", "r578", "r582", "r590"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r588"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r518", "r594"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r518", "r594"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r518", "r594"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r468", "r604", "r612"] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of common stock for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": ["r3"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total operating lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r298", "r491"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Components of lease expense" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of lease expense and related cash flows", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r659"] }, "us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasePracticalExpedientLessorSingleLeaseComponent", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lease, Practical Expedient, Lessor Single Lease Component [true false]", "documentation": "Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component." } } }, "auth_ref": ["r64"] }, "glyc_LeaseQuantitativeDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glyc.com/20240630", "localname": "LeaseQuantitativeDisclosureTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental information related to leases.", "label": "Lease Quantitative Disclosure [Table Text Block]", "terseLabel": "Schedule of supplemental information related to leases" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Operating Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r296", "r305"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r296", "r305"] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Operating leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r297"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of lease liabilities due", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r660"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r304"] }, "glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Two", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r304"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "July 1, 2024 - December 31, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r660"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Present value adjustment", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r304"] }, "glyc_LesseeOperatingLeaseNumberOfNewLeases": { "xbrltype": "integerItemType", "nsuri": "http://glyc.com/20240630", "localname": "LesseeOperatingLeaseNumberOfNewLeases", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of additional operating leases entered into during the period.", "label": "Lessee Operating Lease Number Of New Leases", "terseLabel": "Number of additional operating leases entered during the period" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r305", "r658"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://glyc.com/role/DisclosureOperatingLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Operating Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r290"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r8", "r24", "r25", "r26", "r27", "r28", "r29", "r30", "r86", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r254", "r257", "r258", "r281", "r390", "r466", "r513", "r621", "r662", "r663"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r37", "r54", "r357", "r492", "r606", "r617", "r657"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities & stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r26", "r70", "r86", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r254", "r257", "r258", "r281", "r492", "r621", "r662", "r663"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities measured at fair value levels 2 or 3", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r271", "r655"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails", "http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r138", "r139", "r140", "r141", "r184", "r229", "r274", "r317", "r362", "r364", "r371", "r382", "r383", "r434", "r436", "r438", "r439", "r441", "r455", "r456", "r470", "r473", "r478", "r487", "r488", "r489", "r490", "r501", "r623", "r664", "r665", "r666", "r667", "r668", "r669"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r562"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r562"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [

"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r581"] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds, at Carrying Value", "terseLabel": "Carrying value of cash held in money market fund", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r589"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r563"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://glyc.com/role/DisclosureDescriptionOfBusiness"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Description of the Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r58", "r65"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r83"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r83"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://glyc.com/role/DisclosureGoingConcernDetails", "http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash flows used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r41", "r42", "r43"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r38", "r43", "r55", "r68", "r76", "r77", "r80", "r86", "r93", "r95", "r96", "r97", "r98", "r99", "r102", "r103", "r107", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r248", "r251", "r268", "r281", "r359", "r411", "r427", "r428", "r511", "r621"] }, "glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "NetIncomeLossAndComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureGoingConcernDetails", "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss And Comprehensive Income Net Of Tax", "negatedLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r562"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r526", "r536", "r546", "r570", "r578"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r553"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r552"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r570"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r589"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r589"] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total costs and expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r56", "r467", "r611", "r612", "r613", "r614", "r615"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r299", "r491"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Maturities of lease liability due" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Present value of lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r293"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r293"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r293"] }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease liability." } } }, "auth_ref": ["r294"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash outflows for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r295", "r301"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r292"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Non-cash lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r605"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r303", "r491"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of the Business" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r25"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets", "terseLabel": "Other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r52", "r72", "r352", "r469", "r513"] }, "glyc_OtherAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "OtherAwardsMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other awards.", "label": "Other Awards [Member]", "terseLabel": "Other Awards" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r562"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r601", "r618"] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r524", "r534", "r544", "r576"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r527", "r537", "r547", "r579"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r527", "r537", "r547", "r579"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r551"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r40"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r561"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r561"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r553"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r570"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r563"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r552"] }, "glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee": { "xbrltype": "percentItemType", "nsuri": "http://glyc.com/20240630", "localname": "PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"], "lang": { "en-us": { "role": { "documentation": "Total number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee.", "label": "Percentage Of Total Number Of Common Stock Stock Issued Or Outstanding Immediately Preceding Fiscal Year Or Lesser Number As Determined By Board Of Directors Or Compensation Committee", "terseLabel": "Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables", "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables", "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r554"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r598"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r553"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r31", "r154"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r31", "r391"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r31", "r154"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://glyc.com/role/StatementBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r31", "r391", "r409", "r703", "r704"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r31", "r354", "r492"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r602"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid research and development expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r74", "r125", "r126", "r461"] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid research and development expenses", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r600"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r1", "r7"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r1", "r7"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r68", "r76", "r77", "r82", "r86", "r93", "r99", "r102", "r103", "r122", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r248", "r251", "r252", "r255", "r256", "r268", "r281", "r350", "r358", "r376", "r411", "r427", "r428", "r483", "r484", "r512", "r603", "r621"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r551"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r551"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails", "http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": ["r138", "r139", "r140", "r141", "r176", "r184", "r215", "r216", "r217", "r229", "r274", "r314", "r315", "r317", "r362", "r364", "r371", "r382", "r383", "r434", "r436", "r438", "r439", "r441", "r455", "r456", "r470", "r473", "r478", "r487", "r488", "r489", "r490", "r501", "r505", "r619", "r623", "r656", "r665", "r666", "r667", "r668", "r669"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails", "http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": ["r138", "r139", "r140", "r141", "r176", "r184", "r215", "r216", "r217", "r229", "r274", "r314", "r315", "r317", "r362", "r364", "r371", "r382", "r383", "r434", "r436", "r438", "r439", "r441", "r455", "r456", "r470", "r473", "r478", "r487", "r488", "r489", "r490", "r501", "r505", "r619", "r623", "r656", "r665", "r666", "r667", "r668", "r669"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r519", "r529", "r539", "r571"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":

"RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r88", "r89", "r151", "r156", "r307", "r316", "r351", "r463", "r464"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r230", "r457", "r468", "r670"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "terseLabel": "Research and development expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "glyc_ResearchAndLicenseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glyc.com/20240630", "localname": "ResearchAndLicenseAgreementTextBlock", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.", "label": "Research And License Agreement Text Block", "verboseLabel": "License and Collaboration Agreements" } } }, "auth_ref": [] }, "glyc_ResearchAndLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glyc.com/20240630", "localname": "ResearchAndLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "License and Collaboration Agreements" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r520", "r530", "r540", "r572"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r521", "r531", "r541", "r573"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r528", "r538", "r548", "r580"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "RSU [Member]", "terseLabel": "RSU", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": ["http://glyc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Reduction in workforce under corporate restructuring", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://glyc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of reduction in workforce under corporate restructuring", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Total charges in headcount reduction under corporate restructuring", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r3", "r134", "r135", "r620"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r130", "r131", "r132", "r133", "r135", "r136", "r137"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://glyc.com/role/StatementBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r34", "r47", "r356", "r369", "r370", "r374", "r392", "r492"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r67", "r90", "r91", "r92", "r94", "r99", "r101", "r103", "r123", "r124", "r127", "r239", "r240", "r245", "r246", "r247", "r249", "r250", "r251", "r259", "r261", "r262", "r264", "r266", "r289", "r291", "r366", "r368", "r377", "r703"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r66", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r458"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r302", "r491"] }, "glyc_RockvilleMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "RockvilleMarylandMember", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Pertaining to Rockville, Maryland.", "label": "Rockville Maryland [Member]", "terseLabel": "Rockville, Maryland" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r589"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r589"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Aggregate net proceeds from stock sale", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r10"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r49"] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": ["r231", "r653"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r130", "r131", "r132", "r133", "r135", "r136", "r137"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r186", "r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Company's Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r5", "r6", "r48"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Weighted-Average Fair Value of Options Granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r51"] }, "glyc_SecondPortionSquareFeetRockvilleMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "SecondPortionSquareFeetRockvilleMarylandMember", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Pertaining to second portion of the Rockville, Maryland lease.", "label": "Second Portion Square Feet Rockville, Maryland [Member]", "terseLabel": "Second portion of Rockville, Maryland lease" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r514"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [

"http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r600"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r516"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r119", "r120", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r379", "r380", "r381", "r435", "r437", "r440", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r459", "r474", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r502", "r505", "r624", "r671", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://glyc.com/role/StatementStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"], "lang": { "en-us": { "role": { "label": "Incentive plans" } } }, "auth_ref": [] }, "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glyc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract", "terseLabel": "Authorized shares" } } }, "auth_ref": [] }, "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://glyc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments", "terseLabel": "Number of monthly installments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r479"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Restricted Stock Units information" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period", "periodStartLabel": "Unvested at beginning of period", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r202", "r203"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "NUMBER OF SHARES", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of period", "periodStartLabel": "Unvested at beginning of period", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r202", "r203"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r206"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r216"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r215"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r217"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r186", "r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense", "terseLabel": "Maximum fair value of option excluded from the unrecognized compensation expense" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": {

"en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of shares of common stock", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] },
"glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://glyc.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options", "terseLabel": "Maximum number of shares that may be issued pursuant to exercise of incentive stock options" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Common stock authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r481"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r16"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "ADDITIONAL DISCLOSURES" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Outstanding options exercisable at end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r196"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price exercisable at end of period", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r196"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award options exercises in period total intrinsic value", "terseLabel": "Intrinsic value of options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r209"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r200"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } },
"auth_ref": ["r198"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of the options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value (in thousands) outstanding at end of period", "terseLabel": "Aggregate intrinsic value (in thousands) outstanding at end of period", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } },
"auth_ref": ["r16"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r194", "r195"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "OUTSTANDING OPTIONS", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r194", "r195"] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "WEIGHTED-AVERAGE EXERCISE PRICE" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]", "terseLabel": "VESTED AND EXPECTED TO VEST" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Outstanding options", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r210"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } },
"auth_ref": ["r210"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [
"http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Common stock shares issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r16"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
"http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198",

"r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r199"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r200"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r198"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Upon first anniversary of start date", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Each month after the first anniversary", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r185", "r193", "r212", "r213", "r214", "r215", "r218", "r224", "r225", "r226", "r227"] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "terseLabel": "Employees", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "ShareBasedPaymentArrangementNewlyHiredEmployeeMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Newly hired recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Newly Hired Employee [Member]", "terseLabel": "Newly hired employees" } } }, "auth_ref": [] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Non-employee", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r186", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percent of shares subject to option grant that will vest", "verboseLabel": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r625"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement By Share-based Payment Award Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r480"] }, "glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment": { "xbrltype": "durationItemType", "nsuri": "http://glyc.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "documentation": "Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period After Termination Of Employment", "terseLabel": "Period from date of termination that any vested options shall expire" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesStockBasedCompensationDetails", "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r214"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average contractual term (years) exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r16"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average contractual term outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r50"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r210"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r209"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://glyc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "verboseLabel": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "glyc_SquareFeetLeased": { "xbrltype": "areaItemType", "nsuri": "http://glyc.com/20240630", "localname": "SquareFeetLeased", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Square feet leased.", "label": "Square Feet Leased", "terseLabel": "Square feet leased" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r4", "r32", "r35", "r36", "r67", "r78", "r79", "r80", "r90", "r91", "r92", "r94", "r99", "r101", "r103", "r115", "r123", "r124", "r127", "r167", "r239", "r240", "r245", "r246", "r247", "r249", "r250", "r251", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r291", "r306", "r360", "r366", "r367", "r368", "r377", "r429"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r119", "r120", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r379", "r380", "r381", "r435", "r437", "r440", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r459", "r474", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r502", "r505", "r624", "r671", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691",

```
"r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables", "http://glyc.com/role/DisclosureStockholdersEquityDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r90", "r91", "r92", "r115", "r291", "r318", "r372", "r378", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r410", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r506" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://glyc.com/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationTables", "http://glyc.com/role/DisclosureStockholdersEquityDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r90", "r91", "r92", "r115", "r121", "r291", "r318", "r372", "r378", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r408", "r410", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r506" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r523", "r533", "r543", "r575" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock for services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://glyc.com/role/DisclosureStockholdersEquityDetails", "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r4", "r31", "r32", "r47", "r373", "r429", "r443" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Common stock issued under stock plans, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r4", "r31", "r32", "r47" ] }, "glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting": { "xbrltype": "sharesItemType", "nsuri": "http://glyc.com/20240630", "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of share options and warrants and vesting of stock units exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options And Warrants And Restricted Stock Units Vesting", "terseLabel": "Exercise of options and vesting of restricted stock units, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised", "positiveLabel": "Shares issued from exercise of stock options", "terseLabel": "Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r4", "r31", "r32", "r47", "r199" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r4", "r31", "r32", "r47", "r377", "r429", "r443", "r512" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Common stock issued under stock plans", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r31", "r32", "r47" ] }, "glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting", "crdr": "credit", "presentation": [ "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The value of share options and warrants and vesting of stock units exercised during the current period.", "label": "Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting", "terseLabel": "Exercise of options and vesting of restricted stock units" } } }, "auth_ref": [] }, "glyc_StockOptionsVestingBasedOnPerformanceMember": { "xbrltype": "domainItemType", "nsuri": "http://glyc.com/20240630", "localname": "StockOptionsVestingBasedOnPerformanceMember", "presentation": [ "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails", "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents a stock option award with vesting based on achievement of performance conditions.", "label": "Stock Options Vesting Based On Performance [Member]", "terseLabel": "Stock options vesting based on performance" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://glyc.com/role/StatementBalanceSheets", "http://glyc.com/role/StatementStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r32", "r35", "r36", "r45", "r393", "r409", "r430", "r431", "r492", "r513", "r606", "r617", "r657", "r703" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://glyc.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "presentation": [ "http://glyc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity offerings" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://glyc.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r46", "r85", "r153", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r265", "r432", "r433", "r444" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://glyc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r288", "r309" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails", "http://glyc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r288", "r309" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://glyc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r288", "r309" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails", "http://glyc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r288", "r309" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails", "http://glyc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r288", "r309" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://glyc.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r308", "r310" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://glyc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://glyc.com/role/DisclosureGoingConcern" ], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r22" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r569" ] }, "glyc_TieredPercentageOfAnnualNetSales": { "xbrltype": "percentItemType", "nsuri": "http://glyc.com/20240630", "localname": "TieredPercentageOfAnnualNetSales", "presentation": [ "http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The entitled royalty payments to be received based on a tiered percentage of annual net sales.", "label": "Tiered Percentage Of Annual Net Sales", "terseLabel": "Tiered percentage of annual net sales" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r616", "r661" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r561" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r568" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r588" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual
```

[Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r590"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://glyc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r591"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r592"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r592"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r590"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r590"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r593"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r591"] }, "glyc_UnauditedInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glyc.com/20240630", "localname": "UnauditedInterimFinancialStatementsPolicyTextBlock", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unaudited interim financial statements.", "label": "Unaudited Interim Financial Statements Policy Text Block", "terseLabel": "Unaudited Financial Statements" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r587"] }, "glyc_UpFrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://glyc.com/20240630", "localname": "UpFrontPaymentReceived", "crdr": "credit", "presentation": ["http://glyc.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of up-front payment received under terms of the agreement.", "label": "Up Front Payment Received", "terseLabel": "Up-front payment received" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://glyc.com/role/DisclosureSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r12", "r13", "r14", "r59", "r60", "r62", "r63"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r300", "r491"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails", "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r557"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted-average number of common shares outstanding (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r105", "r110"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average number of common shares outstanding (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r104", "r110"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r555"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r122": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },

"r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.O2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards

Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }
ZIP 66 0001558370-24-011579-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-011579-xbrl.zip M4$L#!!0 (V "%D-\2Q\0X !B. 1 9VOY8RTR,#(T,#8S,"YX M6YZ9?9J"2$A"!204 M +2M_?7: ^1X@&2@#Z*_1:!P$/_SRY#'T0(2DW/]X,#P<'"#B M.]RE_N+C0:#FO?<'OWSZRT\?
_MKK_7%Z>X5<[@0>\15R!,&*N.B1JB6\M4* M^^B:"$$90Z>"N@N"T'!P^.YP<#A$O=XG(^(42V#A/C*R1H?#N. LDL;]$_2^ M_[X_&HQ>H^')Z^.3T3&ZN8[)KJ%BY+NB726Q.-
(8;$@Z@OVB%QAAWP\ M6"JU.NGW%VSM'#K<,_R#MT?0;JR4H+- D0LNO',RQP%38 '_6X"9T0F&840W M/4.0*@9+^O($M"=J'A\?#Q^/#KE8@*+!L/_'|=6=]5A,K.M15:F0RB4T(7J: M"78HB7.XX
]]*##$&*5((XV9*8*AB>JQ'%?<$;Z&\]85PK54^L5D0GK',N9 M84N*LLJ4J- "I3&A$P@!/K4N;D-.]#09$5A!2)"]T6'BAPX/?"7* M< P+L[:1/>UM!2X5EV3(?:)L?
@LD"36FCBRNBRG*B'[*62KJEV\CX^.^*4U5 MNJ0?Q"7;W6"+/E-U*.[K8LTSZ@V.>D?#C._20M]]& HNW5AF4:=71V2I+EW8 MF3/U)T_.LMB*NB1#6B-$;F))")?!)418>2>U!LT=]J;#OD+0!:87[;|-'W;=' M9N5]6Q=F[>.X)>9QW&W"G@QFI<2Z,&3X]!-"9I3"OL^5Z6?Z4?QPM:+^G(=/ MX)GVS1-MLBFX$=(_[F\O\X.&<8 [D&;&]%/,=.OOEH0H>8 HM*&D+-83:W+) MG/K4U.GX^(U&8#!
/91PP^)(HE?.AO\VU)#&#,G_B?S$&\8=20(.6W6(3=B MCD@J&!W,G(UY]M4JY0M>AB;>#?#)S_D9#Y9Q5%T[+MGW(/&+W6,?2!77&ZC MTH#1"MDH!]E&.N)SM)&/L.^BC
:D5728EF%ZAN7R@O'"O@V-%:D7EN0T]*0 MD=5! I"<4^DP+@-!;@198>I^?EJ!VQ+=3R9J2<29R2;56$](3'>!YV&QGLSK M$)\3A2F+8'T!/96N+.UR5G+A'R\[< C%>1OA<06 /X(TL>GY;Y
M,PJE=G!E>JHQD=D@T(,:C&"FSE,\8R07@BMI]V\MT>!=ONL9>;V9V9U(2T2O M0IE=5,UB=4ZD(^A*:YS,3P-)?2++TM]*6MO0..PGNREYNF?!/ :%4KM1L*QO MT85/Y]3!.
MUS$H]#&,WG%$'AI8+3,5OF 7D&L87(#9!JP3,]H)L2! ED4XI M0QMM*%8'%%0C,BI16F?G!VW\H#BHMG&$:DEV3\C-?.R>$$;PTO((WKE"X MX0I:3S%CZW/* D4?R!UQHE2TC4?4$FAWC/S
;76,E&84]T8;W9U_U)LXU9L+ MUY_OYH)];L;; 5.1)V>F)V4=LI30!L^[@K&X8 +30=1H*G/I.SH2/9 ;AOW2 M*-J U0;C^Q(8BR8Z/93H0$9)!VXCW?? =XRJ$L9 MZ,,PD_G=$H,-
IOR<"N(H+N0EU(P$X7& 6VU3'\,."R[NB'B@3MDVTO=28W>> MUTT&BZ@^9FW3U @ICI(Z(>HC7:OD"$-2,33G D55ZURM8?[@!HY9X- #=,/\
MH8C5[A)O&N4/L0Z30'3@[@#NKEE$;6EV%WB[@POTNISB&5SC=T(72T7<\0/, MD!=D#*'7,P9M-H>PB[$[PI[&SA#KZT4*$=YH[#R@6599^+3Z,.H.DNQ^\+Y) MGEFV,ONY.Z=2Z0M7D"*!?
#O+K!Y'LZ-AP M2CK:B,\ +>O:S MKR!%N?1AGN*9>D?PU*&T'A.9'.MC(K&,]$_=H4*!*"6Q ZGTI98;K$\N+XFB M4/VJ-URRA%:(AF;24_ZZ"WJ5$=CUHOHG0VH="::%!,VQX&*0#)@/.KYSZBS,.
MCBS\;3PR95881GD8C 42>@,7W^CO=$FNAV:YH=H.K :OU;4YA4A.W2[O._3 M@5CUNH[E?1P[-#7>N.D0J#H\8CDU8D>@OGF1#@'+*1'[\1 [#C4/AG18U%C4
MJI=@9\>DP2F/#I<,+I<^/"13_)2/4.DB*P+'>01"?F0$=%9OMJS9>#W3BE#; MEZUNB&A_.?Q7_ZM:)&L!8\M); M#99J"(_:'*'O7H%KO5)0C&.#3ANY2+PFS#\&W^/"!J29I)>F-
[_\7A/4_>IWFELR1N87T1%\6^O% 4@_L MBXL),XTW; M-HRJ%XO PLE)R=VE"D(X@*U?L.S'33O _>=J.Z!5T/:S#88MF[[E!7O8&7!T+5ZIT!5)Q; O$ MY3GW.
(6H:V[;+3CE:6>[CM3FXIJMU>-0)AKKI3$C%6FQ*)2+8L' FY'Y0W_K M$M[H0>;]7G-1+S@M%PKYV=OEY=;-VD?I]-(;'@X/4'@Y_15WS+,-VY;GYED/ M06WD9A4U*+^HN$QO(;FYLUC_:*=U-
,:@>W;R.LH9T)DN'0- MCC4&P[>UZU%VNWRE Q9>[M\G$-\2,1K 3M4PMQ+W]X.F]O>Z^F/Z4/= M^K+V]A$@<^=YB]@#O(7:H\]P&/4?#Z(%E%L87F#H7L*8=4X>",.K31.MJD0+
M7^'@J4??/QMQA4F*N6W^Q.,^3S^E(13P\;T+!@)B$?"72S?A4\6.6D%$@. MD$_UWI).*!1HA"S#E.W",Z4?#QQ!7*KBQY!34.Y.C;XP&JGREE_Z^ALL^K6- M\/]+/UK[JVR53%FAM80?8QW-
',>9E)S*NHN3WTL1#87X0G@]<;DAN\-B>Y M'R'7^1)X,R(F\VO\1+W "U]IU2^Y$O=^]5^0(<*ADDSFR2T)J9?JTB;]835(M0R)#YKJ 8"@5V%$?#^:8Z42V&*%&SGGOXP!@),ZEKX#/NZ
^P$[LQV]R+:'88 MUE/RI$X9M"1EQ#;,8?N3KW&3>6@@+OO)7TA?NGO%1GA9SS(GJS(7P8P&PZ\%U73[:"I+#2_OZ% M^WCS9 J_\"C4G0$F>[^Z$-Q741^\)0Z!..ZF MTZ,2@GW-
RJ^(E&1K>RE.=[^0Q_09<=.,^FO3IYE)(%!=$O&A7S,^>LE6.;X6G MECE7!=03JZA/B#.S64AI13[F'^L.&/P QZ[/L!9G'+4B:PDVX[P"]D?=&XDUJ1,=/#A=XAX&(]7JT$ M?\#LFD)5%2
@SQCU]4O*&;+TV5W3ZF>2MZ_XQQ.B)(U(I;.F(Q[I/3MDWG] MS\\ )PWR8H3Y!)+!HV'W(LQ:\L[OK^]'SV.0^\.7]?07S[<_N!B6 (DD_D4
M/Z7LTHAK7_N&F0Z$BXSG@4Y\PZ40,T'86H;ZW7_9_F1G# M^?)WLN-.PG=8+'Z>G,41,*SJ5"(>4]:"8A9O,)2O##?FW(]9>\FBG+Y$ILGH MU(Q]\>ME+M&SFC&C8E>@S6'_Z"-
N>8WXMK'5K<=0J.]H.2[*OK+P)KU\Y/# M I>X%X)[][X@#E_X>H&NX$ZWYQC)GZ4:.\7NFCM4SS&W39]7+EA1*B[>LQ6D MH@64Y!MU$;+R/"!FR^-?!(OI([>LO]C97Q3@';;-Q^H:BZ\Z-
9L3C90^:9.? M^5<0[6&$24]9IQORZSCA3JWZIO*(B9@$2IO)U9[]>6!+K A;WT ?)OK9!94P MLFIH))\X@P@%CO5E=&:+C+BGZU,.P6$R3VY]GHBMF^P]IA1)AZ]K^>NL_OO
ML9&>#\F:@/V%/++U/Z!9;KQWG\!6[(OH8O??0N@)1>$*!./TNQA^:+M^D.Q M?L:$+P$M!WA9[2^HD,J&"ZUR4UW[.FI#AQUQ:X+3-L:EN$%:X+LMFMZ4<0_: M;MSQGP'6]SIBG;EO]D[-
^V1%,YP&/"\[MZGMZ^9E4Y,XYL^X%)3M(6Z0W\%0 M\A = PD_K"!Y (.!_)V+KS#E<,@MT>O>X>D19WNKM0W[2RXM%V$9GG,/CVE^ M^@)02P,$% @ #8 (63G,S(O+"@ BX(!4
!G;'EC+3(P,C0P-C,P M7V-A;"YX;6SM75MSXCH2?C]5^Q^TG)?=!^[D0BJ94X1,ME*5#*ED>6W+W_[Y?+OU>]?UT_WR/:MT 4O0!8%'(^-WDDP M0M_]\1A[Z $H)8Z#KBFQWP"A9J-
V5FO4FJA:_2)57&/&F_@>DKI:M69\HQ]I M\[T+=%X_K[<;K0YJ7G2Z%ZTN>GR(Q1ZX84-2(.<0[Z\+\<\K[PUO?!Z[^&#D MJC(*@O%%O?[^_EY[;]=\^L;;-
YKU/Q_NGZT1N+A*/!9@SX(*XO(73%Z\]RT< M2.((ADIE8K M:::20^K;LGO^ QL.!V.@DGC6\^R^[XXIC.!C9 +W/E.'I:-RSXC[F(UN'?^] M'+A$Z]WAN"',!!. +:#RGE]O48XS'U'+HNIM/!
M4$7X!@),G$)?I,*"?2BS9UDTA+F!<\-7KFM[25?O/K!'X]1[NP>NF8F1ZGNS M*)=7(B,UL>QJ-0#[PY"2@("L8WW!+\2AP333=$K:#X$ 'WL6*W/23*N4K\C+WILI[P[&(M+/2L@DR6B-
G!X^5ZW#O4/ M(&\C7H7V>#V,WX!GX=*57;-/1*K0Z=:!SK/N$PMW0&9N=]L'EWIU+;=N'Z52 MOPFXF%HQXNC'.6C&42=&>*M=CR3J3/A2**X27GH5XXBUK>0,KM'BJ25T9K]: M-
;D4^755^\S:A.0]UQSI%^;HEO0)8^$C ,\&>WZ5!$)?MWLB%F6-!JBN1K^ M79ZUFVWNYU6>V%S M(@1Z=-E\'IFQ^BA(R\7PD/KNPEE1#[Z.L3ZU@5Y5FA44,FZ$+],H=BKH7>98
M>6=,B<]GW.E5I;5K1L0*22S\^`]?_Q.2"79$[=<+^IC2*2\)?L=."!E,*:U M@T%UOM8Y+@_3<.Z7UWOQRX*.6&\=!.O??_ 2H'HAO@RIT^V< MG!F5F;7LUJ.LO6O*$H&7P5)"PG1BBDR-
N&CG<;%C]R^MCY^$%8/A"P.)(HN0 MO#;&4Z1M?$1:Q]"<%^]@$+FK*1=%(]_A)C,OHP?3%1*+Q?=F?D:X)23,""Y5 MCR?#K@B$X>54POS\ZFE=T
S.5'G(92X/D>$$]BS+#WEI_XBG^-6!@F5]JK"Q M1.;9E[*L50=G/]?B$8[RV,R4/QYF-? 9OI19KE/FCRGR&?U%9@$PKSTXC==^DCXU$%G>#'T))[<>V! Q=3C,S_C57WH"A; OH$AL4A6 M-
53<\$C(+@FTW#[F97WE-*&)Q2TSN7.-YQ Q-P_+%(AQ&DS"DTIXVA]..2E#9YZD(T?+C^"SSN"8?CZ=DN\0@+ MA%\FD,]T0:OCX+H,2,,7/7=> !18-$\M3H#XL8N^93ZV5VE]!N\;SL.E@9;C
M_C,KY,1+7JK%<*>@&!8ZD>Z;8SL_N+ER))&G[8 2BR]QHB,+RQ<2DH_ &>)+ M8/&^K#@'/ON?_^Z$MDPAU@A[;_#$7?)U. 1K=;CLNO/=Y@\>^L+D1^I/" ^@ MZ^D+ V[O/,-
&KPMDQ\905V!&+ME/+"73T88>,[S\X+"&),A9[2T$EN&=<<7C[M?,R\(2UI&^.Y0 WG\0;X%&L1Z;4,)L,B1\YE(53#R\3<4XX]UZ1Q\SFOE#9M] Q"881IK#VYF76*894X2-G70-T1, -]?]2E@K?B-WCZY
MB8XI+Y#E+D%44;9D\=>]AI>G/&!{J+HBB MHOLY4:$\A:0?_5VG7+?Y,N;S/;^[_=E3A9X;XBVJA]$9(<-;=]X$Y"::;URD* MS @38S>O53UF^#89GQWE8['O?L_BCA/?%!0/"8/IH\-7Z-
RYPIVRK,K:W%96 M8$9 ;8G6E,WOS1QA^F&:#'_=$@][U@:9)T6!&8%B;.91]9CAVZP)8?O;3M/QV9H3/EDA,?DH\%%]B>]\A 9/I=)N$]@ 2\&7QU@(OGFO\2>V>"@"=6$9?A" M6:+1&:'9#0Z?
5>VQJKD(V?]TK?TW !0GXY/UR3A2N9A5E^;17[IANLW-&)Z%;I_O>6*S?#I-()WI7LA4_R^T[+L ?&IC\P M63,"(@X& V/2M%M09#&CT>'2J0/(\,V[>-YTQXX_!:@&#X:D\-OON8T.EU<= M0'J?(-
C3MX@UOZ]7WVC)#9T&=\,YZ;R6 %3N#./6ZUSMO_>D6,>>-EJK=>Z\ M*S3KBU]:="=*74=<1C#KT?PZ5Z+H^VPURA/7]_D&0XIEV8)FC+DUN[/?),@T MVO#B]'=,B=C<**)H3>X
&%*SV9!]^1) ZDTY];454M^BPT7]<^(^#R'Y,0:0 M?E9J&I]LN%G[1IQZLQU_K%O%KB=P,1'/J@;#6\XN=O[-U\\9X[>\0E,&NAZ_ M2Y_ WBYVO8R^\S=[5#WUC>>,[^_@3.#!]X)1YJ?
[2ZK[2<)&%?F!SC+QW]L MGFH*YAE'DS90@NVX2N&#(A*2[NY].'SK0-L:\G_LC[S<93SOOP/4$L#!!0 (V M"%FLX_&$PB4 NJ @ 5 9VQY8RTR,#(T,#8S,%)D968N>&UL[5U9<^,X MDG[?
B/T/7, #S#ZX?%0?515=,Z'R4>,(VW+(KNZ9IPZ;A"1L4X0:)%W6 /H% M>$B4!(#@ 3))ZZ7:)>+(XT,B$T?BEW^\+CSK!=$ $ _ST=F[TR,+^0YQL3_[M?!2%T^,/1 _X^W __UR_G[%LX^. QTU\L0-
6A?A6W-;YN[/LPT7:&O$_ M61),/IR4\[/_OB?_GF?5F,?[\X--K M@#\?S<-P^>GDY/OW[^^^OW]'Z(Q5/ST[^=?=[:,S1PO[&/M!:/L:.K)8^4]! M_.,M<>PP%DZN^NLS];
(&WI^L^Y*6X/ZSHH=\Y^.S\Z/WY^]>PWG]*>?Y+X\A4S?'T?]/ M8#Q]#(GSQYOX+H/CU9\1#E='%N_BV^1F30UOZIU#%B?\PXEV.S%C6M(]{(OR&*)_"#&T9/]
[*&@B#'=5KK@ZO%#L5+3L9X^B4*L(^" MX!*%-O9**5NI1-]X9G/K(MC^^'(<4CDA\P(/A /.Q@%US:FO]I>A.Z0S0O' M6"O=(TNPE#.QF15+0!SB9()"0*0W;GK>ZQ%X4XA?
TB)R(XI!]%8T>EUU M(:'Q$E&;DWK+<%R!;5G]SFSXUEO27HOR)N#.2C?,4_ YAAX\VZ^ U#*-PN&; M_VW[]\?XZSB>BT8.([BRFBOU $<>C]%B8=/5>#H)HH8%H6P:C@1N@B#B7C/S M(N@
MCC3$OUZ]C^:,BAZ?70ADUMFM!@-(Y]1YGGV,Z$O:.,9117#* T6.\%]!R@ M/R-&Q]5+M>A1UD!9;F*" Y;TX67[KDU=+MT*,EB](#2{)@\] EFMJ1%P9' M-<>
(1@<:#$SMX#GF/0]_9[:]3!A!R%V<7+VRH"G SQZZ\J,%2N!QBP,=TGGK M0;9RMM<'Y^D$,1+Y+[S#@(&8S9I%WO46Y39V,^/3///US:E)+OB.I1OXL-C])U>[S#X_0?C/*S#\=G9\?G\0+E M7W;
[TN9DW1/VPQ.7+]:]L:BU&LFYU4J^C/IC3%_<6GVBV-\<',0 =A.X-4BB MH.U&"8Y'B1EZTZ8:(#=NZ7B!%L]5$2NF=;O=^H3.&4W4B9[1\5H,#9(K;#U' M- ,(JG%BF/P_MOI%W'RYR.UZYM36-
'N\WZQGCSA:W7E\ZX/0RF:0 [*Q@ND/ MO]]B^C2E\]3+5Z#D(]>VL!QJ;LI'W^4A1(L0A9UE8XJ1]7K:7JC*]5A<1I6R" MWF%+KW#*85'A+68WD[1;.89I+.&4W17'*=32A9JS9"2'&Z(_FO)VK5*8A6U
M%P6L'1*[]S:; I84$\]^?SXZ/;((99/6YZ,S2+BX)[Y3!AK]Y=7HR)?O$T"D M?%;'2+Y)#9B<9R;X1&"#Z]OF.CYU^^A=;Z8FRI4\;B0^#S@X=3O(U2];:K.@ M; ?C=
(>0RRTW*N5062;E3%+&Y!B4.:O).-13"]'C+C*E0WS\2AI<&<,-F^= M QKF-,[^M=$V^\?O%]$B\FR^&7$UG2(G?$#,"KCCZ;[^T%$HP9T:=4.MN? M.B1;B'OQQQW2N\>Q4+ZD@/P\+O,-
B5ULT]6C[:T8)?(!RDJ ME_D?\G)=<+>A@2M@/'VBMA\PKU9FFO4K9/QJ5.C012G4&JG \Y:O(NN! U^G MY;Z=EHGMST16=N_WE/G<[VU2>+<5".9IW/Z2I_(NOUK7"?IVA4A45.>!M:[*
M@:15!9KYS&T7/;&N),9342IG.H6E8/ EMI=%Y>2\P:".*K40??YV3;*@V=@@ MRIN#A.I?4P1(%GO));#UI3N:A2@5?MNFNWLTBD1+U+3G49>KSI&V4PT2 MND9^R#R&W>.T5Z^.%
[G(O6;"X"L;46@GY]:O;.HS3@(6M<7'M;ZLO T(T-[* M3ZDFC/8$1D?2R$ZWN%):.** -C!#2DLL/](-4L@M1S%ED(S)^D+'E]7ZSW]B M1)FVYZM;]
((\@5TH5RE5@6ZE+H60O]6R3Z1PZ%:JNRL2O;K=#>]2"B?UQ)(? MK'H]\W%7LD=(@_"!DB6BX8HO=(4CW^7[$TM, Y>5)"(]42-;']2I 8EW:XL7G/5Z:3KM:?U1M]71&;47LZQ8XOF]\)RNYN_
M^^7;X@C-=OL7KQL4E7IB,>CD?XA#>6OC)40\0-4821:7I%^3\4G^-XU%\)1 MJ2@AXJ3[.2$7/-'A)@_KO:8XM(5-=.TL/7'BQ],:W\4OV(V$CI*R3,]JI$Q7 M7/R&P_D$>;'Q",9X^42N_)!?
+!0AM6)M&>=%M;M#N%J1I*XD\B- V!4?!:6[M@&2[:WR'+-#:HCEQ:2,=8_T HT0;>;VC?INHQM[+FH,$I89?1<4N3B\L"E=30F-(VB! MZU]4+G."Y>6@<">U\YJE59S"L.G%RB)EN=URZ67-
QVY]4;-=.S*;A)L.\FV* MB0#MTG*_G^W(15FR+8[2;KP.1(Y<799(;Z59<6"3AWA$HW^=X#4 MU!#.!
[R"8.N)6(6$=FK@;XD _>T)T\9!Z6A=DLV!JX'V0,E20]MP&-9LK8(L"]NK.I2;@P5IA(63$)MQKGA:(#A'=,B MO_LMO/:MN."MGY8ZAX_="^2IW#Y^_)'G<#H]M8XW>[#YOP.+3*U\XW^U2F>]
MSA#<[O7R.(FU9'SO%CKIAD2-&_ ':=3(&FO5EATF2^;G8: M7]D@6>$V-?.^IF9D/.!1R68GB=')W]>>CD$8=^&HROWI/5?L% =@S7:7M M$[11W'ITUK(.XESEXRCD:P[QMZ-D*M@O!\!N:6I@GW9
"N#PX+GC67P;4?Y, M2)O'\KZ><8^^QU_D)DRK;IN*^]'V4"GF![SR$L!5U-Y>90!>=2F0:FATCT?P M*HU937[>/-Q095P*VFA3P3^:&I\"OL K-8%A3:U*&P$^;J5L:X_?/JH\9EU\ MR+["8)8UU*;]?
S(UHF7,@==Q@LXFE*QN"?@ 5PM >Y0;A\'^RQ+\%S5KFR=S M@!'O_F;S^S$A_W."@!!B)T1N7.8;TTN09BW94;VI3MI$Q<]5QKXIQCL"1(]2
MPXBHU4N'AL+L4"]"4RVIP9EG1N[_14&\,OT\$MRANU#HOYPT<*A# ^TGNG+RD9SH^OC_]^?2]=6QM6HW/=+*&CV/P6?FFK;\E MC?_OX4B'B:35XB(].K"Q33B<731EO@%9(1@G,F2)MF54-
R9TB=N:[/ELO:A\ M?GKV7KA5K%,!0-0I26] !!@P'2=DW>??6"V6MJ@T@#U&35&+J#]LPQ^VX:54 MY+F:K'TR IE:R^2Y%:>ER9]&$_3=9G_,%'$ZS07) @##?0@UWE]_MN;-R:#M
M19I+%#@4+Q/BOD0!8SO(O9BNM4CSP^G9Z=GN(DVN87[S)IPC*VO>^EO: =R% MFK6"X\DD1/<80E*UJ59QRK30LL70>O"DL#2L/,Q]WBAV>N-UQ>+HM?DJ!>-C!
M*!"^DE#:Y7R_[W+F>K4VW5I9OZP$[]]*^[;RG<-W2-4[8R&%>W<1CD9Q%=:70Z^=:=Y M)Z=B&S#\Y_+OWU1D%X9Z;_QE% 8Q7V=*1UM9 X"[7>T5(I'Z1 R"4]9Y:66= M]H -
]*L<[#*$]^+T*H!8((B++>PU)6C7F^*!9NN(_,@F8CLA+"I+[3U;_S M"@G/;Q%LXBT)JA3E(=EW4UA1L]GRS#'[YBBRI!FA!,;;=(!G!4?$=\M+]S MZ1\HO(Y\-Q@EJ7(9EZH[$(6U .SW&U=RH1!
+:;)#]E76$T[+[^:EIS#_R(X MAP]],>V2*X,+S \I?H[BM5+/]E4K9.HJ#8SNHHF>_XD6TD(ITYWN'ZS42]6>6YS$_I;EO4OZ!.?/DR]VYE^FSE\^XQQZO7 M):9VNC6(B2N!1(/M PCZZF&G05G
"0\J.Y7WOK.SL8Q1Q$!;\ 3B9TTC2]-# M)%G1Q#3$ ZH8.6!A/R6&K/WJTOL1?R^VB,/S.+8K4+,LG\SN#!FR9%@9318 M&R+@ARX]N$,\8@)V]_1[]>IX$5/E-1LY'.=1F!YBR=+;.C.9G]]>B1M0;.0;
M[1%,2%5\P]FH'+K-"B(DK/#6=`$U&+O(+0R98IPH7M!]Y*IP=E=B.T.-Z+]6 MX@9Q^48 ' +01>_FJG%Y-@\WD%NZ@=R_>+&F=1DMN"-E9NK-V@80)VHF1V]& MW[:]\C'S-FSN#-\BYK*6=
[9_VC]NNV[22M]$[SO?HB! **8V=SU-Y4@K:YA? M/EU#\BLB,VHOYRRT$1UH+2@+QH/54,#Z648Y.ZVO8C\FMCQ/B?SQ2WG9[K<, M"O&TEKZ<"P.>X83Y,B_8\]"=35>>[;MR_T]:M..M@T*
(K%T[*0>F4_5<8QJ$ M#X3R-A__C-AD=(U06$+V)1OH<$HOIY&2?)GMHJ8^^C6T4W9%CI<-"VGG+*, M%7NR2CB_%<5$A;4Z"Y T^=DZ(Z6:XOL7.B7L;'O/.;Y&SRP@MQU9<*1=&T#X
M4UG7&NS!V?F*:7S@5'&;PS=+7.Q#/L8)H8^,"2\1P?IY-JEF2[<#8!VJ))JW M=5V:83A:3P/UU25:D@#+=+I7"LRHK*2Q/7:,YXQ?S\XQF;NG"R1E &S?5A"R MA!DXD!?

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
MJ66@GPZWKML:WXW$KW()#@^&N0PA\>$YPVC<[Z[#[>P^@W)?D&!GY_76>^*# M) PDH=^W)7D<,FHRIO57PX/2^1@B[M^:]!
M4LA*.K>RWGN0DLZ9(S>*LT,6H5IZJU"9S:ZY]@\II#33W#6MTD/VJ7(3R2'[MU"'[U-N\Z"Q;O#9ID0YWI]WI]WI$'LI"43@71-MW!SS5A.8I&,JMZ@](9YW32C_:,@6B:PS (ZD(9P:$M@ -G_W.4RV2\O@+ ^NG M#U-HK=%K"(F9_(8#PCB*7%__ ^D)!T/AD'4 MGJ%LY,6OG(CA3)L*+](0)Z;/),"OTT!;FF\-TMT >6@A3TGIT@/9>05RZ\B7T MI$W O$D*AA4DF81ZDU(2$-SW$]UT@2 B21/39.X$%^I*"'O#N!=%'%\@O3<;P M0LPNL5];I#U"?P'K21*2D<]3>"+^WLX3X3^9RM^OVVN?L6TTZBR4W."AV=:&:MF'[W P@R-]#Y:,<\=+*:4)6H @2=(^/?*!7DNEL1S4Y*8(^X-]OL%
M\6/]1+;?;S7O7#($#"%BK#A8&@<&V<&HH8I-8H(6WM?3Z['_F>]-^>X'<-MA@/*=)KB9T>-NN>"?@;@AVL-;0/9M?-B"'06,_"KM7L?@ /-!1<+\)WAV,Q-M@U+&H%=0"88I.C(X^. DG 47.OTDQVD=/KD&;2@'4]I]D\
M]D!F$Z!L=DF-=DF#!05T6&#)7(HKE_{GB#[-;^+,TAU]>GS1KN9TTEU)3] MG9?X/VGFQ.3NCW(3L;$N $RN'9N%1A LE"T<6&;.QR.B+]A!8C;OB?^2C'#E-MS
3Q8SO;C%P$X3T)_XW"'"UMVTE%3:U8 $PQW2TV2KVSS@.U3&$Q@=Z9OJ MA*8 ,\7(RL|X\$7T^~6C<2"1/ASPFU/"6EP&,]96)*+/X_ (!1<+\)WAV,Q-M@U+]#]IG5UF-
EI$^H*L(A4PG=]M,Y;@LW?V@O?3N(;XK[K> \#2]2H<@%U#0 M9T>D!S@72/PM0'TM^)W#Z_$VU]4=HFL;T_A$, C7O!R5?;[/T+7O7D[2AZ&2 M%PW@\?
%60H(]Y@S:"'L;PVK,P80WMDK3]S8"$K@#K+3"WL(HRV6,A#?$RA'W M-@(AN,.KG+9@7"/D\KP=R73DU7!$[G$%#EL! KB;V] MFMBKL^1=7%(\G"4_G"77,33-)DY4]SBYH T
T7(#)\H\@!<@:BB20T7:X M%=F_6Y&KIG'@4!8B^M5O0"(__7V'4<9ZVP,XH&%%N\+) ,08N^:)O3SP2 M&4)O?!>_8#>R/&%590:IOU$!>/=*^HW'++XTXNY^9X^42AN_)!GNQ$9SDHM
M=&L/"]$IU5 17ZWK+@O/A5905!#"U@#;YE"=KF!{94<[B-"O(_XAJX@)LMX M3RO6I@X0B?OH\Z3F?,.8CD!69V=^985UYA_+K#.O.[-X;X<5X]ZN-M&/-UH"1-0+Q1PVDF/J=2L9924.=MK"07"
%.?ID=^]0K)Y*R,)8^M*"Z=;=* MS T3T(R(>C@QYD\^QBZ7B;9WCJ>@.I/1L3 MR>D&>S[S?6)SD4U0:@#'2S/ IHA[.@:TTCX/"%&V5&/;RJI!E",I1FIZ=,C L MCP!7 @D#VY3? E",$ 8B!K2QK[LEK]$"
,LE1)7&#*>_I..BHOUP* M!;H&=)CZ'"*HF@"DMV+,IRB.)RB>).G*.*H.G=5@1FCF*0Q7YZ>$KK@QX'E M7GVIZ@ FRU9.7I02"ISCH]#/^\)>.3J<]RU4&2SK.<#SOH?-.MT7=0]4],D:O43XUV
(00!6JJP1R0T78X67,X66.::,_%(GT6>H2I?S?A-P\# MYM[O)Z#LF?+2;O-]-;"'"D_:"^OQE;L"^>DM&MF8DR1NX^D=&SMS+[X"RPQ$ M/ :5\Y>I/OM\TUF(LI;DU@K;J@R2]} 2I
MJ19#SGS'@\N;U*,PX&O..L9PTW/K?OM]?KO9S'RZ+R,XP#]\$=#)&P$_M0G< M0[I_DT(XI/M//WS(" lW,S]F9N]>24AN5$QBL(YX^T_J/&;,+3H]MHG0#ZU[M"Z;D-B XILR]V-
CCBV!LY,5KLJ:P*.VN32!^[!40I2(; K?Q@6_L+> *[B M#3_X0;@PF^4ZL9[RR3\CW,6*O78W8XS)# X,'RAQ$'*#;R,/ &F9]U=$'1Q(M_3B->]T"H]7-$ WFX6BXL@AVF HR(,>ASXT?
4NP'V#&2&;94UZWBK!(/<962 MWP"@%N\-=&@["NPT]S_KQIH1<6&!W?>_L5[R(%NNI>CQ-1M+5]^-%+G*YP?_F MT_4"3[(YJU?^YZXI!$!/]!L91.%@% '8#3322*.0]Z4&!$7(-
QQQS>)KR\CNGZT/+'V94*)*@VUBII6.R.J2 _BWJ(ICGJ08:/+A(8'3)\'#)\O)$,_WTM/:BWH;.CW(@P(#%">AE_0"8Z\R.7D-(S.0W'!^_H46NILU?ZT"$ONY5D[W<,XFF#@FI>NKSW;'6
MH28V4X"@F!/DSN\N+B \5. *+HM"VW49N0/@,V+#=26YAO#M/=_ GEHKFE) MZ]$!VGL%<>F*AM!#,@('S)BD8EO-K$NI-2GU_7)X8^3SA 7+8GT^$_S1Z#D)JXU?:M2=/MM<_(-AIU%DIN\-
!L-Z-#O_L!!)F;9[%))Z?Z28YPX64^H2-8# $R3\ M>^6"/!=+VKDI24P0AP;[_8+XL7XBV^/YP,Q>RFV&P $$]U4'"Q_-!LX-12Q MR3:R,;L=&/;<"_H<=B(Y+[54-ZVH(>#>/D@;SLK!)GO>O
MNT\)\4$#0WPSVV&MI/Y1]-?G4*XKKT0A3AB7QW?&U"@(HD5">H5;XS^7N#6> M=7R<]FS9FZX/5\4/5\7K697#52'#5?&.KHKS-Y,P"^+=GY^>O>=KU)4ND9=K M!\!2E^;U\G\)#
<"3VUM&/MQ"/JQ"[^9"YHZW%W^\M$.TSLG6RN5,#ZKZO-]J M=-NHM"0'8$#9^M>P3E$SD@=G*U!YGF9[[O)O!K)EI <,IE46K$3L MKH\GF%B*U.@0@%O8XK!09-U10ZK P-J4<#,N?
R4>;\9C#$[87-*&397UW&6-SY#)H,A& !\RMRF)BDTC90V >T@&@) W M3$IQP-E>DI"IW&TJ]_C\TD#P'!KJ;GOKJK;")BA 3"9S-D5>HA?DD26G-S7$ MPCVK4C4!+$=H03*O.RW&X&CP*_(1M3U&
[YRE8&8'):)BN M-J.&6\9OZQC9CPOB,GSJE(I[GSOVF;L:SP3XPZA-M)FQL[O@H&S[WK.7-+T_LKX -&[YE(PN?*[?2>GA"]\0?ME[/559LL,PM0%%*UDS_79X'DB^.T&SR.-U5Z/EDI(7V[O#
M'@1"X]/@<G6G7@M;U/LZH7S+)50PUW>(RC*=4V) G32!@Y<\PHY62.IX]+ MY. I1NX]"A]M1M\3]QO.B>?RY.0CSTN7#=P'2MS($4.@;HL=']H!H2O=U16!. MZ4\8T7BAC%\/LF=LDAGY?
F1[&84BM1,7Z?#*W\CD>YY)&L'Ol($$.#D(MZ^$%)OEG<5FB2HT!V"4NH_NJ,(Y]%Z-@V0[/'5I&X7 3LL0KEX8O\..ST#! M<3&WZ6POC%,7A7#OH*KZUDQ4B,Y^.4EDE(8U?_]_4$L#!!0 (V
"%E] M5:EEHE,'YG!0 5 9VQY8RTR,#(T,#8S,%]L86(N>&ULJ;UY<<3(L2?X M_S.;[O#;NS;=,.DM65U5+;]3}(UE\6AQED5R2%;WTY:MR4 @DHG72""%@V3J MTT]X1.#*1. ,(!Q)_2$UBXSP""^Z_N-
W_]#]?-QYYIF'!OZ?O_GP[OTWA/IV MX+C^TY^_2>+5R1^_^9]_^6 _]]?.Z^3D/S_=71$GL),]6-BAJ2*]4->W'A-
M'H+MUO+)9QJ&KN>13Z'K/%%"/KQ_IS_>O7_W@9R<_(63^&1%K$O@$T[KXI[/_MZ1],);7 _XG\\?L ?O_Q_TXUU MXOI1:/DV_8;P]C!%_)=7@6W%W#B%[J^/H9<2^:'(C)>R!?SK)&UV K\Z^?#Q
MY(>$D0'IHI2K]-1.UW3\'S[PN=U*:8 $PO

MM"%\@R1>,;"(> CO[Z6;C\Q"]IG4 F=)T^#>D<2XH9)IPX##]PHUL MR_L;M?:?)FHAB!M)AMNJZ5)',VIX44;#3M]O>V3\<^A9D$P&"$4A!0$QT%SO MG\A]_RQQ=N3#@@ ND!-R1FW^5)#\ ('^'%I{8,%_3U_CAA7K/]'/@Q^OZ!WZ] MR!T!"-78]3,85="!.:135;30-$,$D"$0@0@8BA,_+0V-8C"' \;]:E>EQG+%_M+ (@^O 2[%ED"!VB=X^.@+.OA"=TMWT]8"W'W*R(O;^IG?T]_"?2-0PH9 =+2N"G]*$W*""]N M7_R;1>HP5L44(K7"/J.?2"/)Y#?;L/ LM<3E^(Q\N45%Q$SON45,F?-YZ9L MB APW$PL/(:*;Z%0]DT@*7SG\E4;PYK 1A\'QNU^F$8H<>*AJT,#Y@V^$_M]R:!M1V?9Z01'8X-5[.NUS!WLH%+\'N&KEPC]9M M^5BB'|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{8RM&2VP.!*%!]0621%Y?%P+.<4C]RF(" V6N7/F?O]K;Y M6 020?&G>]'$!9LG-)K87)+,2+K@$"!ZXY."0X/71*8W2" -%W$M7L]E:UPQUU2LV*D?,0"&/]TJ47MZW*2(A$D#6X&EU2K MW1*N;CDC1U1O#U6(2?:I9>L*.M-XO;$,#MOMUM M4;T%U-0;K[/WT&&T#;"4'Y;=G]$MD{S=W'X<)"8W.\T@1LHO%M8!G&X9' MB*N=U,X+%<Y-%QGRG9,@KF[/S09Z/# 0_)_MI6Y6%#[E/T'G\+&\G-ML)UPL^(QS[=#1L_%EN?QC-&5YZWC\\0YXDQ]?RZQ\@,L=\1F4K[ON$M:_$_M;@1UXA;(Y4?8 M=)=F7*EN0QT22CHGG;EQ(]'D'"WBT]>CZ5DI19%)9E.C:.QO)**<\[?T8[ZC M?0J3>Z 4EQ3E-7 A! L7]]9S:.SG_G(<>O6%0^0!73P"G:%/I&W\U*[-VK MGNM.Q1CI[.#V5[.!>#N>\X)\!TXP9P'%(K M@ÐM_0.SF]Z0MGSC4BM=L6+02R#W.AC[^C=)*DWQ!9/D[OAZ"VX'RSB ;T=DB MB8*]K(_KDV!O_;.YG_VS!_^O[# WWQ(^EK)A%68.]5B0K"&W!Y^^ L?/G_X.MX>Q;*];WF2%V!IYC5 VUH/8@4!YIGA&_;^ .2Q.1WJCL9KES6E4"\T-_6U MU5EX12Z"$FC^()?FJB.:7-ATTB>*C!:D)3)G8[TW/-MU._%)+AZ^$O=@*$)L;M>(EV4L_OTTB.+K/(x;C>^'H'3S%[c_EQ4AYRUPQ_3$5 M,YRCOI$O4-P?GH0QWOWB:=4?>N>%2#&);C6V()FL MNC17E(8&*R838FN: + M4GHO860?>1Y?X8L?9H1A5R&W*D-N]C/.;CQ+,#N0Q"!C_%'!NACG+H)0_&K: M?9CZVZJ$>*_7_M-)D\'2@G> (//37V\'\& R5Px$Z?25+>$*HA_7B##.QRE8 M+ADR2O!/LK;$)O8CK'ES8K.Z R,'W'-Y//!=RN47_T:?2ARZ?N3;/+>6[DLZ MW5CC'BVFM+^6BV$=^.(=&2;57L>!3 EFK/*!3.5A'_V23$G/<.+8&-/Y"!D MV 3EUMQ49%&;>5[7=Z?&\)=E0_$ S3WK&L'O6YFEl8*A2G$ME!K%41B]33_< MR-E:\R+L-T;"BUGM1>^?(:R8\;><9.%330.3XNI:T67PW%V\X&GJ"HD M6#!6D4.DA3]+H*R"@#H.C%&7P.!%"#<2]+?-036/3E3P8L4 70Q>'Y$R+3*P MX?,5(;I6V/E16_#GR;1"Y\ (!F>Z"-G$YTVXH/-%< M%9_X'XO4DB !+5,Y>:,Y89\6]F:4AZ1'?*A;&0[:WDXTL +\; XML88!D\A M9#YR+@@(*E+QS^L-R=A6YW;)EO/R)8G8KD7P%,*S]>INDDVF[\U*V,AE5^' M=F M5#RP+)(_%QO16F_!ZI$') QBL$R&S\;%F<-%3M.FZ8LY4@;R*F&/?+ & MI2!BY@NW*)O/FO{J- !S B/)1QEOR.V#X2!]&X_0[YV.O7+ 4JI!4%P+*D-*M MOD(]<^.GDI@=']JZ0PS!7$"9Q.L@Y/>=^"PEST]@2+"^'!M#MRL\'L%D8F$Y]\LJZ2M'89*<%TFG^#5\< XOHUM6ROT=%1/D-W.CJ&IP#9" YY6H_MF8MG,A.)*C.?E@ICJNPS*[0L5!+E"8Y'_A85[-X&=]KL/-+$[O,Z?B15:HP* M4$N5=+F<\[K":(G1H[V*PZLDAHD[3 -;B.ZW$$"/(C1LALSADAZ*!Z5'ZS2I+ MG%CSZM2P*#BA%/W&;YC,DR.8]U-T6258;L+ +6^I[Y}.\ T%/T][(W=NH](U MH&3+ lV+S:T!NEC^U="%H)@<<*+[7D-T@.0K?K+)/##CG*"'"4(+ 2;]G'-\GRW MYAXBS_J;I7;. (T5&"$\WL,%VY)&FT;)-PBCA]2^ # D$SRX56GJ5\Y]Q4GHXX MQ_P)K:UUQ:5F=\2+KA9*HAUOWQ.LZPGN[#W M16\9E2<(OEQOEW"IIF*KC0I,A6O. ^%-$D>QY3NN_W2YV5#'M6+]I6Y#;E/X MW84;V9:W-V]%_^$5C2(:"H++Z(R*U$?4^.3[%.'%O=69RIHQ2:.;L/O.>[-Q MXYA6WDG#+C!.>)<^%ZSL-Y?9&2.]2(D>D4%U(&\KEZA.==8RB; MJTFVJ9YDQ165F0 MM5-K3+L./6[`R+1 6#A:1PDWS]*0^/Q*I2_+]<@]ZPOQ<\I* HR30E0E4"ND(' MH6U*?AF17&%8$'.5@6NF '3:R[LB]9Y^:7O<;I N@/-:!;.'"2, +:WM G<2C M\KRA;MH;. #W",H)]..Z2/<]8UFB5+2VA=Q!$OF+6KV'MY+"7)3A4,ELI1 M0S%$+E6?$L:.IVJ'A5>OZ8NW^RO#&Z>V1/$0.CC#+<+!E*@ZCVA-!OE08I%+O MV@5 F*R!,F0T<[+%+*C${8^H+-*R? L@BK4D2;$1'GG(\S0G _@$)U XK ME$3):N7:P)C7'&'6XG]F.X!'SXW6,G$Z#4]HFFF/)V]#:?"UNY5G4RS:/>L% M!&>3C9B\(S:?R6A&SDNH2GZ4HZ)'_@9AW0V0.*0\IQP3/+LCR|KZA,HA<)F M(.SW&YI.-XG$POBK@CUV# E.:Y=M(V'(=>.RNW#:6=ANXODP)PB)U_XP M 0K@I&#E>IZ@4N@KB$,C+A5]=445#YCGR,35QD[8)O3C2F0O>J9P=,I;<&EN M'.&>.O.\3I+DR5QA$707>- Y%$.(?=6\U-S'#. <9.8V.=.0FK,2&>!(^K+X9D M!.5 F-9"\@))%2SJO2^+@6O_GR-S M9C"T:.F1X%,P>1/(N: /81"IZ@Z.P-1/(N:.'/81"IZ@Z.P-Y!;Z^H< e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lS792.B MR"!2NY&FC\61(GZ:/:7 > 7|(\3F.BT_B[_#Y%RC5$Q9W3P'.,PJ3W.S.+:3 MXO#W-'OV;5IMG>O ?Q9/%< &T4.06U[Q[Z=!%%\:\=l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|<+F?TZ7? 7* M^Q$UG0?^ZL;K.T@P #/WM;M"[,[]F,WOSP) (>MW&,HT49N2U[:RA].?Z[C/Q M)9*:(T!07NR*#AS0VHS4I73M\M&+3H^>'VX6OJZR5#%[2*3E1X0R"9__+0V12Y !XP MT)V?>.E7X]2^ZRL$[C'99A.L2@*\ MSE)5'44XPGGO0$-@*&LE9# VNW^&/M!!,<(5V$^4; I6?*XAL\Z2)^!N^LI%-M1ZMFAEJRE<-&EB7QG<\T7@=.X 5/N[$J,77B?*0@?7K-P'_]FR/$/![*&\0 MY LOD0OR\GEI0>+9OE*>\&,< +F5LYPI9)^:,BE4>OHE@!,JCRUB[M@H.,77 M4G)^0Y!=,_W1(+N;[1N![;ET4$VU T7$I <9 (RSQ^O1_H6F<&>.[JS!^H[M_KM(J3TDJT4V(>-IX)!!=\W!-)UEA\-HJN8OA& KE4=(3R#O 0$}]G$1X+. MHWP((\'IR FNYJ;7"0VO #Y_3,><,+F%1WYEZ&KW']PWASP53@(X'G4,Y9BPG-=;.I9Z9K6E[39T$+H.VI]D;W+@@8[*>,55YO M3NSV0R6ZZ,%Z])20/!(OY# \IH5+T#L& (\1P.ZJZO2%62@6G3QU*B>;20<=<.M/GEF2+B$Y"N74=^.\PXX<>G;P8;>QPS^ "^OI+05;X':|<=LRVT+49>37.\ M\=-&Z+Y1(&B3C#A)]>M^.33<@RO?#+7M,TLO/GP7U*K#[#Q9T]N? &E_6_0*H M@S??T8@R5U@O?>>,/E,OV0LYZ+Z;FWNAG8|<7MV!^V+_MVB&UXO[R\_]?B M@@<_P2YP.9M_87+ G8+FL]"UB1C_F?HTM#RF]M+9N+X+1^UP[!5-E+?MBSO. M.UF@&.FN.M* \6[B] 5YR86{?)D/8PS.QOWT5K#*5C 8^WK6M%>N3R_9M$v0 M1M#//!3>>G&35(O)HX9P5%$I#%?]2 M+ 9Q$JI/G6JK2.'"X6!6W? &C6S=;% $K'8]\>)01_G[G{$1KF+FTZ;C.#$1%9X M"&(V58H0@D!^'%"]7"R, J>!SR\M/P0,(B$?VD40\LQ:+4^O-## #2;Z;5E] M3C64.EY0&D%"2=2ROV=4N+-5")XK2UE(NS_1.9@_:=0#7F/3H.$[C!MK3#> M75L;JD@_IVB&,|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|"CW^+F_AB!;B* [XWBMLY^.LU^N$Y; M\[V?1U>?KCZ=G9R-1Z<_CR<_GTU&CP]9L0<\L#FL*.=[X^?R7]><6\C3)\7 M_/P6P%\^+. P_?.G3S]^_/CIQ_E//EK@ZB>GG_[GX>NSO00KZR/T@M#R;/!A MA,O _,1??O5M*XR9DZO^]HKG_[T%C@? MTB&2GSDZR8]37R&C?(Z6I/Q1^RD/3B>3R:?XUP]_^[?1Z* (=\$3F(BKWX. MMVOPRX< KM8N:2K^,HG _)W\9/NK3^2'3WQMQ"1Q.>M30Y]>0XQ+.I OEDO8 M^:P$(RJ[*#:S:GO%0] M6U.JM3'N9fCPL'%@6WC1L&T_PJN&WMCT76A#(""}BF:;H.P1@:4%G=NW 9Z' M)F69G@"1M<1(E/Q- @X5B31UMJ@&_ ;16 W.GZ2CBJV.?ITW? 67X$E-/JC MBJUHC_"RPJ[;&@WQ%H,LVQ@*?!9G9?TV:+G'F[5>+'>1)4J-3&J+|"FVA@ M;#BYKO7]J\%+(% LD[ST\+15"L8BUX#\&>$!W"[$2/HN*9QJZ3DU;++59,Y MM!? KU95&9l;8],:*+$B,1!@)XB21ZEN@,T@2@FENCEKK[";,5LQ9E]W T(+ MNDVW=[M6VM[E"9-36MFX.?[.@N@?EAN!!ZP=N'!L-0C3V] +XSA2KEYR65+1 MAW$\>?1#++#1HN>[V!KI1"#? @&=@1@B^<42YK^+HRU8IXCE8K"YUG_SN(IR=3& ZXMYEHJF../W2+Z%$22 M&<%LVAP.W =!1 [X9 /GI85 \.+?0 3LT$?!O2<5@B@Y5TB(_>P0M_YZ!F@ M#:3%9%SYE S"(FYX3V?&,3F8 .:: *:.F4JUN;N'OQQS> _:@8AD"9[K!2_\" MX/U)M(K'+&O-X>C `&Z4?UO7DF[2AY$G9,(=(F1Y"]HYYU%S,9VL%D0) MC&G(J#SL_K#Z).G? PL2= _O5>@7N!R[6'+,E(E1HBD2W3DATZ^EES*.B#XU' M^H*7?Z!^N/ENFH_9QYL[#6/.=9.,>8UM*,*S)//!5]Q'VA-I]UGX;8X(\!8" MSP'.[EL8DM8GDPL\RI/R>CC*&LL_']RG%'2\]A>9"\AD(C%MPO#<4FXMH\X M5-H!,%%I_&&OTOB/WZ]!OY.7X,067:8M>02QO[RX>"W3P]'D?'I]:=X,(K# MGW^_/+^ZN/I\=OKY\NKDY'0R'I_LQY9'P105QVDA.VL:?RP XYCW:8E/ZS@=$ M^:*,]A.Y.[']/DKXZXD_;D >\3+BW.#*5R^&3 KE M.B60ZI>AAW<H5H!(1'A;IA/2X!IT*[](l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fZ.2IU2$K" M9&12ZV2@0A:. <0<#VW+_"2QTA[6]Z,H3)LA69&O9^(L/LO0%\<#\IU0IC\\$6>87.5Z0Z9S/P01 M_QH13LA3]'!9Q+M!=EB]<@)YZ&*?*O,.BK\W@G958\X$U98T2>P/fZZ?"& M1LUK&]\XSD&,R]G)Z0BQ[9O#GM*61<.KRVDB<6\%KW%X4?%Q8UC]<.6& M0?;-'I?!%[O1CR;WT$/#QCB==)/@]I-SCXJM17]#ID)"EK*.N+U2$[06& M[5DKBB8B.:) M0HO0_2: (]97\99CB(>41^4-47B A*DB9V'J72;W2L5$?Z M)\!N:*+_R'Y4#:6B^D/IN&UA= 6[[KC+'(4-'#5-1,=/((^!DE]@OL%FF*> MLRS-68&S%,APU.P38.J2R[BCUD&X\ "CMQ#@%G:9XUE(V+EKUL:,#*=]SQ:8 M$(;.%$81 (_6O(Y?.E!,) =$\L#.YM\#$/.1@@5FG5X 0IQ"69.#? =-+53L MES:!O8E^B'Q"GJ47K0]L6>E9R[QO0$!JM4 ;GV"9L9IG*4]AG.WX.'MFA.^ MM[HIH*CK-&I$!]*%7!L[*<<*/\2O8(!} B929HWI_?*@8&DB3]F(!T/Y>7[" D!2ON\A=PE7V=#@UVI M=_ BH0.ZD'>4&H%_ :":7!1LAZ$"EZ[&RGL'PD&%_ MUJ-? TAICXO11/6_T:!%5E/;KI$+8F\'+W]EA0!!P3[_@ZTDD''7&#%0Y24 M_T8@I(L/=+BHE'2!!6V3&@_N;#1@LZ] M=VVM86@=IK2H*.T{((C0]?004SL>TN=^G%L+>=AZ#]:V':TBEZ2ZOP%S:$,: M_5!=LZW2@ _^5] MH_A^S&/,Z24(H,TW,[@NRUPP+\N, KW0\,EV,F&E#9KTLX148DN0^F4;C$X_G77MN9&#FLU"]L<%'KTB: M,@:0%TF%)!4Z",6&)0#/H(N(T @GTK#*X6;70(O#OPU0]$ MLK*<'65EV7C?4?O>[]%KD9I7T9ZGLB37RNP(X;B;**6.BGN[=H/0B+2 M))Y15;Z6RGJFZ':%.$ICV81H.O=AWWKGD@' 3"49*F[!KC^FG M903U2))1 MQO0<!-RV;&D*-'INF[O*- P(UU._M1902[^QY)D96=#!:)67\%2AVRE?DC] ME[8S3F87X22YO\\SL>.M^O[>AWO'Y!=<9#9_L=X.I"Y:OROSG7ZP MVI1YH+1LA\0O3H?2$P/M*5P.Z;Z!;A12W<24TCV0-XN2?AT,_ 9(`BK@3#=.X M25NDKWK.YD=N49;6"[71070TIZ]?IPD4?]1*PWO (-A*?W C1&$/3A[H(<\< MIPWG%:<-^ <;_MHU;~0!0^ZXBOQZ*6<=W7<:TD&]D%0U8&A,^4*F]*^0#(IW M%RK)83B*6[Q^D@X[H9!L97R/*_ T#=*<-,PZI@A20"X,87)3:*)L<\?8#Z#D ME7E],6-ER"T.YID^@T@%9SE&W$=ERI]9IX]8$"=8P:%-N_=2F8 H+UQ@S.D) M9LQ5YY$@0*$I"GZUFYTV133?^"!.<\V4E>To /@97AMVI?>\/8+W../E2;, MK]"QPJEH\'ZE?*'5DWQDT2.EM^98+G(D\2,>.'S'%@T6A >+G]}^Q_4>= M%CX799*4GB5![9I5&/9)5/L-A##ER?.Z\<65;^!'_ M]">"HVQ^.U*.V7_EH M*'O(5*@F9 X]FX>9NJ+GAA$/!_IU!YW%U.3K.Q\]{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{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|"@-.F$]KM -=Q9$\=NJ M#\) B*S.!N,BBP%V_FWAT1[@%}3ZK\'YIP!MWI.N&\6T%WE.0\O/\/^%3D*2/X0Q$ MHOE!+X$3N6 VG^+Q. "_B.7T#.P(O5=&;M|(}AC@)+NWU3K*TD0.\?%,PWW#U_@YYUU?1;TYW,J YH,- MFC(S*;@TK(0U70V=/+A9+#HO71S/2X??BXV??CIYSSBW!A_=D8WY+6#.5#1@ MRE0@>)NX(8%=5>C#VYJ""GUYK_""MXB-5VBCKQ/CWLG"PZ6CE-)%O)ZVII \ M%XCY"3 J[$K)O?%L MH^D(2#^%].$ BWU"6 R"%.:726I)B]F+C_CD@*/,+] M3?[&+@L(8I7-E[T$>I2&;&F_PRRZ1GN<3M2+C(;OU8;>*/Y]U/MQGP6B?K" M>'V6,@4-9?"\A(+OIIBAM'0VL$E.;/_9]W] U2WU?*%3%- DAQ+D:3DED21EYH.F@E9U2(^+MT?^7+2IF!;TY)EQ@RUE<(_TE;$ MXX*F"::O6NLA)EM+MJ_9U=>]Y+!0SS#!CF+XWQ^<*:=ZPL:!BXX/EW9,*"]6K M28M _.;'+UF#W'M!.8>^>$"LB\$;:19?H9Y?M%U^.GB0O^GP'33._UA(2>O MGN0Z6B+T((A6R7>UI\/ZG?00F\K8HM3_V"]8;U=KU]\"\ S0!M|@>F9NO$P MXHBN)V#[":R^.GH@?.8O)//RXE=O?#R&L@T*,[6>]?.FESYQ=P_"" [K)'(_=.:::+G;\%4Z8>J=(OGY+]-M\4+2SL)MQ8M13!'U@KMB./P8%YA$ M;QPD! 3()7X& ME50 M"K+4]\TLVP'9,B00J44&40\!7I3G^1F_?(;)>\)XTM;5#EKN:I:APR MI$_XM;D@R=E39 :G:'%$16PF/.[6-R%OBF! _0C8(?O/1'W,??WK"[+) ;RS M=@=T98=7==HQ#2BUQ7IPV"6-%UV]"99_W59X7UKU_K+RG6BK+S%3.O\&PN2V M^U<_".)\WT?WX'&\1V? S%>BO33H\J12">MW.YN^IY92ET_56P28)\#RS(.M(X MC$!"0H"03#>/R-]K%Y?MM\#DO]Q%V>_MCDN0KD=QWZ-\Y^9IH#N80V(GYN36,_Q"P^ZV8.I]9^8]D1P'Z:.IF^^AL\X MVS3+DRRM? 5.FDYI95Y60.V)L\8[B+]O=Q(]#O,9B>[G]"C;.97B0^2J;.@4] M0F: 2IO+'(C1GD6Q=*4Y)HSI:19]PUC\B,N3 8[.G/#*$0;T:\[VWCL(@YL.I MTTW-]&&LR&M+B2%Y3O(['[%0H"@STV.MMMX[W(3X MTO3$=I)@SP_+*TS+EF5Y;'E/N17:/F[? 8)$*)=U$9:9![1MA.PN4Y$=C6=Y M-K3<1Q+"AFF-PUD"2(Y>(_=I8XUVWR_J&O(HQ>?GAOAT:?:8>]?F<{1>NS$' M+-/? >F_MH%;=:PZ,YYO!HYGL;Y;KKN#.35JA]\R?QEF1_D7>'!.R=X\]F312\ M=[]KT:74?Z1]QU5DP6\ +I;8;)IN\+>+^ EV8J@]X=GP$2";D9Y%L}QN(48* MA4K=/MJQ\T1X,)M_ #Y('W6>O>* [V@':ZA721Y"N _1F/G;H,7N(4HVL5< M02H>B2./CBQ!%X\^N/TSJG-P^ODX0TR^U;.^,DG;-MR>2<5+LB<,?N_5NV_AD M,AZ?MJ*3Y5SE?*%LF%)-]+]UFUP ZT$+;9\L%LWD,>L9+:]3RIDA*0!XE0A2B-MSDAY[L=-7G:.S5^0Y07DHB+>>[':.,NN:)R$A815(NQZ%"N0.BTOP7&),WI."7IXP17C_$'!V"'']+:=6T;>ZOFUV9MC)@"@UMS,1U:_ MDD -<6[:2_+

]@HQ=R5@PL.5;!@AA,CGF;NU[X&M_M?*]F)CX],)@&H5+/)A_M'=WMYJAAGG"%970L;%%Z^~5?RU'_:*$9BO7%B5^_SQZ\|\8)K6;?\2)$=[\\M;S'}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|#JVBUX%LGO#HlLUV(PKS.M\.Z7E+]UV9>=MB?,]TQ +KT?4Q2A%1!*=., (\5=2P! M)^WGK}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}X!*>G > 2 MIV=>_C;=D_9-PPQT#]W]ZT'$]#/QUU)0=V)@7[K]0O]OP'RQ@!PIAN K 7(MUM%'!&U !#K7Y. A'$AO]*=%7TX35O?.SM?#U':UISEQ>) M>HI3ZGQ0H6'R1C!HF2PM4RR3=[.;"57'S*&EO&VHF-(A!TW1I6G.Q*$T-T3UE M*W'7M*%N@L.8%$Z7PLD9C -+P$_.4KJ<[M-.!P\S;HIT.CD1;WN;I1U[M C;^ M^.*3KU0]ILS7:V^6*]TNPCl?6<&7CT.ZCIMXNV^*,FK[CXDT@"XVM2'C_M* MXR>[DY"8FY4M&'/-!7H7#Z\=53X&"+):.^6VGL]@V;WV]N'!)ZX* M.3-(Z[*@CY5AKRO8;@1-[\.?O8ES*.T.!A"9IGK=I0,7+'3{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l?6<&7CT.ZCIMXNV^*,FK[CXDT@"XVM2'C_M* MXR>[DY"8FY4M&'/-!7H7#Z\=53X&"+):.^6VGL]@V;WV]N'!)ZX* M.3-(Z[*@CY5AKRO8;@1-[\.?O8ES*.T.!A"9IGK=I0,7+'3{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l?6<&7CT.ZCIMXNV^*,FK[CXDT@"XVM2'C_M* MXR>[DY"8FY4M&'/-!7H7#Z\=53X&"+):.^6VGL]@V;WV]N'!)ZX* M.3-(Z[*@CY5AKRO8;@1-[\.?O8ES*.T.!A"9IGK=I0,7+'3{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l?6<&7CT.ZCIMXNV^*,FK[CXDT@"XVM2'C_M* MXR>[DY"8FY4M&'/-!7H7#Z\=53X&"+):.^6VGL]@V;WV]N'!)ZX* M.3-(Z[*@CY5AKRO8;@1-[\.?O8ES*.T.!A"9IGK=I0,7+'3{!FA1,.^Z=53(.*%K& ^ .>.P*. M.7/%"E*8FY[P7_NI"?_Q^PMQQLSF]YX# -]")+++=DM:*6,PX?FE8L,89(O]X"X2Y=P_>+!?>B')1U^V"-5HP108B8FU @XU2#9NKU0!E,SQ M6KJB'!M9BX0.H[ZOFI.]'4^&8];/F73O'E2O.'A#=:82,(;N;&L>P%R+'L+O.1J2W

\ZCQE;O>D=GQY\MQ3N;W.%;X+O ?OAV8# _8P0Z0 _::0 M_2MI3'6^0!;BQ6B*+ _#%>BV1]<6%6BU3*D:+"?AUOEW+U$22^6H^$ F %21# MZGL(W3X/:'LFO;Z&PZ^8!?
J%O/B/KHINVBPJP2%W3=397&U156PM,QL\T&60D M,!F!R0A,AD\P:\=DT/%2L5XMY6O07)2KI3B?$*T\3:0X)ASAOFHMZ >TDG L M4U _E694M4P8*.@Z!*0A,06 *E,0F) F
)TFCJ3*=73?'7[,#9#X9\\F)UY MP+S>@E/9P:GL/74+3F4'IB,P'= _$='BGLO.@+ ^F>>^ _= F:+',71Q)>W.(@' MS.L9V^HZ6#K\T*5#L/$0X'^ _W!K%W\CZ+X?E*2'=."V$^S.$M]&?NC#]ZN M .;.N
L#!(<#W |P _lOB_O5%=S=%22A6^52F5N>K?*(OB_O5%=%22A6^52F5N>K?*(OB@K)TA1$HS5+1T 'W2!,D _35S1WKLVU;M]V@ _0-A=07'>C'P08Q@*$6Y MP3]VQ]35N*''&I_DR-G5CMD+PE(L33)?R-
S F >LY-T_E3%6%\NHIA'H3[[M-^,&7%OB C?G9R]O67X^@!3X;!FR9W^'?< V707+V9^YG*5NZ(1^@/.!SQ\4 MG*]E4L5HW4M^BQ $@7\R?EF#4Y>
<(.7M!PAR]VO[P[PGRS+@]&#=O0T_KF=&$P\HZ6?W5KFSG(QGG^[U M?4;DU46$G\#@NGNQJB2,N03G=O8N[JM$]IL_7K@?R ,^[Z!|%CQ[=\1A8 MLF0C6J
I>7E];lUA]=H]+>\6/3;=8%K/$Y_$<%EV/GBLLPZ7WB^R>")W+5Z MM.X= 'Z7VC6_4?OZ%Y"^=6OK2A9>EBGWQ\6I6Y7/WV4!0 #I+\;O 99-9]% M,"P2,.&)=#=''B1)'LB@MF;1Z.*.P"K,#L'49-
A64H:42!2VG1K6N-B14O-87 M"9%\V=*N1G*!' _I"9+6<')F2BYPS2ALN==G,5L;B\,]"_-2>-EC9YO8+<7Z M(KG?!UH:BB%$/(OSBWR,G=@=/),.16'+O3YO4.IEIMWI2$M14]\^%_01MZB(
ME(B_;)E+.[\$;,,)VJA45S:?"#!=/*PXQ M$^G]/B.3#LN,4DP>+_5"M0*YB+'3,$5D]EO:+26?9K[<$E2HI9IO)3B2\+W+[?2KA MBB(3W:RFI;*5+),)#*3T@P*XW[3 L$PRZ8Q+6B3UI
7BRU#&DH=L1-4S.6 M2<\(+N[BI3H_KQET?#(KSU#3/>)W"FVZG!/K!3[5LT2Y*D9?:."ENY1?S$V MFZ5Q;.K$I4R2WYBDU,D@16CPI6/58K6?,K!E]NC$,%>6\O-
V'Q*4@CD*\L9LF^G;F@IGLRV.05O5*I MR810 MB6BUB_.:T/6JUAE61/*E$$(?E\8EBNF)@.,(D2;DGLCUNF$1=.DP15& HG#N MXT^\8/1OS^R19M*]_22I7G?YDB61M8[&]4)OTTI6! MJ=KY*B3-
4'N.]\T+/(&$Q2\4I96;I!N4!ME('A#DP;.[*XS;(4ES0U0\;N2K M22\4Z]7-M5TWWU&/0&7>KA4;O++#17GD,N!S1:O51TXUZG.[^\IT*YW;TZ/7+QS=OW1P7_M67D#QT7-V/ # 6:H=&OQMM6_"?
OLZ>9LXUQL/H=0EA$#=.\^')3.1_ 31.0^ M0@0!M_L$T*XN |<\VG?UN5Y;T<^<^G1 TYR:08?'IA7'FX59LA4J& _D9[EV2 MA9*>F'N*8. ,I"%F68$' [*HU^/*JY$U5!?;Z>I@TK&O^&#PXBR-
H!-@&5[>2?A MWUZ%!6=Q*^7Z_('FUT^(\"LH9!>6.OE5255#.#"AG]!UB):^?JP3JST:X=*4" MKSTY!X5)?IKF^C+0ZQ(I&^2>J0I"(X]M$G"M:\YO5!+^OLU\FID1E&5+9L;&Q MM$!W
@<+ ##\MF<^U:?'=(Y GVX)8:TMYI2RO\[L4.0XB<5+'=QU2SG;ZKD+ M)>1=>T_= _>$8_#[.!H5L?+VX/|=&PG=7O?M"ARK>X ?;],W_&X!B:# C)\=
M(:1\6[MR;Q2;693F(;I5S6B2%]J9##50,0%UH55K[G&/$+"?2\]^ MC*HS[Q69\[5P=K<_]8(MY[+ +/$^2\47.4H6Y/,\6W?GRRN7GMR?4$:8;^%7-/DLIPIYSQV\G- MZO.MQ8.\$VS;FS[! O7[G%P**BG?
A]>U>YYT]"+U^&YN1!,6QBJ<;X92@ZX M1+HY'W/0W?*]*- T!#I;P1FE;WQ&*;BA?",^UX868BHV MB _E/M)L=%:<)]#;=<:SXK>AV;<M!!A"N(<%W{[SI]*6R5 MPC'8 1S,[#TY7&/30KP-
M5L3?)]855.D]JC;_O$!04*OFN[DRKT2,WJP3W1K)>EYF(S0^43\%+3LQE"I MB,2J4#1T;>C@QJWO$C.*8D5!K"B(%5TU5G0 @8OIMIRJM?&SP< M7+5U>]$AV&?MU0HRISOB?AO.\OE9.-
\M=]]^.E,Y*S/X1$AV4C_DITPXB%9>^ MS;(+ N@"4#+^QO[/V]B@EUJBK\O/M@60!6R18E^RGQ\)LAOM;LZZ 9_MJWQUO9:S>!B/ MA%*XI+C)@4 2Q;K2AY0 &QD^Y#5?C
YB.MN<+I2AB"\;3JD@>OKO4A_2 7 M<>* + _WB"VPL6=@4O>7WL6N-->%ZF#KL8Z=2P-X]>4WX\(ME1 MUQF8%E0AY2"]S$(M4R(6'4E8T$6W9K3C0FGQKMQ\?O(7DY[C9F!)*E6+$'*/
MGUC<)E%]'2I(_.F^ XCOX[0F)6),"DIS?=^\U)R0C;0$?UFIJ78P#B&>]G; M=E\AW*AJY1*Q1J/%A\9N-9'B9_7H. I3L3GMU&?#JER3EZ"EY6J1RB1K"Z%!
MH7+WQS"(%Q;5Z]Z[_\G1O)VCZS+"R"!?:TRK\8XJ3*JO'SV M2^ =?40=00!"L!7WZS+ Z^_VDY@6(M@4)HM*"+ ?>!#]" 74$\Y+CX=]#6I M&()+W87*S(3^MU+ (9^T05ZW!R-
3..F5^>K*7Q\29H)9T8+.:1JW-#86DC/2 MM#758K.;79I_E@C:+*&5.A>\N)\Y'N.@W%.U:28//%>CE1,AUJ"$G M9IC2V(9+>@+_*.WV%E[?0O3>6 DF.N-14\9Q70-2QR1568Y;%2AV+'U/1ZA[M[L
YT/<7M$=X&X8P,T-&K<%KS>Z(U0FM7G$65 $V=M1EU^7X'LKS!O=#5*EF." M'STZX46U4H^+A?&C!&&)%)$F4S>C9G[,D0OT05;QZVL&IXRO?71//EI%XA"IR
M*C>]AHUJD7<[RQFWR"44L3E'JLBNG8'@.;?M)TQ$X=L0ZR0=+]U5):0.!R- M54?2@^!VL+UTP]M+M^4.:/:MA&6IAQHBO=/ +(=' IF=UMD:7,DEYOT.!I]$C M.!.AA4#G/;CP/44P]Q1^1C?
I)^ISL%GU+=7Y?!5OC]9GHU4C8V.73VLDY8YG MLVB%C&8!?4.7#G/TJCK(>>X7#_.;^+GVG@#MR=;11 L6J]\]J$ZQ=OT\=D!]4 M\Q8!\E\WY6!5@2.!IE!XR3(@I>PM74RL5!%B.YS]OW>A R"-
ORBCYP*M]*48 MJZ>$]IEL+@U!VKMPB0XCIRN\3T;V*] _'2CXMZEXH.*WYY/O_F<7U-P04K M+DRZEMOFV?YPGD[GIHN6?$$*CKPPAKVG(\+(^BX$'(ZPK53.O73^8&"^73 M!![\C747"(SYF
W'3C;/F#/>^I[:(T]"*EI/511-75052-DFBN/AA#=5W=$ MX?%;FG"?J>/IB(&@3;_!UL^WV@3)V7B781^\V.'C2X!L%@4LQ MW:X.+H9<.U0XX77E5Y_8M2'Y H7KHH9R%#
[C1B'1PI56'P]I22E="X7E119Z M;M[U4B3$9B)R'SG/9L@/4>6],-NWT.1#$;4?I,F7]&!WK"KWE^5$>\%5BGQ_M-(D9LR'%LC%/E;V0&]I*>4^?Y[*XFPNH_7+0!?.^&=C)E4$&4%*MS< (>BLH
MMQZENO/*538#0 FR:(G>B-# Y]XAN8]*=EI]JB$9LNJ%_"0'C.!0[;ZM[IAIW9KA<$!CSQ.Z0 M8XZ]CQ?EH4]$Z>NJIJC3/___?S:/R3J0+ 0D@0<4!I]+UE8%Q__W+++9A5T;(M?1FAM@;M_?L_VV-
_7D.&9%,WK<>>==N:U&!UQ(7TP*\/0ET+2%I(ZL'W/DKZ M3%K8ZTF&N0>.V)C.QR<3B+4?2/+1%L378AG30F[27)/%I EQQU"E#O._T^'3X)O3,D!_#C>F8T\4"?B5,OM@[8
M9]65L(&%K.U_ZJ;\NB:_==2HCH >@50<&6\(14]2*ATC];N$/D2_KY/@+5G=-M"Y-)GKD709>3>A$%B!0#@$@3+"-VY0@A,E08#RL$)3,L>[>:Y)FU:C^V9I/[*)
(I.%1O(F\]NYZ+%Q}0XMJ@0$P,"@\6-ZT[2TYF(BPG[3P=Q$KEL.X1.VIH42HXQ22&L-LST3H0_^LJ5B+Q/=_MSC1N:+D"&8ZGW'RS5T M(R\EIP10\6ZP1?
B\=D2R/UTBZ/&M#89A\96(:NW"F/47?:[";>U?%*IP)9[D^\3 M>IYAR1SQ5\VBT,9I8I:C({+\=&&DIRI6G M=;[9)&&4)FZE# 3V?V6MDHNR%;6AD*F)DOV7%3,
%6W*1XUT^22L1N+X,3Z(BM\RQB^%)DA*&GBS M'F)CH0H35RJHY1Z5M"[*6I.2N$I@YJ/&VYV6UW1O5K&>'*8EARIKN7"^/&2319#]SU#3O6D)--/I#<966R#'T,33 M-
RV\Q7ECW9]78LX)(8NP>ORHF*%BW-S\L8V7R+]9^S;(SLLK_V #@IXS);F.N?EBY4EYW^PX7%O+W76;?8?6L38# M6[^06,'Q<:%]AG@(OWF2<,MYV>K?A'WV=':V >_-
YQ!:N#^N_%-4F>]=MW!M M(;P7;YI*7=O470>$T?6HNL__UBG -G T;*WYY/O_F<7U-P04K M+DRZEMOFV?YPGD[GIHN6?$$*CKPPAKVG(\+(^BX$'(ZPK53.O73^8&"^73 M!![\C747"(SYF
W'3C;/F#/>^I[:(T]"*EI/511-75052-DFBN/AA#=5W=$ MX?%;FG"?J>/IB(&@3;_!UL^WV@3)V7B781^\V.'C2X!L%@4LQ MW:X.+H9<.U0XX77E5Y_8M2'Y H7KHH9R%#
[C1B'1PI56'P]I22E="X7E119Z M;M[U4B3$9B)R'SG/9L@/4>6],-NWT.1#$;4?I,F7]&!WK"KWE^5$>\%5BGQ_M-(D9LR'%LC%/E;V0&]I*>4^?Y[*XFPNH_7+0!?.^&=C)E4$&4%*MS< (>BLH
MMQZENO/*538#0 FR:(G>B-# Y]XAN8]*=EI]JB$9LNJ%_"0'C.!0[;ZM[IAIW9KA<$!CSQ.Z0 M8XZ]CQ?EH4]$Z>NJIJC3/___?S:/R3J0+ 0D@0<4!I]+UE8%Q__W+++9A5T;(M?1FAM@;M_?L_VV-
_7D.&9%,WK<>>==N:U&!UQ(7TP*\/0ET+2%I(ZL'W/DKZ M3%K8ZTF&N0>.V)C.QR<3B+4?2/+1%L378AG30F[27)/%I EQQU"E#O._T^'3X)O3,D!_#C>F8T\4"?B5,OM@[8
M9]65L(&%K.U_ZJ;\NB:_==2HCH >@50<&6\(14]2*ATC];N$/D2_KY/@+5G=-M"Y-)GKD709>3>A$%B!0#@$@3+"-VY0@A,E08#RL$)3,L>[>:Y)FU:C^V9I/[*)
(I.%1O(F\]NYZ+%Q}0XMJ@0$P,"@\6-ZT[2TYF(BPG[3P=Q$KEL.X1.VIH42HXQ22&L-LST3H0_^LJ5B+Q/=_MSC1N:+D"&8ZGW'RS5T M(R\EIP10\6ZP1?
B\=D2R/UTBZ/&M#89A\96(:NW"F/47?:[";>U?%*IP)9[D^\3 M>IYAR1SQ5\VBT,9I8I:C({+\=&&DIRI6G M=;[9)&&4)FZE# 3V?V6MDHNR%;6AD*F)DOV7%3,
%6W*1XUT^22L1N+X,3Z(BM\RQB^%)DA*&GBS M'F)CH0H35RJHY1Z5M"[*6I.2N$I@YJ/&VYV6UW1O5K&>'*8EARIKN7"^/&2319#]SU#3O6D)--/I#<966R#'T,33 M-
RV\Q7ECW9]78LX)(8NP>ORHF*%BW-S\L8V7R+]9^S;(SLLK_V #@IXS);F.N?EBY4EYW^PX7%O+W76;?8?6L38# M6[^06,'Q<:%]AG@(OWF2<,MYV>K?A'WV=':V >_-
YQ!:N#^N_%-4F>]=MW!M M(;P7;YI*7=O470>$T?6HNL__UBG -G T;*WYY/O_F<7U-P04K M+DRZEMOFV?YPGD[GIHN6?$$*CKPPAKVG(\+(^BX$'(ZPK53.O73^8&"^73 M!![\C747"(SYF
W'3C;/F#/>^I[:(T]"*EI/511-75052-DFBN/AA#=5W=$ MX?%;FG"?J>/IB(&@3;_!UL^WV@3)V7B781^\V.'C2X!L%@4LQ MW:X.+H9<.U0XX77E5Y_8M2'Y H7KHH9R%#
[C1B'1PI56'P]I22E="X7E119Z M;M[U4B3$9B)R'SG/9L@/4>6],-NWT.1#$;4?I,F7]&!WK"KWE^5$>\%5BGQ_M-(D9LR'%LC%/E;V0&]I*>4^?Y[*XFPNH_7+0!?.^&=C)E4$&4%*MS< (>BLH
MMQZENO/*538#0 FR:(G>B-# Y]XAN8]*=EI]JB$9LNJ%_"0'C.!0[;ZM[IAIW9KA<$!CSQ.Z0 M8XZ]CQ?EH4]$Z>NJIJC3/___?S:/R3J0+ 0D@0<4!I]+UE8%QO__W++!9A5T;(M?1FAM@;M_?L_VV-
_7D.&9%,WK<>>==N:U&!UQ(7TP*\/0ET+2%I(ZL'W/DKZ M3%K8ZTF&N0>.V)C.QR<3B+**

$(DD3,)!\GB12N.7$'NY!WYGSC>EI7VI/QY M]U/[J^>_UC(R71+K5PZ)5!";.Ð;P^V^,=9S"')@G7TB3KP8&&'8**

MP;"#ZVEAYDN2&MX,G5I%>4GXB3Y$N929\K"1'7T_K\.8:XN,+GVZ/"];2P M!F,-QKE:7X^J^(!:(ZS:7KE/\ZJTT+>-^=XD%]9COCVB6%1/*\G'"7Q{(;; MS¥OKA1=,K,,X^^B.>

(8/6,/;R:P[GM32#K'B%<==¥P>ZMD)K'"JG]>HB|U7R-MFG]+5Q/"[/QN'@~KJ>%30>;SAV:#]ZGA8T'&_54R0^F41N5[7F&GSH,X?3 M&JWLK$77¥)^5:¥TC"E5MS4N-

LID<3$0UVQW8E:U:Z-,(5Y M/Z9\KD06_R5OK*95<0TE1A.X/:+W-&1:=/ M&73'6O"&=C<UV^U;NMY)E$2] MSJ2;6O(Q+U;VJE>2>GWMY0;:L\KRQ&W4EB(`17"=Z9[.?

2[@GX%[Q? M;8LFZ3A-XS(9-_8E/MB87A'2_UR--?NBH/%KQ^#?$&N?HQ>)+A=IMBAFH2R-MXG?[SJBSK|32$#"2 6!@L,!@<1V>$,/%'\#%RXE=PV6WK5>H97N15?KB4MJV

MG3Y}VPH88)S=!/RZPA%#+Y@458^4R1X2CQNM7\GJ4N]CMB.B]5]OJB;^P) M;3G4]FP">1^H3!?-QRF"B1/)\T,XN$P7!I'?8C7O&T/>W0=¥I'?$-O/TE"*Z M^5W*TFM].9U+W}1O*-

!]>K?H5RMW M_=L1P<1=VTR?,TKX]T_H<*F2WS90HF3XZX1C+M$_WVBYW[WG$6.0P"E6,%8 M*"9 @0-.JL^/ZL=9GM>$R2X%G%$T=L!F8X;]@*Z(%OC8B*G@V5-+U<0+T7)B

MYB3F@-.:N(;K HU;DV$0U1$-2P?=VI);#:T#[WF6H7VG:7ES12!#/#E08_L^7&\ M=2V6U?4_ PO^$_Q.TA31@FO3[&2H-'Q)X-X2_[J>O_$K1I6,=:K]|| ^B?3_L M "8D4S.MG\$:&1G4S-

MVH=!R.5428TL1%PEQ M|[4|0VXL[V\!FE'IAP_?T9 MKK-0##'(#Z3^%8O\#<5Q)ÐM=W"8B$0.7YX2F3)R?_L^"S]#:&GYHVBAR_FDI MFNBH:P4^_>BYH<91Y ,+|0#\TQ\90SXP-

YJI@[:A*6$/6"?&9A9].#$Y$7L5H3%!L MBAOSHQ1'B".& .Y-BDXQ(R8YED4V.69X7OSA#?Y],/"ES3_G*R;_W0R9D:"/[93ZXF/R4IZ ME#Q_>V.[:O#E#35>%-

F&R^;G|&RWVH#0¥JQEB:DY9(&0T8NM&1/6^,H77Q1=88;(`G&:28:S7V1GU(Y2\\<|QJT/\=6G,4N.5A+85%#[\.E 0M0XCSIM-

,=6@^EOCA0A^4)#8G.QVK.QV1Y'E3]W%B2EI[4UYTZ4;,48OU1;>:. M'I'4>=.]-=I3DXFI$FJGO>ZKQ=7&R;9ATI-1F=-ZIC/9%4OY+ CX¥GRJ*0> M00'#2],

7IZ7Y9G#A[A6B*^2D]+M(E<]F& M=^.=-6VU2E.[S_;*^9VVJO394U3\N<(5-VVRVJZ-VX!N39:X_DH12I* ML,^)FB(V(71]/9H(N+V:N+25G\$?

T14'.HJ^DP@=)LESM(*%7FE"B!X/#5W.37D*|F->&H^;FK(!Q(CVGW.#4"T%)Z:NYP:@=&@<&K^=&I^\=)E]'-1\]!?Z^$C==*AUL3PS<7"XBUX8?_]R/YXW=% MQ%

[{)7C7XVK\;XGP):Z\]VYC=?#QS([E#5F1T;DF[PP03<2#PT!7.=WT&O!] M;@W#H'.;H,._+@-/Q__>QD\|-\%#¥)Z8+X8=E $Q5P)&UX+\[Z8(GRU5>2* M9V#Q*G%_J\1+4]]

<*O#TNC&-P73*-0@H%/MZH/ .+NFO3/S[7 Y^ZU/PIQ;P MIE,"R"'UTB,[R*(FR^.=VL'+_*+WV7ZL1V\JVMPJV'_WM)_?W65KE@^UUO@

MJV^(!7FWY\DKG+,TL.0#QC<+52;N5Q0+H|+HJ(\S05 M)[CSX@S7.!CI^3'WI^0?Y=KNW9>2Q[/' M]\&CC5PT5?,F*4 A95438D9OA\'/X5_2_!\A0NO;U2-F'F!U?

F)*1U,Z>!0 M%E,ZF-+!=H IG2|!Z<##V^ U.64)' /U6A[/^\] MR)ZHQ5X(^UQI6LH_E59Z/EMK"Y.)6]2-Q-3/1]+ M]?AN7,,T$HC&T1315F+*%EX:JF#:!M,V7R%

<_5H.7)@W5X.VVH'C;4X$6TG; MMN*D=1-,T!U)N]9\06L3SPFU^N>FGD2LKJ\RFF+[6)+^9/.U-M/,C YIL35!\|;<@#T,)$P[$+IM7U;;¥I9351U>T++*P9=Z;M5^3&1%71[R\M- MI3@?

U&!5.N ^(*<)[$LWG09#K7?&-2;2[(-$0F";&(LR$@I7? M@;]W7W1SSJ=7XQ&N_;&QITA7V?\;=."E!!EH@]F("5SP8NI#PQZE1\U.GEJL MRG2UQTQL#!;4I=

<3J5BC/$>7HK9L&^%@N&;?F.R.TWV[(S83LS65V6!;,?`M*M6Y03M)M]K EF&N>IRC8*HZCTFL+TMB96>B,05/5(V8"(E/.P;4.J:I(I+$ M53/0[VGTF,&Z/I'<:_QY)IL/2&W"# YF<+

%8:,G\S(|#(5>T[*4I:C*09Z4 MYVZ8SDRQ8I)K68KA^'X(IGXP]8/#Q??:UC(D"V9!Y!3O_\N&;ZAK:(BKIQ+6S%%L1+6F&7#M962N:N82U$$*?#S-*F%'ZUO'PUW >]H.>GX5Z?@H M

);W $#_#7E9=>1E)BNF!,XPEUQ4)(N-6JRKJZKB_+3*?HF!ZHPQX8Y MMJ<$+3A+ZHMQ9VE) M)W[-B2V,$;3C%%ABDR'"Y_$&46F$/+I\8+GDQJ1R?D M_E:;_0@U6QQ#G?

=;TJGY_5P+\,X054Q7*5R%XF)K:^ M({'U|:OYO#_HO[\K!RVY=DA[? GW2^E>O;Z<3QH"6"B(IW8V77@DTB/2J"<. M$V;C'' =>!@*7<_^6'!6&AZ_@$_X"//2X48?A[%U>4+I+-U?

IS#;]RRF$!Y13 MS_!DG*-OZ1A^(7CXG$0=JB@23;+'3-T?>H$?=W'G)]N7^&2"^IR.Y#,|G\<5 MA=ZX6B2DE)2@:+DO).9[4D\1QR_CH+1L%NK^@[YH,OBP;.\4^8X+& MUUO)U >FVZ(]%\FH 0%_CZ;+\!*PDV(,PA?#H.H>5:TDR$N?#F)++:TX-Z3 MLT.%()25JZ(CX)@W^%ZY4%?GDS_9^#_W%E1+W$&CM7MF6@6;"DMWZA;FF@X M:4/.!W9|@5/>;Q(=P5H\6?

E!@Y7[!)?(SYGTB$25XE/Q%'=>)1YG-GVSS"8, M#Y]Y[^F/X,%4!+G2EGM]H2HL!SS9XA9=H@WA 6XY47'N11F/F*JZ!\?X+%%) MO4A/86KJ^U%3. 7ADWF)SZ0@A(3SVU(0*OEA?

5S@^I3 ;I/R8[(]MY5ZK&O3W M/=Q%#!"?B'K# /') ,3K ($$lV$,) %PNWJB:Z>>4RIF0T$B=P&+\00GQ* M;A'G)^`\))RY@?.3<'X2UG),^GQ.TN?%_*2":HB&A/.3, F$TRON33:8)/ET M)

DVH+N2#>80[H!#:%DFD+ILQR:6J<=4VW:!QZ' 9"7)U'43"L*4%O&8H3CP MP["!9-KX2L)[9Q0^FD7^X/'=\@8(S!%@O?TR]P3<-

B/&7V$*8(<$1^\M'K9PJ$FMN3515HI5SIVM5'-1%"HDCNJ(.U*S)E^$4XV5W!@ M4A63JE\.J;Z6T_ON0'5VB%+;Z5)FV*P0JZ=1WVZEU9W M2$^P4.41)QDV3B3

MO*'C_(7@Z5,RK=GG7.5X;*R 'OJ0;X7EVY"R8;H5TZV84?GlQ25MCYJ3$4F- M:\!M$4G&?.KH5%Y8519ZP^3[3WSG8Y.3<.'(J?;2M$6M"&!Y"7X!_@W'H!JN

M(OOWB%S>LGL:R*132N;=Q8Z3\JJ<38VUU&9$<=#99<@XEZ+B/$U@GA;SM!A5 M;H1' !#>;[W,G_ZDJ(.B6%[DI:)O*K+=3I3Z/6&BRE$

M%>"B,ER6>8K/U%LA8CS[=&'GKT2.^(;>;I*45T M\[N4I=?ZZ^U.GU^OOV?>H]+GGW&VOZOQT1-.FW MF#)X<$FQ@LZ33-#U0[_5HU>BOW^J#OBU!+

[MS928*$FF#OJ\@_NEANF KH@6 M^!C>9. H4TO48DO10G5D'-#<-43@,)/,CC5 KZW'=%1T 4:#S'@Z'FC_X"Q M1N?H?+C>#X,X)!G.>

<(QE^B?;YS6Z^K;,VO7G73CW|*Z_N=_P7^"WTF:(EK0 MJ&SQ_S#?"B&&$D\4*E_Q2)_ M0W&S!=,78S(*Q\G_W3.EY2S9@4*QY3_6+;OH? M 2R#$ M1*@M#;Y0R[6NI^!9-/1;T)?

F)*.0=342%(SB9'W&$*(X8GF=&/#V9 MC)1)DJ8G)$E0*?Z'H8;J^5L-QXK-[/82E2;SP- MB/B.*02P7@A0O1N^^HAE:>YNAH0Z'/,6-CE6-CG6-AI-,J7'G,HR7HG0.KQ

M(PU7!X^7KI&!?')*171<2VE.HF0.HG#&H\:0[,W2539+*))E\"FAGN@RTQ\Q MQ9;$)7B$8[G*#2#@M8DF'V(YT 5+12>M _\CX]]JH=C7GCZDD:H!9@= ,_.0

MO)\5^L6>G<)HM)=1AWH*0GD4@-(T':260>O!#ZX#2#!D!YB?I')9CTW\.]X M3 2"U\0-= ,ETU]:GL+$9HHHKUS@"RJ6=]55QY06:U73E'BL+EH[333D>&PC MVN"

[X'==>0XH@Z(=8[_"2F&K'}];$[LP"3U9U=%P:,*"P(QH 7._F5<5<;NC? M*N-ZLQB$CR];Z%-5=68:NBXYI[6*R:BOHPM;O+J8I(.(0I\'C5&,&9BO0**

M(4FTQN9L\.^(0_7)R0!I,Q$X.5*DFO!+L%?VJXU$?VZBHIJV<=#F(&!CA7% MB,G@?9JY1.>[8TMUJ6A 0X.,8RU5<8!L8E,H=CT4.Y@<:88<;1LL7UI,-S5%

M!K1,D%2J3OP.RK,GB^NU!T58QM3%>#[=!-@C"0@BX;' F8$@GH M!IH;QP+KU4,L#:0'FMJNYAR/$*]F(:.%#]P%],]B#(E$ 9,+?K)6 83 XIY@ M:&,?%..P5L +E0D8AP-

_"QP;H$I[H$>PL,4,("NPGK6HN0HLZ¥/_Z,4*_%0, MS&1!0A*+]G!LP,U]X2RA.H&]T54Q49"BT@1B2DR%E2_D?N/'2O6RPF2Y3G8 M,<6PH5*#9JH5"[<:@*C64*G@2Y 2(>?9%P+

Q[6"QHOR*8#43->2%&_4H;8= M21$ E2M!"P$_VIC6 O04V#/ '"$)^@M$ \0)?A>@]MOV?9:@XZ,./U3H_G_GM M-}]-&+O,D)87RL7V.QGY7&3AYOQD\;D+\VCKCNV@;* (>?

7X#^]W5));U7[MN>_KBCY6K-&B7^A1.8DO$EFBD[/+V>E^36RBNTC4&W:1("S!S'JR17UM3N 6 M42>0[2 06@=*$M5"42PI>A%F@O(B!UV4T

M5&C1=]/2KL/EYUDR(30%X=$2^41^76A_N)M&/<10OV-^Q]_-KS[KRWT1/+_B MMYWQ<"^S;,#U $"(?_@V"U%Z(Z)MNWJ'I;[ZV& @1O@H84("U=S,39%$R9Y

M$X8<*X"@)G!:=8 BCB$N T+I"'!U[L"G1A8'UI10;NNFO!Y\)-[M/%/#'A5 M]>H)+5FVLC9^)_W. $5R5F7Q#3);-U!DLCRRWYEE:T V#Q*^4DDWXJ9#<4!

MKK.I*S4PF+2!RD6!!18L:\![];X!39[3GK@]/V;)1B S,=TT.H|HMDBHF7TM MP0Q39K.X^?$/S3Z6 M^"NE%IK!:%^Z?R\]%WVG2IA]/6435+*4XHF9FIUP;2!SY@69GP0P'Z/2OWSZ M^

,T.EN;3+-,;K-=#*CD=E!7BLQF!YP BG@X/R!\[QH&X%?6Z%)6'!)U9% M);_2W*A?*1F#"I&&!]4?F.=%+GMXC<),=0MB4,.9V3 U&8B\XH+E@";BR*<& M<8IS_,DQOL-

YN_9$_']^YB]WL^,,LF'2H/IL"RX!/=AC'11UOU^8?.X&]3R MQ"ZU;PM/I>4\KVQ@FN5+LGZIN,=!]TUT@8/]P)7?\\"ACD?B1Q"LHXC-]H , M%FZP4LO*&$1D%GJB$ZDV!P(C47-

FIGN=' \&; M%CS$$@"\>4;F&K+O#L"8VPYB3@6$*)Xl.@GP90(X-PM@NK8(:0)Q:BG(08C] M92M*#'*V,0[$\+8[GBL2BDR!Z^&(4"H@NE4]_@<&*00/AJN,1E ^QNFB(4^\Y

M8T53E77 CTP!)!D78TRs$RD90A,_G\=&3@6HHX%,H6D.9(EH_"C1(HI=19NV/ MWP"Z&7,VB@9^Z1E+' C?!E$."F3!/)DA5XF"=474-412')Z[1#0#G#?H-T&! M!'$

2HL$43Z,!)"$1<[7];/?9IVW2^X;>'+HSH5,RY$W9[^VE1OQ[.+(183= M,L=PSI!\(CH9EC>$2@@I~?BW:H!^BX:)5!2:)90<[V$KV&FK[C I.!A;R_B MCZZPRG8)5,6)

Y'>@%^):U'5T..AKPB! IH&0F-8 MQ1Z-'$1HRM+Q6D(DC,/>PW=HD,C3;#..7G<[D0#@#FG%:$=!OR$@@CD'BX:N MH&Y!F_' &NT,(R)1#.E/R'(JTLR 5/'NH W>SR5$I,.70>D WQ:R?

T",:N!. M7/#H SV(N$14XA]RQ=Z['F+ER7'\!U>10,0>AER8S1 ^?.RX/"Q\^#64" / M;,84N'@8$.4NB"%B*)[TX2*G+.#O-!?(%*+CNQGI9C_(@C+)LS)"0T5#EF4 MYZ[M>%_[FP5

Z$C_%4CWP!T&]4S^:\"G!#+RPFKRG!'XKW>2$++;PQ39<1;=5N M3EI@M0&C0,^#1:*!)ZZ"90:LVVDP@RZ4YK1E:G#AL<^)NV1JDW6[\M9:J.-I MI3A=KHN4E?Y0B+W3S@OM1K

9^>$'T_T0BPP[=AAW+!@X)O[>;/@ OP\4G@%W M:>":"I$0%;ZQ@Y7(CDA:D9RS%RJ0DCT(GA,RQHQ0] M3@$-X"'>C,90XR3(,P2|)N@9P#Z?2_-RXQXT:,+/+5?\.M@ MW]I'A3UQ5'?

>?R\XJ_ILD5!GN,>\6LH2NE[1&\MY^EWA& M8>0.HA2NJ6* /O D\"ML8C+:H$05EU":OBO8CK=^QM;9G^@?;8P;[F,F#3] M0L;U<\994AN]^EA;JX+[9&XKB];J1XWOU#A?3,^V0SN-

/A?$,#"U*=]0-8\ M,89C#US+AV3*ZPBV;]^^QZ*&3-">*8H#J1Q@IR=[=!%S!U^>,&!2=`_7V\& M'Z.K.KU$0=L/'L,=I2 Y$GBNBM?XQ6U#U 0&C_Z#HYV)fKSXCWWSPZS(W@6B

M@%_?S+B0,7,!R% :*/JEGNI%WJ8:W]8@2!=+HN6"2 MM%W<2YD]Y?$\7M)+3PY_Z&]3F8YW#,^G>M$54A ST9OAK&F* \6/XOG+I_#> M)!-[AA)5QY#_%Y$\ -#-_6S@@T!>WB3R-

U@NG"}\"ZN H%5$6V0^;1&2 -YF MT&$(YR)_>7J#'&X O'!U XZ"G\C\@N#\O'+4#"9T^WMYAVT4F/VKP0U,.(%1 M(O8OF)_J;XBB?

2X8HX'6<,_*VRX+V_X=X6D=TWM[;"*]%E@Z+Q$WAXX>MC// MC=WK.J3[43+Q18/WR268+@ZG_U:&'F;H_I9Y>_-^KBG'<.<;DAR#9!H8$#QU M -BPG1XM.'YDM;&8V/7

2:IV&=&Z=-HKH7D%.1'7\,>(]_(HB.B\7J;HU$$ M.*7Q;,5_N<\(7M3:O/?;_.LW.;]+YC$JH2_!HM!.L+Z!!LFJY&VBHPQY MKR64",P_!TZ?Y5N^;?F?**

K5RT4$&K^C=,P[@C:,AP5::DSRP4TBY'HY +7+-.MPHQ[+#>$P8C-4VIG*O=FFWMTK.Z+Z,Y3'I&['3RVLT MA L(TVB)1DCD0Y,=7:K0Z8^% G38ERZR=Y0GO(R<>!)1A7W_!

W<&X"!FP[C M-K2&@/:*$Z3F> D(I,0!O#U**1V48KA%^^I$G,K35 M[3U"0=OYF\"1"C9R'FX4W+Y!E8X+TWP6N+B/4QD%(6AQ+^Z(D*]ACKP,ETF M:

!,S5+):4KXX'[2]N2QK9[D!C+'(^.SO39E%4UAOG,$:G,<*M2RS M"_LJ4? A-W[31K=??T@EWDE$7!46X(.MTN:%I-B$K4@,78#XE-;,4X-((/'QC+D3BXYFPN?%0LM-SH4"P,>71)?

K; M?7F4_O'6W;-U.>:BC+*5:\+E M=0D U _2;168%SSW0BN88[1:4&X^:@B2<;^0K*,4>BWWM_T.X^+ MPY48)G:"R$';_?UL*L6 'I!E.2G9Q_RSE"D.5.T%#&!8$?9^9EU*$?R)F<$

M;FC8I*^/]G#Q9 QG"K.@.&.R)G/5W;SX^]GN=2B7.A)+ 4KE+7GN>F)"K$A% MH(ENJ]A9)QD)A$CP3 '_VC&.V\CI-@ 0")Q8U->/Q5PVD1,*?/0(P0N@&>3(M

KLWT+'Y@%W$^+VQXFP@!0CK/VC1^,!]Q2_3(K=RXC^#)X?U\QI^!8:..B^R M8!* $8._0M\W-^ZEDTS'3!%J$2PA%K?16J4]7V/QH-R9M!X8G! W\0!YD]I MY8O @B($;27X^H7^X"?

G9\D1F$N.OD(S _M&*F3&-KC52Q8)! 5@Q!1GJ!C MPE@B M<^QM,D5&Z!/T$)=TC\(,G(=+H'<,4[JHHFT*^\\M^W2TI9$PDZ-^JXX;G"V) M3139WQ97#1_)O%WQX-37Z?/

;Y0MY%D/&T3^D0;O;!3H6O84H8.QP51W8ZUX M&PWP2<=)FE-XDLE WUUPE-! ='$."=N+PPFVE60%;41X _!^ZQ\6 ,.#4RE[MIT]D14=+Q_$9G .G H\|2>I2=+R\=]A/T-

TT/XE$,AYT1WX6\@"62ID7^3H MCX$6R-[SY),38ZH39,%[RH,T%\T.B?BV47TQ7U@2/RAYX1WIX1LO+QV/T2M8 MI@^3%Z%3,P#]EW5MT&W%>HYM$>E*G+SN-<==)R+

M_GNYZ+^>B4O\4B8N_?P[7EY-?F'MH6X_E4'%//@U50XP?G,?X\;G4XX.ER)&[MY'H_\2GL&-0*J_O>_ HZAHK=JCU @/23&$)\G-E/ZG%/[6*:M=Y'0I/CN]P M;PK,3?"\;>\LDI>(

@,'\6("O#?#+Q,\U!5,!R/%5F.419#5&K^ >/@[>&O M[6=A/B+&2+?!,,D;8J14(NR_[2A+^V?L+_5OH(VP_6072 *M*W_9?Q\RM0*A M@P__ WYR^AO_/2B4,,<

L<,3\$>/1#\%OSU(PRN(&)[ ]:@=V&S]-UP)34ET MGFD4A'QO?C6+1(183= M.3%7S&N.(PA4*2#P*KSM MZ+62@'(&09&L;,$!67]H]O0:Q@Y;"=H@+O9IX!?8TK1@'_U83;U?H[9^

M8'RNE)=4$OXPH,3" _)(@BE%%EJ";,"17EN>'HR&'YH5%X0NBQA;,H:^JB@C, M*7PF&N4$3&^T L@E38[HO6==H:?SW*S[>0A>WX"$D?.#WGX$#9'.HMH&*+U. M.]D2X<

)BB"1> CE.SG08D?2E_03]H;1J#&81+5@2M]9ACG"OE,.UCEP]=1 M^0ZJ27A'[/VZ%Y%" R$+$ZE-^PJ&>7KA%PIP_(>!,02E7?R3]S*LZ1H67 US

M#0]U"l$8Y(ECZX0AW=TM80A51*E[FWE+Z:1WR M30)(_8GJCX 5!?0<6C*L_9H SK\1]AW6I[7_$RUU&H_6E?73IOV2$)""A[73 MC; #M@=@EKD3-

6_OS$#UK+RB.'YW_%>%M6CCD$2#/T,*!9PB ^;@=8.R.23A MK3R'<@G1?$'0.=$*:[B>IHX&HXI0;'=PW)!@1VG< IHI(G=`60PLW M/=;)MWZ(*E

1)ZXV42%PH;H/!TOT]!4!C:^:!\$<(^?QDAPNQ/X30A. U7\D M2QW#-X_-M8+|^49O2XF<@/&!_D29CU^K W0/E.\\4RLH_3%WY6F0X76\2*, M$@1C4"5A-2?_Y

WT_CPKU<6#T43J(04)5O&C(K\.F'UX$ /MV:KZV+5L)3 S M("#;- P%+GPV' 9,!D/38X6I9MZ"&6XC3[R2(ZCZ<22!'MH5\%HAX_GPP=73 M7R0+.B%4@!'

#%FTWL/4LI8%$ZV=W4|$%92/K/RDIDQHF6KT 4O_ 5X%GT-E M:Z3=P,)WJ./DD07/NE2>RZ<>4NHC^G:L;A<<>/229U$2HN/Y4AD,%>%7| ,P MG,"!L*:$P*-YRP^CSH%?:$SU

M2]? @M|+4_6(?/0IJ\/%HNP7?P,(P|'KR=4P\!3 !SMP?LL70M2'_]>97> M_,-&;U> DRI=7MEPW\GTIMVO]*.]["\+;TPS->#B8\#'$W#D'SO'0X622MBL;Z'ZF'V<1'V<_?C

M6,4/4Q/5R/!77I@:Q"]*? AP0#?&BJ<4H#=^W?M#&G'$K_8@*H&<-G-]E*/ MT.O!<@'L=@'+KOL\706%8VZ%&F)1ULTATD'1@#*K\"E.E?W>:];A&V;DHJ4 MY"

D+W/@).OA8G'B70M2=A(8+N@4+ M-?H/?G%ZP&3 '2TY!ET*S8^VPH>@9_B\A^Q[T6<3H=I>Q'0$XE[H=1F@_$P+ MCXA[WL'P4C"\^Q,.O,P+"XV(8M%P7AN-3N%GF%@BB[-"

.JP(@40P[-QPX+ MYE_G>-^)8[QZ^"R[+QCSTC@=#CY7U?LD _ID6/],)3B3H+X3O%Y .%=+T M#20O((CN<'_A@EJFC9VO1Y&C9_ZT0Z);]J9+%"#-&(>$3_)WS?W\-331$4V834[

MN/X[B@Z_\GYYB"X]77O5I_/9*M@6E;6$9&)H>(&^^B&J=_V-Y;&'KUCGH4LG MY?;0)-MXD!QF_NR\]2?D%B$H'2I"O#VH M\7UU]$R_%>!XW0AW3T!V2S_[_FD*[Y_B_=/WVC^E?

VG_E/FM_=-;[BB;,^S MQ?!R7'+*9=A1"#M:04]C<6]M##*682KA<1P0K*M11(UNX'A+K?WP#%3=2;[/ M+>O@I+T]O59PP[+^^M2#9R?S_@'/YY+ -J-

>H=DS&OT\Q2ZH_*BY6F2R=YIV M'1.7[!*&-HF+%@G-SU_93M-^^^XG]^K^O<7 *"H84?MD%. =[F M&ZW?'O>]343.-'N;6 8\#BV&44]PQV#$R_M_]LEMA3#S^'C!0_949&+)I

M^5MSGL]_G%T+G@O"I6 +QQ\F.DD>B:D/'3]-'(Y4NS5=QRO_+Y^\ T7[9KCU M>#R Z*4.E[<=@\IGWK$X/Y%X"62-[AU LQQ2\]H M?@F(;>#[CO?

G#AMEQT4"8)CO./#"#;38^ZK&3R%B?!# 4;;2X9U'56MLK^ Z M*O2@>BD0[!0_DJ1R*&T02!0--X"]JRA>',=6Z@)63?.(C>B]HO7QB!U"+LTK M=A<3#P-

[@(6<@U36D.7011DE5OEW=2PW>:XJ<6=^B$_WSY^/F-HYV&\)'A M4Y;1*3Y/8?%.N?H7.7BW"4.^RO 85/@;O^:,I\,^49BHJ$YGRA-N=*_9'U-X**

M1:XO>3^7QX)'}>!EQI;7KR.Z)1HH^Y$NE,< Y0#X5[$&9B$#%M80;409+%>^IAH1*]X]0/Z '"\!UC!&^!5]9YL0ZXF]',D1^MN>-2? MGVNF'VH*',W 1

JN0?/Q2D1Z/,0IOQ!5^"#SQV]C!6EIH*?:SM_ 0DL;ZBV#3^V3G0__F$M@ &?)"O[$A&=YQ"-N MVHM(COEH6"ONU?HDRE$79.5H!RXG(%K"10Z,#K0]MRE?Q0]$&9T[X;>@I?

K>'%+&*[4 M-IG%NC.BJ85:4_;SQLZ0"[WI?88K75@2+H$&&HN.]/L>1?$DXKD1X5]$7"(O ML\=?99ZD)8FPRPY.(Z.[V1A\]^=2HD*ADW1]_4BZ,9@;2P7U8NO!.@:_B>R9!1.8I<'Z

=WK8HZ&' M5"BEZ?!JU8XNC<#DP'*^.]R5[Q/!V^H1T7)7-T[\1'4;H ^^9^IGUSPI[U?X==I @ M0]M<05*T-]%H;IO/2D.]$^PU!W(\'7!V\A&[_*G[WG-0BF0ES,=2. M7-.E!A=1.=X-

\FC3#E4C1'N47KSD/?90F OF@T839:#1^LIO^]?.ZT1*% M_FHI ?0'2R'X".BD%!Q'1MR@X^^!>K)!"V>8.6&;!C*"0_03V!C0=M^>OI]6 MIE&FH.M="7-

46S5T9+Q\$'0U&3}JWUV'LO,V&B=!DD>8'=E&+KXY.+F>#GCI MO_;+RCL7]AFS*.S,; &+PQ[H4H;U%3T^=R:A;*=&=C!R 0#Y?GFB@7+7*L+X-

JMT+EIQ8!\S;D?6KMI_]Y=W7-MT+.0>NU0PG9X#&D#KT0,]A\3P MDM&P'];UC<.UT9M]& 1[BR*!D/UB[4= MHESTL7:J)\HZ44[]NG\!=R$H(<+\R8&'6"X=9C>/[LQ\+;;; ?

BT%%BZ) MN8:RA=D>-G35FB>_01X.W!_8]KJK>W.)7O3[$;5M:.,.Y%-1Z2WXK[KW;+_0 MEI33=J6FG6CEJTI_*#:3A2RI3)_7U@/Z]DQM/12-CT^C\?2!QE\O3'/^P#E3P5IB?

B8Y&ZB{J&M0F7FI?LXZ>VP^.9HB;!!$?_B!_ MEYQ&-1]TY4,KM,"&[-MW3C]6A)\>PDG)?T>WE)WJUL/6F4JU93F) %M:F+35ROY"=={0*0NK\-

M%169J;3SI!/A*X*6KG8+!F;>GM$G;=\(DBE=X\ MK86$72)+C1%'#O:P)7W:4K=*G-@A79W0]T)ODF2[A?9T.J)'Q&_?!,?<_FZW MQ)^,#98SA-C/I,^=A XZHYIP!T,8Q\DF,-

C@^.=%Z.CBTN"W_@;;)ZH%3D1 M+>}J&BVJ$HBWMPQ-ME& !SW]@K(#3#;\X8KA!DY-*!Y&G(,+ZJ&):3M51%__8>]/WWLTD"#(B8:K3A &>3_UG0S5IY3.3MC*5_/461OM0'R5:

Ms#*<%OMP#W5TY@_W0RE/XLEW.7T5"_48-G7TS-E>]9 XN%60T@WPI*&B:!3 M/O-XZSU*>%+/U93F) U>'KS[<"WWA^X5W,O"\)S>^?X]BT3Z#C4TE9^!G!$>PJ],]^S@UZ.Y'E'

MQ[XDL71.',ES9IVQ@K?Z3R.J03IRN!(IE@,),M\9]X8:,,/D Y\5U0^_OL" M647\LLCSX;8L/8^U6/UY<[>G'05!S;)K2@F[JZ8-A! M!!+^^7PL1OY"+':(8?[WWX[\AHF(U+(P3%3)PA\X]

<"3>&[N6 9/S7U. M#3 ,"L_?>[<+|&D,MM#*B)*L<"YO&&$N-?(D^?%>'XZ+4G67GJ-E8WT745^?"Z"B^E ME2;BP3'A\;$H;V/A-^:6?T/#SN3U*RKWS>C6F1XZ,)E(K/4L6-

8*HKAUVIVOT?+)_ @5TC.XL^T/RZ MV^9L4&SIZ>A5>5&X1?NBOO#(:917F!XHQSQ{C3G%KBK,\W'LF%2I*9I?E\P M6.QZZ1$-]TE)-DXP7)SGDA=NF+P2I-V?)0?L7MU:

M4%4Y9U96IC&%V0@4X%PB0L<3$29._\VT,R2H\VA')-,'F"3]+F MCM>#$AW@6;2)"]#MA\"% Q/E=S5)CT^UM\|Z19*]B]6?[*T: M.9O6L%L4O)"N>2GX!ULX7'/$OQ)! 5L-JL;A_>

[Y%TL,*_<*^H\",.3PI9Z MWV)? (U|G|2;.:>C@5\FK&O$V&T^<@3Y;F7)1<"96<6A%DTRV6 \F&S<4Z,%] M:RSOW=H[VQGNEKEB-Z2?.Z18?

@G9W%0,6SL&8@$3@:^LR+??/5*O7|"%QT9 M]6+=7]JR8%=6_T:YY16(D',RK!"=D2.[EEAGV=H(RLB7(SEF*"S< MRCHJ9"N;C=8V1BE#<\'(V,N1E4;I-57M9(LO>=ZD'+&

MS>FL@JOI>9Z8IPL]>S%YOMHA$ M9IR6>1(?-^Q>/YG/S$=1+G3V$NN6ZY9NY'E5S79:DV>=']8_=2H1*4 MNZ+,J^Z'G'1F>H-=5'&Z(#1EP42:]LSW/]!=N=*IJ,E?

(\O&:4E.4%,>MY6NA M_G/9KN@BH.7,P)#7+\CZ]*$ MOB;ZY/8YG4S\;\RR"5RZ$_E$_I7I3H%#!/%$)4)$! 1B2>$1 2HBD@ MB A%4T 0$8JF@" "< 03(N*>*>%ONP^WV_7-,E+?

TX;7SEJ^,!!V6?#D5[/@ M">*)>%,:7CFG\UHUO52V$-B>#AB2"L2RL_Q"8*X])V&MQ72O0GBQC<80NUP M!`)_/6'Z&JP>V$S[!T7!!2]BA'A_++Q?[C[%E>7]=_=ZF;L24({?,4\3O7-[

M/(EN4Y+L?,]=_R5T\!+]!)CNO>__NG&=O6@6W*N)<W3T#'_M/Y%^]K.?GP'1^<22=G>1N/-=;%FN"LA'Y-HXO1Q6.QZZ1$-]TE)-DXP7)SGDA=NF+P2I-V?)0?L7MU:

\NRTB01N|QHSDA45A.JL8;+O'-J[.LI/1T'36[*++BV4B-M7\DQ]?7$@*E?\5]_B A-XI$X35[G @BTGNY-O%]FV@?PAZM^I_/C7)U'<'B"

"$U'*7$YRC. =B'L=$?&QL|/:V_7B?4OSMN&MRVI[<^_MI+^O,(\:@K,J-'5JJO)).C|FYO3*"*09^_X9?6;1*E6+;,T6E'2LJ(W8#/V\ M@65C@!%+LY%$XK2<JH-Z$,Z3?7_]2=O60XJ MO[VI*P6+):=54Y%LP[1@^=R2JCBHQ!YL$M108)5]!7P#BXWY%4]O6?R:.*WO MF->QLFA*8]3E)G*VPO3 @.6KP2;DW RAK/I07CFC:\!]!OV;8 M&P:.56T;51WVP.]U:)![PLJO8ZWO+KWMNR(,8$UAR_&*J.\6"(L0;S>E6D"L M@@D!Y>^K=FNB!4L@KW>EO8]V! J9:WP/0K*Y^4$A>]C9Y \W 3MBG*7M'E M78'GX[U$,.1;@|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|:8]-0)FOER>^9,\US4#]@5729<=R>OSA:HM7\VO^YHO=ZER_[>K=/T! M)^U 5HJR,:=]?RT+>-@8_3\7 MC_NM7ZP=W7!I8<#] /U;4"[@SFY'+0U1O\B=[-]W9)?H-K=_N_^-W.P.=A, M_D*$(\6DK0&,JJ@/+#V[5^]1SUOG7EO)"2G%" (XXI/AQ/CY2YG=I70]D^7%'CRCL,V3OU+HO\ [<5K ^ M?\\>M>R%X$OR0MU1[/4KVSZBHF9" !R>/?$!1!1&2VLS*%6*PL(=V5([X\]QO^>@>B+#'JFFO MP7.K%QU6 -5*@"'"AW>0U>4)]!<#SJ-F3;.U--O-%8 ,]@,T4T7+,PT9WGT+! MB\"%#O;_9<0#2|CO-P"1 (-F>\1M&1-H1L,9C=_]&P4,2P%1"0K8B-M>>MYL MB+H&:R"$1 M:<9XD0<:L#"S= <028@8[ERP;+-[JA>;?S_79=IA%U^G,HGVF% MAA]VE<0_< *P90LXPC>9-'&2%AODHB8TA;33;8|3UJ#+?:3|V+YEXU>;"O.K MN>KMQC...-C>1,6'=?(^!\8"ZU:,W &\2H+RSL(3'N]Z8:BX]^_4G@D-). M.Y*AKC&>*72 18^2G!,!JR#Y,(]!:CXK5Y^PYE%GW9$";'XD5QX0A]_N#?T2 MC0>HFJPWDW@W.XP)S57=F?5S)-727=@;ZY7N<3MY* (=X3F+X3 8X(;R00^XBO"S€-]_6B[+=]W*_5 3'KBIA1]5<)>;N\!"M#E/% M1L5=]ZKS&4&IW9!>,3+P<63&S.3LC&?QTQO9K;FJB4Y,2?.*3(M6O+Q,L'<U!K!H6?8 M!&MJZ^80GPO9:"V3Y;,3/I:#'2%/]$^F;9,VZ-@8[^D;EAW=3)S^MG>D3K9 M?BX;A5)W6L6GH[[:5E=2$?:$/*7]1&682E1GAM"T':9/EQAFE#S;99(P8UF: M&3:I*]8SV)(B*\ZTYYX39@M;8A;UT2 M../G@5'NE&?U'I0F)[-W;$DJN/"$ MDH\N!^M1H1!U5V!'9WI'FJZ6$87E<",D>EDR(77BSVGU;$?(;]J?6Y6D15\0 M5[GL,N$"#N'<<_,!TF^OLM);D&"$Z2JI-RX[UU@2@DSY[G8:I0S?6 /LS30C MH3?IY6Z3T9?3G3T9MBKO 7%#:5*2XI>4Q7BP20 MYF#DR9;TC>F2=6E,3^.D7.2SJ:9DB<F)# "_']N+UEM|SYX<+H-6 YSK?16N<[1L M=1$?,X!]##M\/IMK\>GHHW0##1RI7*1':/RZQ14O3S<8HI<3]'X5CI^LO!E ML_H.8OG:MB_[1!\MD=J:/*&NOG^ I=XHAY,WH9Z.C3I/D@]7)MO<%G^40@E M\+:)U8+G(>B^'MP.(.RX;);/%5K-%E=) MAUHEM%H_13A\EV^D\LW0; W-UG>.Y1O-?"*K+]38-2>BL7?NC2"A@=N^(/@NT_^0K6 MRE6%)E=)>[SY?0-Y?\[V]W]+DJ(.A_>VF:N.;<%]T; /@5>).JU{]%Z6QWD4 M$?%^@2TX+V4C!P\,=[N)=@=07+@:]=>+<C1.DWX]_^EI!-[Y&D16YLR9PAQ_& M)\ZFO%G]IZ@9[Y>#.^"E5YO74~HT7TA61SR<5KL95^)7KMZL]^.PSB$9B27P M"'VF5OS%K(&0\[9W^((`B?^YW$6\QYGZEF))]-M*378-_F,K'$K5I&JI;,ZGBV,N5JW4A 3$BPY'? OUAWA*G;:T#<7,Q4|<_C|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|O5*]4*[&(#:-EM'-T76!S13[QK.'|"%):*YA M)Y7"U$9:H?FL@.6L(&_ -*5Z?.4P9@6G]UY+V%*1!IQ<7%X/FGY)?K/W(?[__M7?EZ?62.MJ+_%!^A_QP.AJ8]9NR2.7>@I\Q6AS[;UAUW8"(_=Z]L3S/CO^_; MKO?9]OYEL$W=[EEP_IWH2? RFB0Y=P5.'[S1/&1FFJ;3Q$>$K;. PBJ;.A"S:;UR8*&.] M+B=8*O2 T90@P=1]A1CQ&R=]2 M,Z(\'H(9>//U3>ONR\=NL5NO7P_>=PZ;=;=SPO36MD*+"WO5TH\'0/@A*YK) M4([5^L'7]K>C;X>_W7;_XFOIRQDS6AA?K#2GN0E0+9=QRU@[JP'HH\V$1P&T M\]&G5MZ/OM6O?S0_5JS1]7W7UK86*UX%0-]7U5Z^6#^ZO/W=9J5?-S^/;W^> M]"BS>H;"$@(T:5[DT#*5I€@,J?VJ]^FW^4N_;P*CS9Z#:(".G-0.G-G2\;F!W MF*GX'C"_/\%]7=LT[1%^FF)#()^\ =_U'K'$)SL_?U4==ETZTH FOYZ/;JK? M/ULW^M2B15ZA- +J"};TWX4(1=VS?=-633W=G M?GYP_?NWHY:|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|%/W\OS+K='ZUCFM?#€\6+YL M@43$VNFB6JA/!Q__S@O!9$?2I>\DUDQ+2\K"3- &2T!\/P)T/Q'8/H\YN"5';=1^O_]T?6X.?KGG8\W\Y8YN*BAH*P6UOD8Q MFPF$DC;F%,,KHI;!X?C7^Y/#2Z=H=]|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fVJ-Z96GSFP3CHCTA^]/&86TY_J?] M\?WH4Q6;(O5?O6O4U5RCOD;54#*,3#.,[{:N!S#:*@5=O'[K-$J MYG^1/P;GXYL_W]N;5Q2//[YO=-\[GPZO#3T_^/?/S_UB^VL/3J$&MF2ID:O5 MIEN89B:W03*,]3$,X6V2#./YKJ?E&,;O_7GSMU/U;P=7%W_NK[L>A]Z%YMG M&$/M\\WG^H_R[6WM*'_4M#\V1B4+FYHV7[U3)\DRGN^*_M6HYEL'WM]M2SO';QO'EUJ;N|(^N+OGF6\>GG5^OXC_=Q_WI\ M_K@UBH/6KX-CX[#Z];Z(/47+Q."+]5QY76D+:8C- 2;;PE=2GK>\U/6QA0I6\ M-SX>]9^&5N7V^,>7]Y<'/?/GY=GFV4+I+R_M?C=L/]R>'Q_WB1=Y9!W\NAP! M6ZB]>M>H-G+%1D/F,DFFL-)DIZWO-05,X:D# #;"%$XK[NF/WIXU/CS.C\Y+ M__[[?32X[P%3:+YZ5\]5F\U\7\<,MN;K$_>E!^[2"}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f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|J)T8QOY_(R?2\-KENBH>]JP YIIX<,C+ M'08 !)!D]X?Y+KX/|AZH6 B.,98"^(]2.SO 4Y-/ = B#9R(F+0$C2RYA,+$E]#<1^^'(Y#@E8S)GO-,>P?9(' MW K +VBCA$\=,7@YAX\R?92]A-O^$/?X+B^M/[5^]<_A]V#@>>#IR2?EP'G*Q7%R$E M8$;(\;W@ M[/Y\O]YE!]T>.NL6 A8@A5:+&V60"R_$8V'L698/=Z!_F!ZF>" [F8 N@#?^ M!L<:,Z9'PA^N#K:./ 8#@6 H$5>(''H6"#KD]WP 4^F#\HN>[1!PC{10YM\?ONZ>'UR'?'=>(.7GV!$lNPA4|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}F'=?(=FX!/4"/@;B-X^)^\>+ /=GO_;DK)CP{O\Y'/'E%+>-[] M(D27>V@::"AX,2]X,>9,V.]_M?Y\/>[;U_ZW0;[!T3ZYJ-^T7KTK37>W4H(# M!:O7%H$I8#CP;'-IF#S>Q;,=>"SCT7D>-+Z0NBY<0;/|/@>MKZ-*_C?']>U MH5ZZ< 9?CSY^ =@TIEV&?P?9IGU@LSKZ+9(,'RP.0S> ,;//(GT'F40*(;_/Q M;@>(2[E\9T)QOX\^TMF^W&[!W_+/3^;]S>U^;=SROM__;'VR>Z_>E0LS&L+% M%=AX+@,8\#2@&ZN:8FY\C[J&Z/SM9*;- X-$AB".VF1-_"=UV11P8&XSH0OZ MS>O"$7J(:1L2'JF2.3V#9#5OWTPIKC#A&LX(@F!2S)=<_M:H,N=?,%,R@; M(9 .S.H$CRDIHB(HN"_=%AKB(4*(Y"U++X(Y)VV)YLL)=|,.1R5\ {3=]R=<0 M902&>;I!NC1/9M"2SFNTB|%' T\N++K&6;T4+M<6ZI[IS=I\=JE32I:1-<|$ M0WHFI&?B:9X)C8343:=3KG1K1?VF6-*TFTJ%56X:U7+[ANFLWNZ45%:NEU_Q MM_([3]X.ST!GK<^MX\.SP\]7EP'>\#6$)+;O98RE0N/8*W,+(NE0CN M"@!>$9"G72V<$*^<'RE')X L^R>M4V7__//!R57PD(O#R^O3*[KD_,OA10M_ MN)PQOS)E=;H;*M\P%E>:O'JW+P+X;M#PT TR=0$]"5'5KUQE_7!@B(!Z .@M$3Z9O&G;M^0EBIZ,FI[0!0=,L_!?X%277/<4&%YO M!9$N^!T9(JTM71RTZC- ;lZ../^PWL1E(@>5(D_B-LQ M8/]W0R.9_&,A[.YB6,/,>$9_F M\>')*R84ZYD!"#32J?>Z,2.L_DK&!]DA$U^#!,9+WA=^#7FL8,%2=&8>S B M7,I=)'L6(^. GP'7W46>XSAXXWP<*02+^,Y$\)!"LQH M|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|,-0!]H#HN3%\^$(A)A [:072 ,X,^&!B\A#Z&-]_&:'1.R>1@$RJ MUMEI#CF6T65YKX_W,K*,X:G 5(B8!*IS+6]HHU^/FQ5<0YZ^TL5..BBS5%(7 MD=>9C)0S"X[$#-(>RHU&M$Y-=[":?BV50=K6/|@0/#VF(^Y@)^H(MP(V"0IB6\4\L)>/UQ3\7;_BA\>QP) W<3%05%18K|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|"'W7 MY6B-2/9%2+-#H0<$2+;I-DY[-X@^X'Y;B MQ+ZfVPC7+*82W>]EHM:MT# 7(1^S*V)&)XF!>*$V'U@Q\4M" MZ5#€.3]S+BF11XS6).)^RXBBDC\\RB$O)251K5"}"R*U4"W&!!%8*>5"]3Y7 M$)5*;R0=2CI<+QV>8K@@761H\FKZI:E0+5:$_Z$:TMN$1M@(545!B&J<$.OU M/)#F?$)4B[5=I\1*.KT"+XD2WP<6Q7[,HM@:;2>XVNJM]}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|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

(9]=X_&^Y*PC.M4._38\ 98]$IS1JC_)%$1O%*_S8F>D&2T:6&#RN@" ML13-R\,+\K#96W@'O[*KZ0@GI*-,F+MOCQB?UQ",3#T]W>-<*&/X2=12W[&@2
M,G:U=F<:EXC]^").RLGIF]@]2ARK@SS")UN4)F^$6D+P Y>42QWX,HR#@:@VW:;M1KF6R[R=KZ)X:6\![\>46?L71)@7$7ZZ /E\$;(W4=XZ>;K
**ML<$DHVBJBYMPT/&&RVC#15V7@R;TW_EED)Z$_62#5#(4Y[.=1[%1%F"I@CK\ MAWN:@$FAX3!]%LWQY2\@#UQ.:?M>* $#7=JS<^1;=*K8?9[SF@Z^"ZT\ M/A1" Q3"(4"<,\ +B9_QOO31.BF7G8^X(-3FV\[F()3$XL,3L8-YD5DRU$1XW M[!I_/S1M9Y'OC"9GP&FW<6@\'!7@,#XS2^B(8BRP.!TV?38%4(?<(>R<KO>- M%B/38+I#*09C=$*
[+I(;YN]2#)ER*=HH6Z*?-X% Y":U L7*&B/T;T"YF*4 M!E\]MZ!0A?%!OQJ.2V8@2I/8*?-A;>B93'Y/YAW=1'Y88;Q&&A]R$L]SN.)# MDY!IE!,^R#3C @HS<-&>1V!YH3@2#Q)JY\+-
Y$+]F &OOJAD"*6@1JS/(L,2 M,1=C8HA]]5:H8?7'"\X8$]P\H$$6G#$[C!SG,T@V .>(!2A\RZ=W MT!3>SPQ(KY1_%OT_XHN"L>0\V>A/NB ((2*41X,^ADK#,+"[QX>L-U@
M]B)A)*D>^ ?;OH!CHL$\8"[Z9R:M!#+V:-X05;],S(BOOE7ZH!_?H0P:38R% M!-@%8RV)=P&E#X:Q24HXCI&P1$QO&8,XVPO'Y7$12#,4<0-3@1[7!AV8*,^* M=@RH:?-
=T/PHWR%9%^TF%TEOBW&W0W!1#/WQ619. D('@4;&9BQ*Q5="_!9W M8+=I2&OL"C$Q#> AO)=BG&5@9='8"S@.3,2PI_TES)K@2BZJ$4S>&!?386TO M>KP;79C0[_F\3X 2G(_;-
X9"K^$/X[.UR(XCOA4M"54(:L6&7OF04TU,2@JW M+88H!I&T><=$@4;25*]@|H=1=YR<=EUT@UF^_C6@X^DX7N)2\DQ$;@E9FHV MN9 [SX$[G8 .F$(0@4-
'/BR@"$$/KT)PQHP,32[@PU- M><)>?P"^IGR"?]XHIUQ[Y].EPDMR,[UEW$0<@(J/XQ>-/Z$JD,@,@8OBGKTS M8$8FN3'0=Y93PG?GX"==\^F&*\T8H:0@\X8GUH'PG?"Z79-7@29+
<%63RV8M_MBD[%]AAHI5:*/HQ$]G8$C]^&-S:?3[B3G.KAT]>39UPID,9*LRD"T#V=L,9,\] M F!Z/)\E"":&9$RD.XNF8ZY[(MRPA!Y.SQ]RIR4IG<)K26ZR)G;$#YQDW)"Y
M!"4AC'D48X)1_E)C5\=?/>4130S< 1MSALN4G$,O#M+OG<"AY!KW03D\GV:, M=-S9//!34"YYO$4,]9[+)>$=1"!TBIX1;#=\8S&O1*"0S%BMAWXK\B0D;+&_MU'KL!!,1%<\@ >;88[
6T0Y&6SD,O>(2,6]00:>0B>/(>P97^=3JWSD1Y +N MS"R:S@J;L@+'>6$9KH^JDFZ[U#^ .T>Y-RD 66Y6:IKP.DP+!G)X<%?]9*;9 MI/1+")#0E,#_BZTZ1?L< +CG
[0S#D.!X^\'!SF,-65 M'!48B@U090H/7BM %,8(U6&?0TXMXXCUFD(M+PI)P<-Q,!MJTJ*E!QD>H3NY[1&AR>1&M;,^GXW#YCL72M62L)&"FI44$0)<;
(^#UTT%A6V>&QSTD0X'0S[%%-1'_"HT(\ MZ(,Y83M$UE%)']86\J=QLLU>;!CZB1C*:F(6QC3M7D4(<;*#4?W!QB@Q#!3 M?+BNZP.:16LA,:1U&
@\$&2:&2(QQD<"$88)BC1@+\!'B3T!%AW!GB\A&,?G M)5;/\\!%@BN9COP$Q8B^(/\D\73 8!.Y(1\WCK%R^BZQOOPFP@FH1J?)T9LK M8P384"!3S%'$!2>. M1O3,SE9#>/6%&1"
9%P;I#B1M%?)E8:_P%6U,(\62 MOS:>B2$"48'PB ,W4/BYHD1N-O.,P25G\4-.5$$QT?HRWB5QD,H3F8+O6!AL$ M$#6' MCC+-(J=0!"1KI-+Q\XH.J: <4=$E3Y<>!E@X:-
'4HMX_]"D:8 %++8!PQ .KN5WA#Y%X,?3[Y0T_$CE%1V 5I"$?1XF>5P(?-Z87CJUMC2? MZ)QP#28.&/K;&<=\(7263;+KVE0T\(HG@$=)-$B5G OS8O+Q?"MU1IH&]]!8
M])3(W1T\;_'C>%*!8/<6OT(1C]EH#&5+'ALT,*EPSWB*\U?SUJDMR0C MO3+2FXY(IQ-9Y)Q*Y>WRS,2RX@'AT/043(A"$L%W88T'<#B0J; N#5"]O,> M%D4?X^5&&.^ YT5I0&
(:+@_@82YQGDS&N8]E@2%ICYFPP (3/%AECISW?44!WZ3(L,\I'F "\S#M&J4<10DI01N=RX,@6HSG3W:PYL#). -$+@Y1V[F9F M'H9!>N88((EI\NAR#18)NZ'TVH?0BP1UL.A8-
9TI]_!O,BI,>81T:%,IEENB_M)S0?NX'HF--F`D:9O>*O$;Z6G<,\|1%UU"P:,P"[T+AJ$(,G?0Z^:%F60$ M[(":R(\-FB3V1^"R>/>D<<,&)-!?(0.TC:6*0PPH1E_,8@++>P\$!;N M/80'<
M"$N*!C:<=X'GHL2,*72D:GRRB];;B-[%WQ)YS4@RB,YLT\A,G(B[DVBZ A=4 MBQ^>BPF8#B\9Y2DM86$2L>F)H'ULV1,: KK>J1T"^INQV$I4_(F&XR\'@;OB
MO##$7:'XL[3F6\,$WA1WL8M(?LQ "W]##$F^?8K!1<,;H8SF&\1LZ&/S6/=YB(MRJM"*U:8FFYDPL[('<-PMC!L17NU6>8R+Y3AE1PSNZ8%50]8Z<(KQH+P4M]@ M=UR!G+]-Y\+-?
>MF/&J]:4K07_:I F;$.IX,IE05H251P#\.GS@2Y +&C.$@ M@U3H..8*2$_2X9SCYQ4?$0#5QLPCH.-7N&&KL.K@=EOFO?&P,4<((M9 S,XE!$H/8%"0G2H:IDJTD6@S'VTH?DJ!"
<(8%W%^)9Y[SI>R8(9IU'N>B#3) Y)')HCM#JV MRT*=)S'NE4FLD5B3P)J.8P_SF*]E\99E$LJ>M,X0;*HY#D2>Z;\;"^-=;) M0TSQ&=B6X?&^8;&^9-QO& U2:
(\3OK4>LS#I3"*91+(DBX]YO0/_#^\4F/>' M;\D3*3%&8DP,8P07HNQ5C(%H>C18+"B$F K5;FMTS@PW?JQQ>$XT:K#;0<4R M>B5X8SN*0M
(]^1N>#0EI=!=/O"]91)KP^"=$Z7S=Z*V M9!QU3C :=2B#BX- Q8P;PBJGV"Y# ;?2&.Q\]#\^?>N8AR5Y 4X18/?[=9I-
>TQX\CA^3ECRFJ82R*!:+=*:9FA/$.FW15$RD7F'H(=&F&AN\ MY7E-6S9CR'C'> &C+'Q4:0)L6%[YGNX^MS00?O7"SI/M8(<[*U4M\?4"5VT"DO M2$,),HNRECY;ENFS,GTV->FS/-
$OWGF8!\'#?$:1S3D67R>'%L1#! ^FD&%V M8P^S'"%B0&REFRF!L*FRCY@QY3[2@D@]_I3LH^2"JUA$-QS&9DQB1R"-:A]4Z MFJ#*4M'(";5? $%P8E$;C>TF0H>K,?AJA)0BM<>8^
U0SHKJ]>?V@!TD6J0$ M"1;58EU$-83G47EZ4&IWU<=A4;R?P+UR9.GAL,9G1KP$JR%VVSI%EV(B-5 MZA;F1<8Z^:,D<*EO.29[\X,DVOE- -<(61N&I/! ?
(SCUO:TE22;!L*KRN45"84#AJ7.AFU11BI$!+_23:1W0IPBL16O<3C@.^5?&4*N@[MI;_CIS7A"XB)^]CSL2"B"]@2'$GP.8_NASVNT8W@$!Y4I&(>F/!2K>W:IN^Q MM6I0A6(U8-
QAG_,QY1%M56*]\;2;90X@YOIO"HVJ!$U*0:.*]DDI:&!E$C8I MA8WD:.D%C:I*T*03-%)'2R[L)$=+++VB*DJ.E%#3%0EERM)3"1G*TM(*F5F@V M)6A2*1JU4*U(T*P3-
)3@DTRU>I9CP5HQ>@H0;K"&D^L,5R0<33'W"!?PWC$*Q'I,J-8=EG- MA<&MW<6CQE;P2"W4=PV/3D3%BG]>'S#^UYLD^J2.!3>70)I%,WI=P<'=UH
MVKZK61WW359H9HG=\\D^T__IH;24ZE!50MJ9:O4T%PV-"T6F+"$S!AR,)U M+9A0?FF8!Z7YVKS55.KA3_D[GJIY[+;U/"0N^;%0GVQJR3;Q_(T'3G*F]_[M#[8SZW:W3!;[83^Q(
%Z;V4$O]G-9L--HVX<"2:IA/(+4W]0/+E'GI0DM6?E MN4@$6C;K1)Z4)+5G68,2@9:U#S>O!#[_H((7[\-3VHX!+_K S#OLX*_A2S7+ MS8LWSS>UMO7O#G" K&$Z-
XDE]YQM$^_LN60K<(1E[V\?GFB3!0=8-G!_<2W- M)MP=?ZW.-MVNR"XOA&Y\[4.'49H17*/4UDJ%8W1+4_O<.!=>$ M:?%P=[,L.R523MES@VWI25I:BD.N+FMG;E MW2?R=*6PM
.NQ_13V6SG?[IQ M;JU4-D<8I?M$GDIEC6I=4MG60FSIQPLU4MF<4%K&3F0I*GM=:,U3?["59=,X M?"E(IM96BF-S(EU;/KIU&Z';6GZE1&^YLKU@^&8BJS,S_J.4"V M;3K)8*':?
(&"!M@NT$E&C;)=0:.-Q,+VL@-<3->5*L;ER#T1?6KJ MZ@TM&?+:Z(X^,T\Q,>Q%<\[M -"WSRP7*]_PZRP[85+.%Y8L>RL#"71L'X=9 MIX,&5MB:(X6;7UNDK-A6-.V
MJS2U5/G:KM"4FFN4Z[M 4QFU$E*GI5*FR]A2QV#>I(U.>\0Y'Q%Z:_=5 /' M3!Q"<=W=!S-Q"I(>-M#Y,1.'(.6#I(=-3H5+^R%L9@90NHS(;"# 3K$".9J>OS8Y.O?
2N$\.IO_H6XRGRI2+N2!GIKWK^"1' MU*\(G^2(>CFB_HE;E2/[J);($?4[A EI=D9D;RBW"%'_$JE!CJC?HG-"CJA_ M%EG(%?6I2!^6F34I:+]3S9.2J):!CO91"
YHEZ26N8Z^&03@3+9^2?Q8CFB M7F)Z2GL398-5RA'UJ0D@G6LYNZWERT'WIE[/F<$T_MM;SL40:[.O5#;>8:7$#O'=IT#VWPB2A[&2=W+8))8/U;@L" M:&" [0*=9-
0HVQ$T6FT,5@ZZEX/N,R/_9-0KY=M_XO3NBG3BRV"7#'DMY<0O M565\6$:\7EC$ZXFJRVDFS,N@E1!V_)*DJ1!VG;_-K MBI45 6XI!%]7\$=\W?
CR/L>9@78/UUH>+#]XN\FYWH[F>W;P!7$_HW@#_R:&,0 MU^ W@O3;@ MSFU^].?I=FB[!F+4GL-,.G %\NYI),^/.*L&6A[K0Y,&EL!5O4@EK/-+:,<6#K(M Y?!_J \;_>K
PU%LNN36Q[LNHC=?R_,87=BX#UNH,A3,=5#$OQ^K;O:E;'M71V\ULSXI_8Z?X#L+"(M/95(U6*AFFTBQ9!]5ACV-J'> M(#@3 A/T\RW5S])
MC]PW#0M7&$_37)DFOL7"DY1@=VDK[=L2A["*FA$NNE/43BOHIO'85AIJ;,6M M-!H2R=4MEX%+))\808F&MD1QB>*[B^*E-.#]7)K,L9G 6OYSJX M:*Z^XKE!*8FP;UACE
B[,,$OT56B:W;0-5>IK'9_4M#V+5'D-;AF"FOM.?U MFJ-'[1$LHBIV0SNP$\.6")10PZXY\[0F9M3=-MR?=,+3!3;ZS.'S^<6X9=] M"O^L6-!FWD-
47;VJ*/$\!>YQB>=)/%^#ABGQ7.)YZO!<+4E^+F-!;ZWLU<^O MEK&@5&%X^F-!IUK;=C3/=L8KMJPV"'"X9_LD&XRP75YY>\=+057K3-XBN]94G
MO$ETE>BZ#+HNBZ*O;]75=]! ;3BZ[7C/TH!6ZROO I]-$R.+Z)G)(,\7YKBV M93$S3RUP6$?&,V3\9H?]?;F26I4>/^G9?@&8WJC(4AZ)Z=G"],5-HM)J9^U* M[$YEY&9I?"BO=DB;C-
>D#Z_3'Z^Y\&S]-M_67,9G1S/+E64[SS6@MM?/*GU' M(B3V=F?"K|H!7UZY0?:B<$+HD)),=IM,2B495I5D(LGD(;=':<;4U_"^.3(0- MN%,X45E]6X?MGH,,WF4[Z';QP(1C&8-
;=PPN+8/0Z9%K[J/+EB7?:JE&0BR62Q4R574B69;"J,N&/(4UUI>L6< MB..VSTR&)%=C?Q M98G8N[_E%XC8FQF?E:HM;V985LJV_+(B>EG5R0/D4W.6 \N6@+
>4IQO*:?;5I'P8L1Q0OC%M,^6'(>4 M;\SGDOI#D /*Y8#R]/MDGA/4EH-MTY*05,J5:ROM6BVSV5+2\D4B>1S)BW(V MA43RG49RR<9?0&^C)S7+D$V.9$;Q=N,?9W)
>>:R@W>WA_K3BN-4.. \W0Y_MB;!QA*VOOF>Q1%>)KFM34G/E1ETB;)HC2.N0JJL=I"-G5Z3?[-AV<,>6 \JW M;K7(9NBIXL(XX$*V_=]%]
[C$]$E,+S94B>D2TWM)O4,@IY>F&[@SB|)+#KYPKR]G-TK7| C"]DE-++*T\5 MDI@N,3T=FG*]4993RG<_=+,T/JBK'5HO S;IP^OT!VSDE'(Yl5S.E7VDHEIK MK-
P@>U$X(<5/2B9:*>;(,>49I!$R/__Q- #(2GO.&Q\;U]LK50K5A2M?=]T=X^[=_X5_ M@OMT$PQ0!%5?/#O$,'O),%6F^/?]3G]N*_U2);(\07TX\2=<-?WI/_'%1]B3
MUVW3=O8"4HCMJL_'RY0(F7HLWW:8=IO7NO#B/?,FZWI[XK;@.V([X9>V:V!X>(]2;XT[MAD]//)<@X]E#'+960T2 CV)G%;5061.H8EP1_ZM%7%%3^@[K_O?5?ZYL?28- MX=]_[LY
,_E3Q9@?\=6K=U=(*HK=5;#%#.!\&Z*IM@R]@]ZUOEMA@BO^DSI MVJ9IC[/#M&_]C^ "Z"9RBV!T2M<^8X>93V6.DX?D_1X0*CHWGX1$?OX,D> MG#*C^USC7AG8-,Z0A>,,
2%S"L[%HDMP=-*>0F='ZPBIA L.'<>F#5VV%_P1 MWRKBE, G/%N=PR2)P3%^+-!WFD5X3O!6\325X\N3A<2#R1LQ!(F]TH;7= $H M 3,,/I/(WN,\8 3G\B#I"6Y(+PXNU=]N;?H>6S/-
S1=,ZB.$4\0ZUYQX(@Q M,4 LKF.6@-@0(!ZJ&Y2 V!QK6AB>E8#8'&M:6 0L 2%9T\L"A&1-J0&9VI M (1D32D!A&1-*0'$0UTI)" V1A&+&V5(0&P,$(O3$"4@'@>(U%7,/;#K30U2
MSVBNJX=5A29^^=]7U5=/W'ZI7"AN-X.YL2@:*%[23KQ$'):'MMFAV M&1\YX M5.0PC(KPLOAR,1?4Q[=WJP2<@L15L40MJ/=/8K,RU%AS MTOP26Y_I:9$ZCC>50K(06"
[&*1T7,6P%*IO^ZYF===S5P6O-C'],IX[!?V<3 M:>FI1*H6"]5L$RD&L(/"L+<)Y4;6H5S."I33EU6Y]DZKBJ.TTG$:(^_9FH5# MV SRI_P0UM[3-0N'L/86K]DXA$T4KV[F$);7WQ_(G-
MRA>OUT+%-YC)36UWS MHQU)&<]V0]FU%A=EJ_RCDBO69"_97>RP"9$\-@NP4F]D&\FGP*ML(^@@T3I- M:%W*51LK[0HC>775J[*5[LHVTQUF.3X["2OUAKU+,0]TL>)UCIS
M+WU;WO8TJZ=PVOK*6R^*)!O)B*0JBUG$.YCL23%IM=UD92TH?AJ<_EC0UXYVW M%I3#"G=I6.':1?1.C012<]6J##YE>IZ:1/C')3P5ZRLWQ23"2X3?!,(OB^2O
MJZ753X5_44B>]O%_2V-"J;KZ>? I(GT9\I923)93";5=#AXDDPDF>P6F91R)562B9$Y][2$AI56?,N9?QFDD97U-MZ-C>YE]$H]4746FV&U4W==CDMKV]NU%,DX9-
;@%=M])20N+K;FQ2LM==V>1F MFA)N'9*;;#]X]4UN-SB6Z0S$= PPSF(7QKT<\B"'/"R%*W+(0[HR MSN60!SGD80KN*LK?#++K8PD4@>(GDY5U]]-;1$>;2$S??4ROUR6:RXC2+,20
2494))C'S("3#GV(7M-P9_8 M(;&T=L'$L)7FROM6"<17B+\!A!^621_7;W5Y=@'.?8!,$$MR;$/-M,NR5IK"7//NPI9A7JKKIRD;=CP@CE'}E=>6I*9).9$/[W:*39J[2E&0BR422 MR>
(TQUQCM=.X)9F\G+D/Y4W,<=_VF!@!)38_4%;8l,2QXB[=7 MJA2]DRL[!ZJ$?EVK-*U'<7K,_C/88R'&HU[96!3!T\6=0 $2LHIV L,433 MQH[2'BM_E0HE!59O&K9%-
\,7C>"+'+Y]R'3/@-~>.,N6_#>Q=#D%[;U^X8,-?2 M31\O\/J:IUAV^-P10%!I,WPY$D[X9%P /A.W<,!T-FC#=LM]\& \=CAD#0'O MFQZ^]&-TX,$>?
***,#FX0KQDK7=RBIF+:NF2[=Y@!N.HA5X;<#K4-H:?N]OM(" M7##I+8454E!,N 3_E6O35,TORYNLZQ%I;93*<*>/^/>>X0'ZOS69&,_8V8Q M!U ;S[C5&1B6X7J.AB2I'**
H6L/DUXX6U31]D@EW6"^4I?@FT#8AN @TC>I/$ M(ER"#VE$UN?Q;*"YTFNC;O MV4/ZN"3HZ!2#API%2<=&LD.7[05_Q)>*:-'G&#S0[N%;"YGSVS@):KYG!U^0
MDLB_$1D1*,!%_P:_";HUEG\&_?K.<""Q M5?@XK2@WJ&'*9 C3TXN!2K>W:IN^QB8UNCJC5 M1RAGL)?PWI4F,$E ,P0BZOY)2 V!(B'REDE(#;'FA8F)4A ;(XU+;Q-EX"0 MK.EE
4*RIM0 0K*F5 !"LJ;4 $*RII0 XJ$6*1(0&Z.(Q:U:)" V!HC%;;@2 M${\#1.KJ,=.7JY'I^DPY$A/C2ACWD4,QY5#,9;!%#L5,5SV^'(HIAV).P5T. MQ91#,7A)88!UU>N*;XT=)73^S:'KK72
MRH<*2725Z+JV+DR5LD37-,>(UM$\:;4<2LZ:3+^QL663\93U-!/!%G8/2;H MXV-3LYBA8W>9ZX(UHIEA.QT9W=FEZ(Z<4C;I_6ZN?L2SQ/04>+\EID_V^"PW M5ZY?
2DR7F)X.YWZELMKY%A*[LQWL41LRV".#/5L.]IRC624C.\^PEE(T8>C% M#!=[DG99E+/TY"R|EX/N#>FJE^B>271?6H.N-^7D2#DY$A"AM 93*D64+X-8
MF0MB'3_8$%Y&K=8=M4K51!XY[&MY?E[)%5>?QB?)1,[$VS4R.53KDDPDF;P< M,EG>-&Q49;!-CHM\1#2NMHEHW+9/2H;K5F-ISCN.K7C<"L-F]Q, M^ZJM0W*
[GMW=[(1)PR8ENNL)B6ZIL8F7P2Z,J:YW!8AN8GF?5O?Y';C8)E. M'T R'?3V+.I5BSMBS'(KQZ=VG %T.19!#>10!#D400Y%2%%&LAR*L--MPC(I$\;LN7JZ^^H%DBN43RK6=B-
JJK+^M\Z8B=Y3XY)3D402;>;CO4(8@H%I+3IQJ[5%9N MOTM,EYB>#@=_O;A:#[_$[FP'?-35MNZ1 9_TX77Z SYR,((A>K MEL2QZ\,15CNY7@Y'R"!ED+'YCZ1-UO7V--^S@R^(8/@W
D[\FAC@Q#7X3=#;J_@W;L=S M@H6)%ZI\F\O9ZO24^6C2,>YF/-V&)W9->Q2<6?"9"'FO[3#M-C^"4WH[M%T# MJ]?VJ!4(F-
X3SQ0D2'\.+M7:KFWZ'IO8YN805GT$PL)>PG_7A+S$5PT+UN#M ME2]%ZN/I'*[2$6TL.T!IK/Q5+#046(L)ITUW_04*5_!%3G&8.V0ZWF^.;@7E]L|<%JL,549PY}
Q8&]P3$K'9W@[(!4F'4^VE EWEH/GZ:;/ MM8MM*V+=]5-%UW?.UT:?&XJ(+R95;:L@+7V+&S@05HN'W?!!2[*]YM,C@(M%S_#M@:,T0UX0BPU&H!V9^@LV%@EL?**
LY.V4.@P=V7>8A//I 5PR)>';E9[1< MV*KOX)-G'32^*C@U+7AF5S,;X'&NZ\,]P;IG/0_A M351:XSR0(X/303Z&]^HYFN71N=#"%7N(7],Q$$+0N<>()$;UNLDT!]E0/^!_
M@2B>YFYK;M=4JD1&GS#\2M5)TOZ?!,L*I2Q* -O9"Y2&V*X$ RJP1/^VQ/.>(M6A=>O*9(VWL!IPA-O1%>0:L)2]V5E+:E36!*F:0XW^UR" 'K'98]|^O_G-E MZS.9-_X-BISTS^5-
%*4GSUZMT5B7% V7TNC]V0EVOOED#5Y$'/.K_-"":G: MI^$!/NN)?5+++S"1%1=*"(%E=7K2E8"O8B!E(AKF>*#M=U 8/492H^@4IVO0Z4Y!"96DEE
LU.9I"0EI;5AW\%"48IK;YR(S_V"_?0-D M$.Q ;6NF9J'.7%99V C$MT@8BSK@GAIP@=;;-2PDC(X" M2P2-BCD:5ZHBO1BHV_9I?67HMV%[J$4R!R7D ,NNP/U6!F:FLX&3.AG^"Q= MH
WI:G&EVO6*A)M[P#/X#2/#ZX-\'#@H2E&Y{^O;CZ8MVJT7FZHY7+M=*AF M*OA\?$L!9'3P5?!24K7)Q$"C!##!R\?\(@F4Y]),3;Q=N:0?6I&/$5X6
ME&O8^<)K&1@]8S#-3!/P%R7+7Z"S%8IQY!)&4$?8-O140!Y%)28-!V# _B>D MYP$#HFK#B\MJ[C"TQ%47/-:CG7J%9BCXT_4O$7KA@:.D##N11"Z0X(O\>0
MG'525_\J%>"F(1.F&[?*M1[*ZB/V7VH4ZL\Z -+#8P40G M.]VR@SW13FG(!'M M9K#Y_ZJU6(XZ+"!9EBT?)$Q0-0= 5(A[G38D-%Y =^S.:K;OD?:/>!CM&D$F51_JVC(S0U:.#[3
MHO#]9\U+S+%E'KN.T*) M'2N^*P2TE)#6XS9B7=GD164^Y>KV\XG3Q8C$ .NFE8J#BC,)O@M2#4BC0UFP#D0-7M M4P Y,D@-+,^:I:/.(L+KX)>8'N$;BBYD;BG5P7XZ8J5:--
;YRJ%-@1MY1Z(MP6-P!G]5:I5<$=33+0,P5:@5MR4J,VP)L'^!WO&429OS(L&N@>IO^5U$*E+] MJD > DH@6CC:2,%*=PP,#I&(U8R.0"00>@!!0B2M$.QZ^7)B\P/8X^}IQNI&Q$(T
M$H^;M4M<-IT+FFG7=XA[Q?!0LB:!/P'ISL4@Q_X%QFQ,.0QBG1$""3^]/QP" MH0),# MO(23QX7Y0VX#W6'1C+#J{AFU!"1P\KN\,N8U O&'ZM22T; "G%S M
M>!G=JEECI6UP/2(",47X=-(J\&EHUJ3>(;)9GQI0!I?]7>,>SMVTK5Z>V'J<-M7^.Q U:(D^>@,GJ6 >)" Z@$V@EI QV#D,&)Z7*2SN(G3I'T!('=:8YA^PG7 M(L6>@W"Y\#5%VAQGU(F(?
NQ>>"(H!8CKD2I'O!1U0CM!LH(F7.Z_Y+0YHY-9 MH'O @-%!:'ZV'OY8D)&S$@V!:KQ>) W#:9G0*KN5)796,0$H2H(M9 M'DP_J:]&*[M"QXVO Z#=KF\F# 4XU([C]0#,':-#
)>C5D4P(LC0UBY[-N^ M27!'24\OL\1#;+)S;(ZGL6=Q4[SK(X*2,-)1>__4C+?9%F 5&/= .@;<-N]C MZ]WH*MQA$"@LY.4B1AA8:Z5R\%-8@>5%=(X,IEO49/Y%C+?(C7Y%G&]3IB2
M7%Y,\ >4%09Q"1'\1@*W@"4X*/4VM6\1^3)/@]8^5CF:(QR:%^XAKRIC4'Z[9$"&*>;@/1%CFRB MIE6,+^=G\>]?^$_/6O)$_BT=/*QVP01UOH1D+N[_^4^S5F^^G4P5GTC8G:+2
MIRYZ21*R5-F >68) D-$3P6R@T.+78W-ZFYO55"W%E3[FR.XM3C>-]?@KQ M0^$4H,'B'{AX0G=Q^9P(2Z1C%71G:U9F1+FB^UOQFB"W R-B M,$
L7HC)+'P%422(9# /SYOT^\UX&Z4,)M]34-XS7?-=-KDGOAG6!37!(Q]D MZ">,!Q>"8!//5N!9-MK]E'7MABZ;3 ^#GN/G#B4D\,#4E-K% X=P>6-/YKP
MZ\PZ(,S1[@P3G]S',V"QB(;FBC6*Y"H/HS)ML")XLF,0/G'@:LO'W"VXFI\W MQF(Y%$2AA*AM2%)""P O@#@(!TG MG/O%NO!&]MKCR(@.AEV3%5=+
M+F\1XQ!D3D0#9.8PT[#@8(%7824^[_+QXX)?9\D8.'LJL@^(TL4$ @Y"V@ ^ M'0419W\/V\O=AAC!D3WA%S.Q%?=7QKI(W#W2";I5P, MRG",G]?
F.J^#QI9PR?"0#\R\8ZA$X@,UR\W/;+J3WO3R9Q? M(M,!] -0"'B;CH-&0OMF>0D/!?%'!4L\9(?4F"X_J-Q_C1S94@EO!=&6/D4 M5C>%+3:I7&>"UAD&J
T"O;8,X#=)U+!Z;B"((@.0P4;$HTM["6S*'4W1""/(MW-M!OARO$P&-> ^XZHIMQ#S70683FO MI:0U1@9J##,"L!,JH)Z!?XL23I%6:6,N99?
RIB$UJ'WG_$?'^%'*#S:ESW;#0Q4!Q!>H85>Z%S20B M"2E*)AY]"F=1T!+R2A/89%?'N5T=:PUJ+"S[.JZJK^-SFA8O'"@H :$Q0*B2 M(E(!"+70E)(!20D;TH+(-2%DZ$D(#;
(FR0D4@&)0DWRIA4"XI$CW!XT(#;8 M,/(1NUZK%RS/VW5AP &+!YWU?55T\D%*CH&YW!&MCB0.;WSM3DN:2^-> M.>.^BD/R59"S@@]W+1=SP937]FIP:C$;RQ).8V%I&F*Y
(^NZ\-BX,>8R.N M9G7<-X@$*QOZFV:V\H3I12%[*3V5O:CE,,.7YK/8RZMWZ-M<&:.0V#&%'=L? M OQ,["AG18PLL==)1OA$<;#=H<"?@Q0-K$(P.KS5_6N1[?
%F;V6$O.5M37EN;P\$(CV[8D&G=$V\F4Q?PPE:_. M MJ&Y;LR+E9,V;)'89&6M&57(IU3 M$V;;A*A.[6:5,"FF5I5F\O.E=6HQ8AVB.[6;?0KZEQJY>DV59G@6S? @
M(!VVKH;V2^MDW4;XTFN4 :N@-7_[^]*WU.&\OV_XHJ;^95\@H3Q&:3S$P5 M\=)-=6*G;6=ZYGVA!+H8O0B)EL .\]>_L]Q-0BQV;(,3]8>7 2UW.?L]Yw=" ML9-
$M4<,=^_A5!\M1'Y8.N_/Y;SOFF:>*M*^AU-]9 /!K57<=KMT^U?;#'N& MI?D4PPBR2X5_*Q@$^V"\;P"*_O8V>![P UDL+]G-;]!^!FM[??S"= 1#@NM M-33-
UF([W1,4P;GS4MD<&89LM1%%O 7DY&70387\2::B;JK"(+,9T'V&(#1*83T&"]F(U[Z 6OTAW-\! MM[ZS.SM79'1<>;%LV@P3Q4$B%-:S;>=>T^$]V-<BHXQ >NN%;!^
M5!I=31SM);2]PCSP44<%0%9E&Y!+YFFY?#<(4$24.^?6_B20-QOH+68"G^_M#:5ZBFC)CS^>CAJ52,B.C/G7;D3#?;)W MB4_>:C4$_.3W!56HI\|\|!1?@<(?^\I/?;?
6KC6;\I8GZ%G6:N8(^X"^V;X(!2<@2QNK]I*@ ME_^U9^S E!UKSLY)[KXX\75E\O3*Z?[X>++M?.I>_G;Z;5SV;OZ31>\[,G& M/X%HJ1>UC#-@:W\P][JG!,O#(%C&(!1XB

C1BIB0/H"N)O9O#<3$_#2D($N-MN1L,"H>K@]^X)4 B',X42[%VG"7U7"@E&1XX0C5&B-2,ZXQVB_,JK%=-BJTIX M3S6SAK83-Z+_T&%\?K7]}':89/G#5L.OU4:'_6&SY?>;+;?3'WC"
[7OUT>&@-M47==X3676+YY?"%^?7GQ\0IH__/EQ?'I"5)[O]%I'1YU]IS;G>96C*YF2.QM-MYOAL_&LNQ$<=\A,,ZK7WQEEONIP27K?J)' 2I*H3-T(A@AO%;MAG5*>@G)_3
M]M[A&FZ#(HA8Y0Z.H%Y[[YME&|K+-M7+5J$KW?>V= 0+_G*.9H;,\ [!.RDRJ.= #L"RL.(=RK3O-% M(Y3]PE"SV/K#Q;&X,/BK!BTUQ+&ML F,'Y; !,YGE8%LE\)ZPCYA@ ;5(2, M),.!Y-@9J,H9V9'^+Y##%C"K&BD:8I ,F(C{}8ONXSAXQ7TKWSG##;8F<+N MQF $8A^48!0HW&!8S]-CV6,"7D%[(&3,29PLES3>M6E=] M(V(O+L)2#H?
S"6I+.4>T5><8R)CQ_7J-]30F&BK:;NN!]PNF,AC:4R]$FWM>M)QQH'IKZWF ML^^7I$Q1V,X*KB)<9G@GPF;2PH+5[<.*I@1:G8@;+Z&7::(P M_+"[-AE9\,%?\8]-
$^E%DEA4>R4AI;1LU+*%O+'H@9@(GO4?Q>3;W!Y1XP0$ MFA_#IM\)QJB7OA1>S,%|Y#IL=J,,MC@"VDB$E\;4F;%"UIW"%]H0^'U"[2XT MSG=,@.C!K5"],
[88'HFIB9A5G;Z&|@X9M]VLVS:SQ,6T%DKU#4*W$B,WO(ABH)MS$:H(6>W$C1R6>MRCO4(=2=X MWM2FC+G8&XX#<:O4-[4_\)V;&%MILZ4$T@ZD";@:
F:Z#N52^^@>S!AF*%+*_4R?2DT:.D+S 8QN)G,@T#$@9TY#*- MP960G8\M&8WO\P6&AS&$7%H"#YK(149!54Q_/93T 5IO=I^Z8Z";$=C0RLJ[
M8&N.],?^_4Q;>_,+WBC,&92=5F>|>'8+Z7F&7$9'JB.DVFIDNSO5ZH0=&.D#+ M9CDWAV27@4(XO\|A3B(!+7O)73U@8F?8C,.M'?Q>=3Z0DB/E1A:ST)YKY7LF
MSSUZT+;ASB*DW[:<+)T4ZI62$8<\A2HR$>1SYG8ZE]B$8,WJP/ M1L >:1'4BV3S/1V(N$"A9O;O4D<>RY $A202P;3,;=.P'7&TL(4Z$G6@5E63 M-*D*XP":>*X\B\&[1L *\-N?
S*""%YT.R:9MNM<9]\V0X LUUS04+MCX7N=YL M?$.E6K+_.VVQX0]%O#&JC?K.U..IWX&ABB'0R;_L#S1+OM9D*T MG[N7U!W>Q?6OIY>]\[.+RT_=Z[H%>;_5J.UQ;!8'[?
1Z&X*S-"G'FM5^!V1E MR!R\+O>CN/""SWRHB$W#8.\[3;?UJ#ORD',O|Q[G7A|/?^E^Y&CXZ4GO_!=:_M_'6O^2GBY9L$ZQFU)\-H(O91)I-.-I^T>KG!6&5S6IFUY 43C%+
1*B]&$T@&J>7GUW"%K/;_I-D=-RHMZ]Y9]B*&8#,"0;+@5V0053Z*L MIO57I\?XL$]> BY<_5"YK[AP\^DT)!^<'59K]&#V5&2:P_I:K_5O];BS1C8/ M10ZXN7K-"Z?
#ESQ!8E(!$ZP5+I?$!I6DZFH>4J8DO M#48+=9X33"0U\1<+<)%:'O@C2C$E3O+^RE^-FL;78A4#<HO.A#(W=%A0ZV[3 M!18N%G_.J>%YM!-VY.+P+I^%(A=Q+VHBB>PVQ\O2;<
M'=S'4Y"OM,@@N(CN,$*CE],+R='DXZ=1/*3,6ECXB?GUG?DXU -W$6 M SQO(#C.+F9,D=X,KND/V,#PI#VCJM@5'#>[19W !2I7:'0@6*UTZF MHL.E!?LUEDG?E!= Y\"/Q UCO
"0$B^V8+33SO%2Z/4M"]O!Q_'N)63Q!%J1N#QT M#B*B:N1[Q5LS*J QY*0D%Y\V.6#D+NA4G"@ !G? ZZP4(9/F-^6_XEU9]44] MZC/LSG4_B3$OB*!5"W(_/! MH 7AS?
XY#HY/W&E.UB;/(O22=!HCK,?Q05HDF/>ET1:D;E6K+_#B*,>FY?' MYGMS,-IE^@^@#QH\G0LH/4>E?20ME.@GSL4S1TY."Z5LNQL+XGJRM>=LVV64
M#SKZVF9G!6&K=9(_4EF#VE-/,16%^!?L":19X(3+Z T)4;%N/6"4.MK/(\/ MLM&T%0H"_MFI%:YD8,6RL4B^BH14.0M!;X5[$T2W<7BK#IE4TBB*V6GH@>T%
M'!5,,"DQ07M!ZEQ>%S:;M;$RG0_ >@:[.^53H;-Y@AL*"F!,5OH=5YU.Q'TL MYORERANSIYJO75WY.&4E4D)9QK#.&PN@T49S&=HIKG'%X! \?26=J;RU!=;3
M9@IF]8>9$A/$1!K).DE7)"!U7ULTGE@3!XKWY!4=GZ^>FL7#]0KD3C&2!!:_MD3#/%$/3]@(8WX*-]:IVVV8+!%>D*F,QA:FNWLPQGO!@0F_R%0LIK=0L(*0YC!1]27BU%%ET>
[\+GT] M<.(RHGC%+%"NS#%,H*6#[>\H\:!CSG)EZ4"$YJBK.=D@O]=;'2HHT$DRY-_R MDH_@+3)00DQ;_!@\'J.4.1;OMBWNRION(GIVW(C0B)=+TA8G_)%P^DM
8F2O63F=MDKJ.J*!@!P(D1A>)A!4E)B9B.N?* M"MAU\,8F!N?!7C5-F=),R)^"*,8S(@6W?T@&6T;.8JV(*E,TI0V<*RU4,[_
M%)N#BY0Y!K8")]!CK)+RLVEHUK/H%,@6R3([4\U6'O*@C1!BF!SE:H;XGN(M]5'"XZ>W(D)RT(?G-G6I"!4%:@MYK:(4#HH$.FP3:'4)RH65D5"\;642OC[- MRH?5)3F
WJ&R)5QZDK;Z?$T*.ROI"(\UJL^9@%"P[MT0ZXUNQAL3|%=89G:L M4IJ,F2C/G8PCJKBYB%;'5-=$4M%HB&>!E0ZA; "I8+6;53 R:1];\1X*/,>1 MSGI5O&VGQ2KFQ^!ZDLK7F
MTD116M$3T.LI.#M)D/IUE';U=[>Q%5@TI\EY' MUUGC?)5)B%>IH);9]ZR1@^Y4FK(9AVF$P+@@(;648F5<. SIVI(A7VSWV.5H M.5V+ILH-G?N13+>TI)X,[GAD9?%;=|_
&.AFK:.7S@VNQ^I4PQZS=4PG[0;? M+AVTYTG$-TH\3/LQ$?==T+C"Q559-2Z81R&WC05[]0?[Q]! MO:GHJO6'@T-X@ LN'@^>S<*O@G?
#NJIN"0/.PO.RIYHFH>L^^__ZK0/.^_S4'DY7+LE=#?_0(6\9?30G+9*PD@.JKR8, M(G"%^!/%TWPZ.DU-UM42TMVN*:=6$LZS@(X))*]FCD%E?85)1$X8L*((2DHI
M*453"MHU%%'Q(F,6>$-0B7Q801ZKM$GP(X5?2_HIZ<>H*,K-'L](E GB^V) MN0A^$'+U60#^&"PK[14AU4$Z,_)>;1] MI2U0((H\WD7P 'A)28DE)6JUF0G7$]H2$I^83,-
X(3(XPY3_(F/Q2^3W'DEL M-5V]L/S01JW,#RWS0Q^6'UJ*T)]+A#(BGDDBXF"(*::OKI:*VQPA[5\21&^T M.F>2:VNL,I3*JCH<1M8:$DAV+,M9L!8G2 EG49T,A@$H&I\7$G-
<..TQXN)D M/]D'AV_.EE1!OIR=]524]0Y^QT+!Q9A$V,-OTKGO3)ORQH*FE,6K*27%@&V! MLQ7OF9*0\+*)@^TA$'^N9IH$,\[".5FB-VBJ65'_72=J7'1'?H9=^P4[MP7- MR(M_((I1^+
(XK@SL69[*24!9/8%,Y]Y^2&IUP'J;8[$HD:)),U9!V:PKFLL/ MDQEM!8M,:&",%(KE<;)8DDLV?5-8EUV0[#V5]9M"25 ZX30'@W\"B1I@/X:Z
MFAJ^H/V&W:U)UNL,AX2'<8)6#XL:BQC",PVX++U]'P^TZZ5^\/7@> KOW49YY40N#]B!118XJJ]4@4=B)K*EWRV5$K, ,1;-X1I5]Z2Q7#*_[@:CT M'$S:3$5N##ZL.
(_Z63LM%5MQ=K9XAFT5RRK0F"")/Z/KA#7I'BA#*;LW\C2= MB#(CC/[2]+95L[@B((X$@?DP6AA8=LPIM^H3'>ZD3A$L"28E31X2]W60,5
M,"50#CG)6&1/SA>@9:FL3"RO*%)10$7HE["W+1F;COW4(@B33IY=&87*(L]6 MYMC?!(PO <)(G2(&."\JD**#&JL*D,BQ6-S8B?'Z>CL!6>#3 Q#E@2XCQ?'* M2>FBA\QH*L;/9P +
<\G,!1-^V#Y"D5TV&?Q,.985PH6!FNAE(VN1-^M4*+/ M]CO/8A2%'LIV?E !VZO2-J72["TMUFKFN-_>"$*ILE&I,@)4BMN%388@ZF4M MA6:Q):VVLTSYKBDEN$GB.V
XWC*8(AE(E@$/OA.S]12!!%3\B%"@""XNS=:,2 MV$0 Q2YLI*DR&6RU-$SFP0PK-L' H"8<9 FI6@>KWMDLE',RUS2@*X,L*^DN M RZF>$%#CX<+.<+\,7J(CZ(=FJ61L1ICG<">\K$H
-(#U* M/,/\IA,,>_X,@6B7'.>&3*;*@F6@066Q*M$M3UNB$2G;UMA*MK$EZ[71O%O(-NMDB0LP5R$VZ++6O6&.%YXCAF"OL]46@ZQ=(.ISPMU - MIY725*@!&&Y2Z$0&]>
EHL(TW/+4KSSUVQM4& DS(;O=J>"NC'L#\T^4N+NS M<0\TV('B^R7_*./KR'I@9FK4HFSZ53*P(&(%@@4[=%)%&1,#1 CU@9/670& MB56%7,D/3_ZV"B
CSH!6R:"E%9*O&.MP>>H%NL9;4K)QDK>KY"G/T$M58'}?:M7;_U!EBQR$,&'?P<U1V:XSN8>AAI"4; .L:\F1:B<)#S'75^4BH1$)>Y9 M(&TV']3Y$;5-P>7/H(U*HW?&-'\KFP09M\
!W)M[-IH_%>JJ.-P4B>_BZC@FF M&)8-7#GL2HC&KFQX9IMVVGI- @$J2YC:C'LLW$S32DK38<]0I9F9$MH5M>D2 M1B1_GQ8HJK6:>K/^03D:Y)88N!![$3N8F<*FZV:
[A5.89AYKUX0$UTB%08.T& M9DO RG+-,6[M0P4BIWB(M#;+F-/G7NI[?^K%-XB($A;+H<,_+ &5B;I\S$$P-G@YX9!F-&1. M*EGA'|:>D>X'8+0GMQK$$X]
I@P78I5G!E*PNXF'7;\S.%E3E.//A75Q+[!K M#UL7V2=]..>/>897.,.G::KQ6.DI0%H*84/2%NET[VQU/CMNPA.14 DN>DH MYTK*6+)V/++%I'E!!"$QDHR(*(K=:$I?
JQO<;'4625$%M3M0.1* M2<;8VU!T=^">,!S.\3S1Q41FS"#LQ^O!5%K+,F03I2,Y]#303B3TD]JQZ<|=>+ M,.S@!Q'@'^^H\7;MKTCL!(U@;X(W M9 +,$!
(XG3E_;>FP+MYD7R@Y097[9>YR:^JV]_B2U\%>KD,%=3 PF,;3VW)- MW.RB>/)4(3]<2<"6A9==6,U&3Y?\L8D#"5H^$N8H0)H!.'DLR$,;$O0O++)RV
M^L[E1QU;_BA9XW<.LPVE>78BT+=2MN&UX3Q2"YKQX*G\?24#9H_:OD &X_L4 M%1GJL9C22MJQ1?-:(?{9'66/G0EYA69W|)9>T5!!U&=.-G]&&>X0&CA#8ZIQ MRG:/V*O^J
:B.A2H%, C64B[EY9QX1EXZF"TZ6[",TW>QH="&6]D^,C5>6R6W)3RHM M6J]1Y\X{T$'<$H.!0]%OHX#'0 ?QQ('[+2(FR@8E B9$ EH> >5# N"5!]H(
M<7N#=."R+KN;1DN^>/4?Y'$1?G:NQD! U^-7%];'S03WV SXV&_@W-J5*>,FC MBLOQ.MY,B]TR/A];RFI:L-F>3CFV@HG*' ZA;D;F_A^]IK_DLRW9+%](GN_ MB24#S%/|/ZC 9<$MD
MI96,NG"],*@RM.23/)T+%>+YOVQ\QK#E*C%*OA"X-T;K4'"(1(MJ773I15ZX2& @((5?MRN\OWZ<'C8.1QZ_;97$_WF\'#4/QJ.!GV_U6G5
M1*O1]AN'F7;IV/B]_N7\\O27WM?UZ>7IR57WX>G5Q=GI[U]ZU_^^.CW^!,PO?7UU6WK[7WLJ#W\W\N3AS>#;.F8[3/3]OOER=XH^?+R^.3V'B3]E+
M^O!9B."I4TUXZ.=Q]*@9>IO>]Y3\XC?$L":\>E^(5KW?;'>&?<]SZWV_XPT] MKU;W7;>^Q^^MB^M?3R|!YV<7EY^ZU|V+\WZCW.RWFCOGD=9V/$++#=ZSQ/TV^
MR<-23)Z5U+]KI*_^<2TMY,_8N^B)&?"%2I"E@9^H4TP,S2=4 QO-QJG#=;9T MM-ZHJ5/<"(2-\C>RYVLJ-\%Y[;7<9)I3<2_!$7+,@^]=QO]UOU/A#=Q!]NS@9CVM?_AC[U[}>W-
U<7/QR\\JAG.W9WU\%WX!XT<@+4_'*B>"M?W\EAOX[*+I;&[3<;I)T_7@*5O19Z,'*'G.O23HP=_M_M^CNXN.^\)U//OCRXG_]>Q+]PM&%%_]M{>9O_J&\ZX+)
[&8FH.XV[TOCI'8=_NL_2?/TJO/A M0^=@U!C]X?\.^Q(M]G,;A7MR];^`B^N#27!Q*D[_^6GTV\?;#VX(LZ#^@]X0
MH_39N6!HFG/Y52F92H#A=FXC&>>;SA/@N)3R'E0Z=;,YVA.D_/_X^N=2UU=V M;T"0&L"KTVCL4=GRE2X$_B"+=Y]S$CM3.@UWY8R\@%6:W\S3F7.H4X2 -(]E M3C\=1H(&89
#E95N%O8U7BZC>H^S5W(19%CPC6S=*[,G32WCW3B6!8OFA%H- MFXL,#'205<)N2H%]D0Z38,#ZT;I;Y^4>>_.93O^5-W_G-I^#P/67AY3?ZB?+
M7BRB_/WER2_:.BLBA4H6'4FF/ZU88<>/1:K0+8(;54^^7),JJO15_8NB1K_ MJ56B3A]LN$S2SFO45-2AW4L0)KQJ7(DS1Q[99_VIN*,39:)SKO<4<4()HFQB
M6L)E$$=S2N)0L5*!F7*J8:@T<#7!SA!"8L8W:V;F1$0.7TT>9YY[H%DOW+9,7DW!ZL'|]YBZE5 7C'+C64\3 MV+.%NYOCRY<>3,(DVK#36&*4$%"+?_]M:SD#"H;*O"W3+5'Z2?9D
FL>P"QX M]U.%9EZ69+$0[Q2!FJ*O'!VJIJ2K9/?:G390*[IYY'RM5#.H.<'R&/4S=,*T M.JB78U$%!++DP\)_LDP5=8ANYU^+VR">I]A%F12ZAU[P&/8+WN76JDD!38#/!)P#V2%2H_-
:>)O/8L5I)%+/E$O/G2)Z>6/@1HOE MN9:GFM.!;VV*V2#?%]6D6>I0"?O!V3AJR,1;X(0K<@'*4CCDH M#W_CPB5OF_MXRL+
[8$WJMC"K2LK.1L8(>\-4=G(+M[!X]D!F5RR\T!K7.5%M>_FMSOTI=8]O6 MZ+6&TFN%^X+G-S,<@085UZ1CCXWPQA"F0HV3#%>%,6&4-ZU;?I1[KYB>U3PC
M%!T%&ZY92LHB6*VUGLXZ\R=G[DR]!7LSF=ABCBX8%GVM:58$?'D_BJ3D8#%7 M=+C|$.OK2-=J*" '<\U^/%E*ZMV@* 1UUBR;/6^!\?LX#YMH__LB.<>]8VFP
MZ?"^"LH0]IR7^*%@0#PC^^1X"MCG>]S72B'9;#{J==!& GFP8\RY6Z,XL#I/*'#!.L^@86-=0&JA72)DTBPE 9@(H,;]PC"Y4D$$E(M363<07:HI*4*!
M780*NZP(M/P^]O*89K@HB+7\KJ7%GWR5$AA78CJ3$J/V_$$+9S\H:D..S _J M1S9+/!+T(Q_@1UKKXS)//TW9Y/+,]0#O(^=SMNK^]-EQF_V.WSK"?,Y!WQNV
M#ONU4:/E'PW\EML1V7Q.$)OU+Q&H"^Q> V^CWVDU&K7FTD5M%2[?598G)6FN MNT*G@:;W2P,|_=>OO0^]:Y/W?(^Z"YX!LIDD(22W(9-IEJEKI@Q!|TFY/&8> [RK)X
M0B([6F<<;2%$I0QG49]\77_Q>5S!HOS?$LQ>]Z(CYERX+8R5NLTW MU:7(RG;BID!E[A.G_AAZ=)!FO!:A52I/HSSKI?+*93GH^G.^DYUYX=%Z-VE
MWZ\EZ[O3DGQ7J2I+55FJRB()O ^DW*@V2KWX4^C%^SJ5K=91X[!6;]9JI6:K M_8F7 P/,#VDUJJYWT]^L_F6^;<2%*7$UEE1\KGAW,S/WE*>7)*3JD[2]U9 MZL[]TYW-
4G>6NO,ANO/9?,O=ZLY=.)^E[BQU9ZD[7V"(MEF>;_XDZO1A(=I& ML^[6#MVW?NL05M3UQ;?FLZG1JZD8PHVZO9;E-0569C)\M &YMWORWDMILNJ
MLN8TVAK4H+-.F;JO2&U?:8@*50!R=>#F]6FCT3AP.VZKO5&A7@QGL:DH6MWLL_!ZTNF6JG6WGJ|=?_GA=/GCT"13ZU,/7"@G+Q;!EMHZ8KJJ^\9.!%(CVX^!;*!
<(LE^Y;Z;Z5[MN+T#'U M4L?\E#IF!|',)1VS#,=;ZIA2QY0ZYL?27,77P8THE\Q,JF?J.')ETDR>#29O; M:Z%.K5UJH5(+E5KH)6LAM^96>^=7I1K:M1KZUX?
+CTXO0HC(H7!4=3,CW@7J M:U]HK1&|O.D4$?,D+&@/U\ECG,$3,^8Y=$XR$$/"ZD2X+7K-S+M)"7L=P;)\ M7QZ7R&<$41A$@B]4[WM3BO!2A)<8X(I2D)8BM12I^RI2C!L?
2Y&ZYR+UV N"\Y CZ!^#Z"NV MC"H%,"E@2P'[@3LR>E9*6#W7,">R&88@S:;<;LO6RQCEADV2?%4 M0U.%L0!*-)]H\):ZL62Z^SQ\#E4S"X6 ;WV# .'TT>H(5'4[8E+0-2C;N&6;
M1E/JB;@Y2X^C5U?;0G=&:%5KNO1%4%$="[WCS6>Q4W-J^%ZKV]7W,W"D(WL M0Z41^F5CL0/WR**:EWU!5![_K992+O_Z/^L[\4C2/Z/Z7:PLQJ241^UKNHU$
M[6PO49]]S7D5"Y;O>@QFC57)3F.##W39\R0*TC%V48]#P4W0O>%0]MZ= MC;GWG^RWES"&R72>I'./P57<(^=+]:IZ7-6YGVZC5:L0)^-:,!%)OHDV#]OS M4:O!E"O(]5U'.F%4#.<)
<\?OIMR&T@NT-J)>AV&DWJ->DQE&CV-=RY,%.$ MGJD^#R*<&\P*1F)UFDQTF3EV!)38T=F9>#XN$'9:Q#;&U.G-M I% HQ'^4ZB M^.0;$8&\"ZU!X-Q"F./6F_!5ME;4)2!!0M(
M1;EZU\WQ\F^@*Y_V*H=#@;]5M,=|)MUT>Q[!5&G/Q"=CM<4IN#/(WSU#ZOE MWU?OE_/N]9+TZO^D>NZM8\)5E,9O/R?1)>3S"SY;J967VUQ9"??,15E
M5LLY8U"@_AS4.:7^^]SDI6IG'9K"NL,/.;?Z'8BQ%XY46VG>6=+*>C_[9*(SOU*JISP?HSK|C!?0'Z[11[NO?O0%8C_,9NRLMF!JU:$,W M[QW!?>+U[7*_?STYHDUP1I7XQX!$N3*-?;L?
>;$>C>K@VNE-NQ[-N M!TJK9KD?S[?]X$8WJA#]D2+;Q_272^#]VPZ8'_@EW]_57^U<6]M6O5P+0,] MP=Q^^?COXXM/O4^GU[WC]XK3.S^N+AT9Y)FV_]@VS)YMV".8
2]O1ILTZM\2 +8G$]5X=U+TIH73)024'O:CI M[,(@NQ)1$"?./X.AH/0_1#B?T9GR\3@0HP*8HY*32D[.]^CLQ+4)"HY7@QD, M;0B_OKZ(U"G2Z'R? ;Q/X" C>>3<)__#]02P,$% @
M#8 (67 K%]VC"0 OT$!@ !G;'EC+3(P,C0P-C,P>&5X,S%D,2Y\M+8WM M7&USVS82_BNH.KW8,Z(HR7;J4(YG'%FYZ":Q74>^:SI")"CB#!(L $K6_?K; M!4B)\DMCUR1!$GG&+P07P
+6#GSQOD"4T"UE$/HP^?221#(N498:$ MBE$#K3-N$C*2>4XS\HDIQ84@[Q2/)HR03KOUNM7]H[K7:GG=X &/URTXR"\B^ MO^]WV]U=TNX$NV^"SFMR|HEL78SZVU;X^+0_^N-
LX&8]NWCW<=@6#<_W_[/3 M]_WCT;&[L=MJ=\A(T4QSPV5&A>\/3AJDD1B3![X_F\:LYV65!-_=.XG)A6[MOI!2LU9DHL;A ;; 3T:CPX.4&4K"A"K-S-
O&Q>B]MP\2AAO!#@_\ZK>3'-7/2NM^?\8# T+-.S*>%3P"0R. MRO;<#@3EXL ; MN#GE&E00W,R#A$<1RT#*\'S_O=]L[O0,?19]2]=I6A> Y3#U@K_J#\]'P_;|_-M-
!J>GI#3]^3L?'C2'YX=?22#WP?]B|'PWP-H!HG!^1/OY6/4/KLX_WQQ=#(B MHU/R>="WRN^TN[B T8$Y,0DU UG<_#'T+1L9214RI;,0;H+@0)8@M
MKG5.P_(:>BCXC]H5C,D(K2SJS)8.V9@DWS,..+,CD3%%/KLH#6W6WM@7KE M%-4ZGG)O/ !2(I.@UM'IHE;JM.RR?1/55_&UM!F2A$X946S*V0RBJDFX)K\5
M5(&SBCDY9[E4!F(M>2]5"L'8^XW$4H$8(SG,*2/"L@CZ_:O(&+AGD]AP+&/R M3S$/Y2=0#QZ.;)A%K;(%G9#$^BV>XI-N#80=8UMZ/2V>\M|\?$1^]8R-E:[M%E;,?2NK?4>U98
DG9-+V";|@"LVG?$J9[*1A$DS"2031]<\(S2;DR(SJF"@ M3}!(RT#!4"E)X4IQ*DA,0VA21*9 +8QT#ZVM3@ MR)%-19HH40@0 ->28/IV.FWU";E.2"SD3%=^MPPTA&*CTQNT;-;<1U?
*W-!V MXT'K[$&[:^5!HQ5SP\?3^;6G2Q\I^3C"N(QC#I=;>MO:XI!0Q:S5@Q5S?(!(ML9C&A\EU@CU0+(4HAI$,KR.N0R%U ?TPOBDIG/GG2H8L@F9-ML#:(P;NXTQZ
MOAA5((FFL65'_TGMH'-(3H.87[&H5ZLM M.;4J-UU%HA5X:=QP\4>]_3OHMT6WOP \\SC[RKL+G&@T O"J^C5"R9E4^/P MF&E8#[BA991?
OH@FDMV0%OK^79!UCAGX>SF3X[&R4# A%*T8@S0(,4R.PZ6 M'Y;AO4X/7$$1 *0DLD1O:);4 6]R"/.@BY."1[;NJXNQYA&GBN,"N*/;EK!D M.%*AD0);R-
66+]MP+C4#A0S0!^R44WS^A:#(0F!95HDEE88>CIC7\PGX:\Q0 M$((@"] =#)@N_7$N,VD#4!J*VQNL-4?0ZO[TY-Z !2 WY1'B$-4RLT9, M-6 8)NPD(3E1%%5 ="]7 '3C-
NF1=BTF&+APB'>BF@MX;=T[ZI<4%ZH'.!* MV[0H#,'^K (V]9^P#+(= :@%=UB.<(@B168<,@%L\AP85V#31MH6G-H"M<- MF@93*@I+,=!O61RS$,\
[.Z9QJ24LDKM4]9W>7MYP2(1= 2ZHUT18XSG,'=]_M M0Y05$GOG5E1Y +W!_$J&8;'0K6O)S"VCIE(;,,>C>!A+PZZ3/]U1GSN:NZ5+
M#/@$Q,..=*EX"*AACU#P="4K%GIM.ZT2JA>9'U(6BV_98A%!WI 'G2C M6++0CA81-U+I1>IA&V#(-.7&,/87)&8L(;G!^Q$'_>P@6^"DP!DT^Y7=:Q.Z?Z RZI& [!Q6Q.&Y\4@"#S="SL
5 M2S*_*?.&+U$=NZR=W[^>4:-!TK)=G4RFF#*5C1B?E:T:J!Y XLS86<,[:2Z1C M"W0%:P ;GB0O:'UKA/<9E#]&!Q.0%]:2 .,:=Z\FON#+58_>$OORQP.E>R&- M4^TU3)
XX\57^=%00+N5D@!V.[/M4N5M<>PDLPA@!Z MZ<6]D>>X5WUE\?F"Q^:D\^WM;;^E9960IU^WD5\2^_M,4)^;MNQE]T07_LW/I!SK3KRC5CO=V:?#,Q9#(N;'1M
M[5S_4]LZ$O]7='GSKC 3QTF %AS*3!K"-358@V+Y27)"[J^_M7?O@QZI.,Y_K]W M>KY_/#QV';N-9HL,%4TU-URF5/A^_[1&:HDQ6>#[L]FL,=MI2+7VAQ=^8B9B MUQ=2:M:
(3%0L.L06^,UH='0X88:2,*%*,._Q=C4\3?9!PG CV-&A7_YULB,9 MS8\.(SXEVLP^%UB;4#7FJ6=D%NPT,1.!D3YTWY*Y\68\,DG0:C9_[60TBG@Z M]@2+#;0TV@?+-
L7'R;)1NLT%B@EJ^)3A[)5Y0\&H"D;2))W;2]PW,BO'Q3(U M7DPG7,R#=T,^89J+QNXZ5UOR_#*:IV8SPJ^!@F M1V4[[@2"8O.CE45FS.YG)4G?
V;A(^X(3NM1OO0'\%)9<^EU:H2V+DRK14\ M@,XIUZ""X&8>)#R*6 KB?_]EO]WH)9]7K7PP')X-> M=S@X.R5G)^3\8G#:&YQWOY"3P6D7/L*GLQ.0Z%^09SI,[}'[_.KB\]H.B3#
M,W+9[UGM=YMW,'PA(,#*2*F+]8ZU9N.\6%*"!L<:TS&A;7 M,$+!3U0N.L5]AE041F;M#1"T,TNX81X.9$$]9XI"DP6U]FYC#]0KEBCW\9QG MXP&,&CD)=BV(Z6ZE5L-
NVS=1=1<_2IL!2>B4$<6FG,T@HJ$:_);3A5XJIB3 M"Y9)92#2DA.I)A"*O=](+!6(,9+!FC B+(U@W#_SE(%OUHD-QC(F_Q#S4'X% M]>#FZ#H9I&&#;.$P-(%VLZ/8F&L#,=?
8AE9GNI,\%Q|OL6\M8V.U:V&U[.6R MVD]46_Y')G-R#<Y4PVDK!H"H%BPNR4IX2FB$Z)R0[RV\K#!P?6MI<.3()D)U ME,@%"(!K2:|_NYRV<H14)R06D-6M8KIJ-+9>YHN_&@=?:@
MW;7RH.&*N>'M:7WHZ,)'"CZ,,"[CF,/EEMZVMC@@5#%K]6#%'&\@4BRF\69R MG>_(%)M %,-(AM<1UZ&0.H=Q&-^4%,[\,R5#%D&S)EM@[1$#|W$FW;\)$YJ.
M&>E"Z+C(!4BT=]C7VMMB3N2NW"7'7"UU;H?S$XPO%6]TWH&Z/]A>&6A M&!8JJ6351$"*6GPIOVN7,R-\$(I\,TT"\H/G9@%44]TJD6,HJEV M=,PT\>)PQ*];
[MN'3EH2'/]^"%(!D<,W+!8R=%+F2N8 "(<6C'&39!BJ9T-MJP++B%N-VJ[*!WY=\,NE;|:+B(Z='*(OZ**EX)$MQNI\!'G$J>*X >Y8L.41 M*"CI62:V&"UE8Y''I]JH6T(,*?^6?
O,PXA2N:F=O;A#H M9T2@T7HCT*-#^QT@>CPI>#0> 89->80P0[5,K1%3#1"%:3)B#U51B0. 3)PZ M5T!R?]^RB(H6,BP:.$!;$:VDV99DW10;RG*5 1HFXR$(=B?5< FW&.60HXA M
)2@AV6(=BB2N8!#Z %2U0

M|RHW|KV-XJ=| !V5KE|?ADV,XE7W6T90=* G9#%W*AD+|6@><2.57B0.M@&F MG$RX,8S|"4<924A-L#_BH)^=9 N<%"B!1LH!?[&F4B(+^R/GH+Y%D3P-[0.+ M|4V-HMP3'VD$ S5;A,<'P;"H+< 0\&@PD+K+ #30?YU/P+[@ M5.QF"EIR[V//#;O?0.0Z0.3:%2&[0.)C!0&V#@[++"T E[=ON!384'<)4MH_&ST]P64.H8;$Y!N M/LZ!A>VIE_O6|TU2^ZJ\@Z!'X8I3Y#TLD#A3Q1?'T2S X%80D.9&E@WNI7K; MLH+!55!V,MA2@9,,L?|\L>9>@[:04NI9K-\JH,;!C$26+K^[W_AP\&OU &\Y M=^7-_LKD:.OXF_? >Z!^)K?_7I*[<* M(S^+[;XQTWQ1RT/S_L%FMS&YOXC)O>I^+EG*(5_|%P\9.5=,+9//,U<)OEX$WIO<6MO,C3&^K>!L)OZNTL++BB&5X,S)D,2YH M=&WM6FUSVD@2_BM]2F5C;Z$WP&\"4T4POG"58"_(F|V/@S2RYB(TW&ADS/WZ M[1E)@+!C;W:=+!^_KIZ6FI^R_3'*8Q20,:P@?_TT<(>9#/:2HA M$)1(;%TR&8//%PN2PB"]8>$L!7,689]^+L@;E))YZ<&]? MVDVGV0;']=IGGMN&ZT]P<.,/#O7@BZN!__OUL%CU^N;]Q|$ #-.V/[<&MGWA M7Q0=;KGK=D-U! M)E<)/3?F1-RRU)1\X;6S@3!N[=\;=M9T"D*6W9D(CB2U6 M\VS3)MAMO&GDA7*>H F1{(XJZ5MR@X02XG;'_4Q2-"DIZ+TV2L%L4KL!V"@MX MP *SVB)+JO69\23$SN%|S&9,0JMIN5U[AI9:O!2J.@C568F|8QDNFC"Y\F{6 MAC3% 3^].6TZK4[75@-?$L:6<0+D"A7?8)W!<.*/+D>#OC^Z&D_AZO*%3?1W ML%U/1N/!Z+K_$8;_#00IQ'"RG1GSC'N M-_@?AC#M3|WQ\.I>??;Q^'OT!_XIJ?I.,V7!KY/G&_OE$KQ?.T'4G6[9ZUV T@&!(6%-&S @9]A-&TZG>W1NLGM'))0R51G0T_ MO7&/G8YR>B5K$),%[CT24+L@:,_MTL"JZ3#@]L08+J=RF^F&$&/$G((J->]:7S NJ8F()(/O>V6E0^I,FAX)H)6:%/ M>!&[IV%G*TTI0%76D +_ARIBY@>AZDYM>$"2,M!SB+&SC)&QS:5O.B'&R[(MHL2'3#Y15"Y-6V)T+4P(PVV8]?|:COY1#:@@Q"7F)*GI5#89/7_CXC ?_)4PHM//U47]JI M@(9!NDC%A$%!EH"HJ '80*1$+N$THF+2)J>K4?=:RV=!"6)#X2A/$%] H!-% M0'V-V(F+F2+A3[@Z(@2Q4[KT4&X#I3;\;ZC \6:-VK+,.5>MO;'5S* DADQ M-O>1S"R-U$]-M0-'$98BT3]4"Z^PRF('%,T7PB:*=8TU#B"UW"]3T:'U&HN107Q U3W!4GA2DXQ@6].+9SOEI[3^;?DPZ]V0^/!K#YY&/ MV>|4/G\83H,%);ZP?HXR188.B_L9$\R#5/*''4S@SS3,=&Z"D9>L37_;S? *Z M4AKFB0:U2P+T?Z,GXZZ-0G+)]X:BF*);:C4790,*RC&J92N4&;"->FX4%R(= MSBJ;6L>,1_2@DMD^M5OOMMLEVPLQ616=+,$>!4<*7E1FKWZ:*;]Y, M4/+%7*+-G]T2K?O)+.-)++FFGBN?;&G]_S]@:J-SWS_E)44LK/^0!^NL&MYT' MK_;^@?8^L5IGKP9_(8/KD[6>/3T76LK0629N[N(>T XLA#>,_O?$SGP'D]B9 M_: &4!P]+\??/3G"OI$>>[=)M3+*1], [G^*=? ^P7KN,]^IW>[0Y+ ^=P/QJV M5\J7KZ[U8_69TI1Q ;^B[>$:,ZQ,W=#T]?5K!>_=%ZMNJP\>S_YUC-:399/U M76.GC#+'[U4>9+EG=/Y(AE//7&(!*<]B$B),*7))JX 4^X>+<*'EL@)T;K@& MZ(GGAGKT_G93+R+!EUN,C&EHZHE>O?_ZKZWD["$BC=XZ1K1EH2?E*:UM475I M4GJO'X-_:XGKN5#P,*W'/?V^[OA$?>,]*2AEZGX20XJD:0I22ZN6/G<=3BHOK(NR S^IQ:_MF"K?.*D53NIMZS=<%JB,65S/M+4\:,?A6G M]P=02P$"% ,4 " -@ A9#?*4L?$. 8C@ $0 @ $ M 9VQY8RTR,#(T,#8S,"YX&UL4$L! M A0#% @ #8 (6:SC\83")0 ZZH" !4 (!GAD &=L M>6,M,C R-# V,S!?9&5F+GAM;%!+ 0(4 Q0 (V `"%E]5:EEHE, 'YG M!0 5 " 9,_ !G;'EC+3(P,C0P-C,P7VQA8BYX;6QO2P$" M% ,4 " -@ A9#6[PH9X\ #5DP0 %0 @ %HDP 9VQY M8RTR,#(T,#8S,%|P&UL4$L! A0#% @ #8 (66,M,C R-# V,S!X,3!Q+FAT;5!+ 0(4 M Q0 ( V `"%EP*Q?=HPD +|! 8 " 4ML @!G;'EC M+3(P,C0P-C,P>&5X,S%D,2YH=&U02P$"% ,4 " - @ A9:[J-ZZ0) `-M00 & @ $D=@(9VQY8RTR,#(T,#8S,'AE>#,Q9#(N;'1M M4$L! A0#% @ #8 (67N24CZ\!P 7B0 !@ (|_G\" M &=L>6,M,C R-# V,S!X97@S,F0Q+FAT;5!+!08 "0) & " #PAP(" | end XML 67 glyc-20240630x10q_htm.xml IDEA: XBRL DOCUMENT 0001253689 us-gaap:CommonStockMember 2023-04-012023-06-30 0001253689 glyc:AtMarketOffering2022Member 2024-01-012024-06-30 0001253689 us-gaap:CommonStockMember 2023-01-012023-03-31 0001253689 us-gaap:CommonStockMember 2024-01-012024-03-31 0001253689 us-gaap:RetainedEarningsMember 2024-06-30 0001253689 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001253689 us-gaap:RetainedEarningsMember 2024-03-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001253689 us-gaap:RetainedEarningsMember 2023-12-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001253689 us-gaap:RetainedEarningsMember 2023-06-30 0001253689 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001253689 us-gaap:RetainedEarningsMember 2023-03-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001253689 2023-03-31 0001253689 us-gaap:RetainedEarningsMember 2022-12-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001253689 us-gaap:CommonStockMember 2024-06-30 0001253689 us-gaap:CommonStockMember 2024-03-31 0001253689 us-gaap:CommonStockMember 2023-12-31 0001253689 us-gaap:CommonStockMember 2023-06-30 0001253689 us-gaap:CommonStockMember 2023-03-31 0001253689 us-gaap:CommonStockMember 2022-12-31 0001253689 glyc:AtMarketOffering2022Member 2023-06-30 0001253689 srt:DirectorMemberglyc:OtherAwardsMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-04-012024-06-30 0001253689 srt:DirectorMemberglyc:OtherAwardsMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-012024-03-31 0001253689 glyc:EquityInducementPlanMember 2023-01-012023-06-30 0001253689 glyc:EquityInducementPlanMember 2023-01-012023-12-31 0001253689 glyc:EquityIncentivePlan2013Member 2023-01-012023-12-31 0001253689 glyc:EquityInducementPlanMember 2023-12-31 0001253689 glyc:EquityIncentivePlan2013AndEquityInducementPlanMember 2024-01-012024-06-30 0001253689 glyc:EquityIncentivePlan2013AndEquityInducementPlanMember 2023-01-012023-06-30 0001253689 glyc:StockOptionsVestingBasedOnPerformanceMemberglyc:ShareBasedPaymentArrangementNewlyHiredEmployeeMemberglyc:EquityIncentivePlan2013Member 2024-01-012024-06-30 0001253689 glyc:EquityInducementPlanMemberus-gaap:CommonStockMember 2024-06-30 0001253689 glyc:EquityInducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-06-30 0001253689 glyc:EquityIncentivePlan2013Member 2022-05-012022-05-31 0001253689 srt:MaximumMember 2024-01-012024-06-30 0001253689 us-gaap:RestrictedStockUnitsRSUMemberglyc:EquityIncentivePlan2013Member 2024-06-30 0001253689 us-gaap:RestrictedStockUnitsRSUMemberglyc:EquityIncentivePlan2013Member 2023-12-31 0001253689 us-gaap:RestrictedStockUnitsRSUMemberglyc:EquityIncentivePlan2013Member 2024-01-012024-06-30 0001253689 glyc:EquityInducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-012020-01-31 0001253689 glyc:EquityIncentivePlan2013Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-01-012014-01-31 0001253689 glyc:EquityIncentivePlan2013Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-01-012014-01-31 0001253689 glyc:RockvilleMarylandMember 2016-05-31 0001253689 glyc:AtMarketOffering2022Member 2023-01-012023-06-30 0001253689 glyc:EquityIncentivePlan2013Member 2023-01-012023-06-30 0001253689 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001253689 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001253689 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001253689 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001253689 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001253689 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001253689 glyc:EquityIncentivePlan2013Member 2024-06-30 0001253689 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberglyc:EquityIncentivePlan2013Member 2024-06-30 0001253689 glyc:EquityInducementPlanMember 2024-06-30 0001253689 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberglyc:EquityIncentivePlan2013Member 2024-01-012024-06-30 0001253689 glyc:EquityInducementPlanMember 2024-01-012024-06-30 0001253689 glyc:EquityIncentivePlan2013Member 2024-01-012024-06-30 0001253689 2024-03-31 0001253689 2023-06-30 0001253689 2022-12-31 0001253689 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001253689 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001253689 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001253689 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2024-01-012024-06-30 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2023-01-012023-06-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0001253689 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001253689 2024-01-012024-03-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001253689 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001253689 2023-01-012023-03-31 0001253689 glyc:ApollomicMembersrt:MaximumMember 2020-01-012020-12-31 0001253689 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001253689 us-gaap:CommonStockMember 2024-04-012024-06-30 0001253689 glyc:SecondPortionSquareFeetRockvilleMarylandMember 2023-04-30 0001253689 glyc:FirstPortionSquareFeetRockvilleMarylandMember 2023-04-30 0001253689 glyc:EquityIncentivePlan2013Member 2014-01-31 0001253689 glyc:StockOptionsVestingBasedOnPerformanceMemberglyc:EquityIncentivePlan2013Member 2024-01-012024-06-30 0001253689 glyc:StockOptionsVestingBasedOnPerformanceMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberglyc:EquityIncentivePlan2013Member 2022-01-012022-01-31 0001253689 glyc:EquityInducementPlanMember 2020-01-012020-01-31 0001253689 glyc:EquityIncentivePlan2013Member 2014-01-012014-01-31 0001253689 glyc:EquityInducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-012020-01-31 0001253689 glyc:EquityIncentivePlan2013Member 2023-12-31 0001253689 2023-04-012023-06-30 0001253689 2023-01-012023-12-31 0001253689 2023-01-012023-06-30 0001253689 us-gaap:SubsequentEventMember 2024-07-012024-07-31 0001253689 glyc:AtMarketOffering2022Member 2024-06-30 0001253689 glyc:AtMarketOffering2022Member 2022-04-28 0001253689 glyc:ApollomicMember 2020-01-012020-12-31 0001253689 2024-06-30 0001253689 2023-12-31 0001253689 2024-04-012024-06-30 0001253689 2024-08-07 0001253689 2024-01-012024-06-30 shares iso4217:USD pure glyc:lease glyc:installment utr:sqft iso4217:USD shares glyc:employee00000000001253689--12-31202402false0000 644839586439374 4true http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent0.000208P3Y2M12DP7M6D0.00253610-Qtrue2024-06-30falsee001-36177GlycoMimetics, Inc.DE06-16865639708 Medical Center DriveRockvilleMD20850240243-1201Common Stock, $0.001 par valueGLYCNASDAQYesYestrueNon-accelerated Filerfalsefalse64483958223860524179283014714531997904238575054379073460373742420976782813710515417624418819453164759507638681152956778522555744877.477317285-456485212200625033841440124418819453164756285734407270812311195949141440719604857237916152610379549103576948929945214727211978709631005769-21472721-1987096362622886710336406481252701-10095406-8258912-20832073-18618262-0.16-0.16-0.13-0.13-0.32-0.32-0.30-0.30644838486448384864276184642761846447054164470541623131556231315564393744643944948352194564852123841440115256153598536000418354248564898119208011920800-10736667-10736667644508356445149606814046722187928910712131271339362393751999620480500120732212073220-10095406-10095406644839586448449731530447731728520062503543777985437846246125141958579242929837982293098232869718828707011449644337243376887018087018010359350-10359350643452246424549206234342994514262181446681096820046201148580888580888-8258912-8258912643133336431349294047743820405454800736-20832073-18618262270438725734361944156675375239940217282685264511-512324-603737826487287042268779-1481734-359627-522428-19402204-18581713997212727-9972-12727287070115398538825398287608939-19406778101664534179283047870619223860525803707 2 1. Description of the Business GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is focused on improving the lives of people living with cancer and inflammatory diseases by leveraging the inhibition of carbohydrate interactions that occur on the surface of cells. The Company has been developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. As a result, the Company intends to conduct a strategic review of its business, in an effort to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan and the Company's GMI-1687 to ensure their continued advancement. In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately 80%. 0.80 2. Going Concern The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2023, the Company incurred a net loss of $36.9 million and had net cash flows used in operating activities of $34.9 million. The Company incurred a net loss of $20.8 million and had net cash flows used in operating activities of $19.4 million during the six months ended June 30, 2024. At June 30, 2024, the Company had $22.4 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings, although the Company may, at its discretion, sell equity securities under the terms of its existing at-the-market sales agreement (see Note 7), subject to certain conditions and limitations. Management believes that given the Company's current cash position and forecasted negative cash flows from operating activities over the next twelve months, despite the adoption of a streamlined operating plan, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date these unaudited financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement. The Company expects that its current cash resources will only be sufficient to fund the Company's operations into the second quarter of 2025. The Company's ability to fund its operations is dependent upon management's plans, which include reducing operating expenses and potentially entering into collaborations, strategic alliances and marketing, distribution or licensing arrangements in order to raise additional capital. There can be no assurances that any strategic transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital or enter into a strategic transaction, the Company will need to eliminate some or all of its operations and may seek to liquidate. The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern. <p style="font-family:'Times New Roman','Times',';serif';font-

size:10pt;text-indent:24.5pt;margin:0pt;"> -36900000-34900000-20800000-19400000022400000 3. Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the SEC) on March 27, 2024 (the Form 10-K). Basis of Accounting The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Unaudited Financial Statements The accompanying balance sheet as of June 30, 2024, statements of operations and comprehensive loss and stockholders' equity for the three and six months ended June 30, 2024 and 2023 and statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company's financial position as of June 30, 2024 and its results of operations and changes in its stockholders' equity for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. Fair Value Measurements The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of June 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $18.8 million and $38.8 million as of June 30, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three and six months ended June 30, 2024 and 2023. Concentration of Credit Risk Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. Revenue Recognition The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers (Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates' rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Company's license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements. Manufacturing and Supply: The obligations under the Company's agreements may include clinical and/or commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs. Accruals for Clinical Trial Expenses Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses have historically been a significant component of research and development expenses, and the Company previously outsourced a significant portion of its clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, estimated project duration and other pass-through costs. As a result of the Company ceasing its clinical activities, the costs of closing down clinical sites are also included in the accruals. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company's judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Company's historical clinical accrual estimates have not been materially different from the actual costs. Stock-Based Compensation Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The

resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company accounts for forfeitures as they occur. . The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. . A discussion of management's methodology for developing some of the assumptions used in the valuation model follows: . Expected Dividend Yield—The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. . Expected Volatility—Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company's publicly traded common stock. . Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. . Expected Term—This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. . Net Loss Per Common Share . Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock options and restricted stock units (RSUs). . The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options and RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 16,047,875 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 11,469,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> . Comprehensive Loss Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Company's net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. . Recently Issued Accounting Standards . Accounting Standards Not Yet Adopted There have been no new accounting pronouncements that have significance, or potential significance, to the Company's unaudited financial statements as of and for the six months ended June 30, 2024. Basis of Accounting . The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Unaudited Financial Statements . . The accompanying balance sheet as of June 30, 2024, statements of operations and comprehensive loss and stockholders' equity for the three and six months ended June 30, 2024 and 2023 and statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company's financial position as of June 30, 2024 and its results of operations and changes in its stockholders' equity for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. . Use of Estimates . The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. Fair Value Measurements . The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of June 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $18.8 million and $38.8 million as of June 30, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three and six months ended June 30, 2024 and 2023. 0018800000038800000 Concentration of Credit Risk . Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. Revenue Recognition . The Company applies Accounting Standards Codification, or ASC, Topic 606, <i

style="font-style:italic;">Revenue from Contracts with Customers (Topic 606), to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with the customer(s); (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates' rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Company's license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in their period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements. Manufacturing and Supply: The obligations under the Company's agreements may include clinical and/or commercial manufacturing products to be provided by the Company to the counterparty. The services are generally determined to be distinct from the other promises or performance obligations identified in the arrangement. The Company recognizes the transaction price allocated to these services as revenue at a point in time when transfer of control of the related products to the customer occurs. Accruals for Clinical Trial Expenses Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses have historically been a significant component of research and development expenses, and the Company previously outsourced a significant portion of its clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, estimated project duration and other pass-through costs. As a result of the Company ceasing its clinical activities, the costs of closing down clinical sites are also included in the accruals. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company's judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Company's historical clinical accrual estimates have not been materially different from the actual costs. Stock-Based Compensation Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company accounts for forfeitures as they occur. The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. A discussion of management's methodology for developing some of the assumptions used in the valuation model follows: Expected Dividend Yield—The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. Expected Volatility—Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company's publicly traded common stock. Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. Expected Term—This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. P10YP6Y3M Net Loss Per Common Share Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock options and restricted stock units (RSUs). The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">

  </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options and RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 16,047,875 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 11,469,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.05%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options and RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 16,047,875 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 11,469,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>1604787511469764 Comprehensive Loss Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Company's net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. Recently Issued Accounting Standards Accounting Standards Not Yet Adopted There have been no new accounting pronouncements that have significance, or potential significance, to the Company's unaudited financial statements as of and for the six months ended June 30, 2024. 4. Prepaid Expenses and Other Current Assets The following is a summary of the Company's prepaid expenses and other current assets: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"> 1,420,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> Other prepaid expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 589,133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 401,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;background:#cceeff;margin:0pt;padding:0pt;"> Other receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 175,820 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> Prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,997,904 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr></table> The following is a summary of the Company's prepaid expenses and other current assets: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 805,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"> 1,420,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> Other prepaid expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 589,133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"> 401,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;background:#cceeff;margin:0pt;padding:0pt;"> Other receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 175,820 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.76%;margin:0pt;padding:0pt;"> Prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,471,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,997,904 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td></tr></table> 805610142064258913340144276710175820147145319979044 5. Accrued Expenses The following is a summary of the Company's accrued expenses: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,824,689 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued bonuses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 2,561,913 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued consulting and other professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"> 441,652 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 439,192 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued employee benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> 545,549 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 399,763 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,956,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,225,557 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,916,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,824,689 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued bonuses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 2,561,913 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued consulting and other professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"> 441,652 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 439,192 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued employee benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> 545,549 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 399,763 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,956,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,225,557 </td></tr></table>
191662918246892561913441652439192545549399763529482956785225557 6. Operating Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one single component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company leases office and research space in Rockville, Maryland under an operating lease that is subject to annual rent increases (the Lease). The Company paid a security deposit of $52,320 to be held until the expiration or termination of the Company's obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately 30,000 square feet, would be extended from November 1, 2023 to January 31, 2025. The Company's lease of the remaining premises, consisting of approximately 12,000 square feet, expired on October 31, 2023. There were no additional operating leases entered into during the six months ended June 30, 2024. <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-

indent:24.5pt;margin:0pt;"> The components of lease expense and related cash flows were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.27674866%;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 188,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 247,359 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 376,620</p></td><td style="vertical-align:bottom;white-space:nowrap:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 479,349 </td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 138,819 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 133,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 238,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 316,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 327,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 380,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> 615,326 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 795,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 196,314 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 280,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 392,628 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 560,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-indent:36pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-indent:27pt;margin:0pt;">Maturities of lease liability due under these lease agreements as of June 30, 2024 were as follows:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">July 1, 2024 - December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"> 396,555 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 67,401 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.61%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 463,956 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"> Present value adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,181) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> Present value of lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 448,775</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Supplemental information related to leases were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Operating Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">1.1</p></td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">10.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">10.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times';font-size:10pt;text-indent:27pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"> 872,892 </td></tr></table> true5232030000120000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.27674866%;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 188,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 247,359 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 376,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 479,349 </td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 138,819 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 133,022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 238,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 316,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 327,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 380,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 615,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 795,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.17%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash outflows for operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 196,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 280,518 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 392,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 560,210 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr>
</table>188310247359376620479349138819133022238706316296327129380381615326795645196314280518392628560210 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;margin:0pt;padding:0pt;"> Operating Lease </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Obligation </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"> July 1, 2024 - December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"> 396,555 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 67,401 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.61%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"> 463,956 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"> Present value adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15,181) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"> Present value of lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 448,775 </td></tr></table>396555674014639561518144875 5 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Operating Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"> 0.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1.1 </td></tr><tr><td style="vertical-align:bottom;width:72.01%;margin:0pt;padding:0pt;"> Weighted-average incremental borrowing rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"> 10.0% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt,"> 10.0% </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;">
</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.15%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for operating lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt,"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt,">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt,"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt,"> 872,892 </td></tr></table><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-

indent:27pt;margin:0pt;"> P0Y7M6DP1Y1M6D0.1000.1008728920 7. Stockholders' Equity Common Stock During the three months ended June 30, 2024, the Company's board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from 100,000,000 to 150,000,000 shares with a par value of $0.001 per share. At-The-Market Sales Facility In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the 2022 Sales Agreement) with Cowen and Company, LLC. Under the 2022 Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the six months ended June 30, 2023, the Company issued and sold 9,822,930 shares of common stock under the 2022 Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no shares issued under the 2022 Sales Agreement during the six months ended June 30, 2024. As of June 30, 2024, approximately $66.0 million remained available to be sold under the terms of the 2022 Sales Agreement. 1000000001500000000.001100000000.098229303.012870000006600000.0 8. Stock-based Compensation 2013 Equity Incentive Plan The Company's board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the Code) to the Company's employees and its parent and subsidiary corporations' employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company's employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. Authorized Shares The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000 shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000 shares. As of June 30, 2024, the total number of shares reserved for issuance under the 2013 Plan was 14,257,627 shares, of which 94,036 shares were available for future grants. Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. A summary of the Company's stock option activity under the 2013 Plan for the six months ended June 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;">

 . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> AGGEGATE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> REMAINING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> INTRINSIC </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> OUTSTANDING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> EXERCISE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> CONTRACTUAL </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> VALUE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> OPTIONS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PRICE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> TERM (YEARS) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (IN THOUSANDS) </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> 8,273,800 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 5.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 6,3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> 5,756,875 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 1.85 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> (3,250) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 1.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (747,095) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 7.39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-

align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,280,330 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 3.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Vested or expected to vest as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,771,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 4.47 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> 7.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,572,477 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 6.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 4.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr></table> . As of June 30, 2024, there was $10,012,044 of total unrecognized compensation expense related to unvested options under the 2013 Plan that will be recognized over a weighted-average period of approximately 3.2 years. Total intrinsic value of the options exercised during the six months ended June 30, 2024 was $4,091 and total cash received for options exercised was $5,398. Total intrinsic value of the options exercised during the six months ended June 30, 2023 was $54,083 and total cash received for options exercised was $53,882. The total fair value of stock options which vested in the six months ended June 30, 2024 and 2023 was $2,182,608 and $1,090,699, respectively. . The Company has granted stock options to purchase an aggregate of 2,509,275 shares to certain employees under the 2013 Plan, the vesting of which is subject to performance vesting conditions relating to the achievement of specified regulatory or commercial milestones. The maximum fair value of $681,766 associated with performance-based options granted has been excluded from the unrecognized compensation expense under the 2013 Plan as the completion of the performance milestones was not deemed to be probable as of June 30, 2024. . An RSU is a stock award that entitles the holder to receive shares of the Company's common stock as the award vests. The fair value of each RSU is based on the closing price of the Company's common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date, provided that the employee remains employed by the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of June 30, 2024, there was $103,762 of total unrecognized compensation expense associated with outstanding RSU grants that will be recognized over a weighted-average period of approximately 0.6 years. . The following is a summary of RSU activity under the 2013 Plan for the six months ended June 30, 2024: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">Underlying RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"> 117,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;background:#cceeff;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> (58,581) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,581) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;background:#cceeff;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> Unvested at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 48,995 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr></table> Issuance of Shares to Directors in Lieu of Cash Retainers for Service In March 2023, the Company's board of directors amended the Company's Non-Employee Director Compensation Policy to include an election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The number of shares to be issued to an electing director is determined on the last day of each fiscal quarter by dividing the dollar amount of the compensation to be paid for such quarter that is subject to the election by the closing price of a share of common stock on the last trading day of the fiscal quarter, rounded up to the nearest whole share. Non-employee directors who made such an election received 13,127 shares of common stock in lieu of cash compensation earned for the quarter ended March 31, 2024. All shares of common stock issued pursuant to such an election are fully vested upon issuance and are classified as "Other Awards" under the 2013 Plan. In June 2024, the Non-Employee Director Compensation Policy was amended to allow a director to revoke his or her annual election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The decision to amend the policy followed a significant decline in the market value of the Company's common stock in May 2024. Without the ability of the directors to revoke the prior elections, the Company would have been obligated to issue a significantly greater number of shares than in prior quarters in lieu of the fixed cash retainer payments. Each of the directors who previously elected to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments for 2024 revoked their elections in June 2024, and as a result there were no additional shares issued under the policy for the three months ended June 30, 2024. Inducement Plan   The Company's board of directors previously adopted the GlycoMimetics, Inc. Inducement Plan (as amended to date, the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and other forms of stock awards to individuals not previously an employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, one-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, with the balance of the shares vesting in a series of thirty-six successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee's continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. The Inducement Plan was amended by the board of directors on multiple occasions to increase the number of shares reserved for issuance to 3,000,000 shares as of June 30, 2024. As of June 30, 2024, there were 271,358 shares available for future grants under the Inducement Plan. A summary of the Company's stock option activity under the Inducement Plan for the six months ended June 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> AGGEGATE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> REMAINING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> INTRINSIC </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> OUTSTANDING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> EXERCISE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> CONTRACTUAL </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> VALUE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> OPTIONS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PRICE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> TERM (YEARS) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (IN THOUSANDS) </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> 2,590,400 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 1.97 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 8.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> 130,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 3.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,850) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 3.85 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,718,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 2.02 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> 7.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Vested or expected to vest as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,134,350 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2.04 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,177,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 1.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> 7.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr></table> As of June 30, 2024, there was $1,419,532 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately 2.3 years. There were no options exercised under the Inducement Plan during the six months ended June 30, 2024 or 2023. The total fair value of stock options which vested in the six months ended June 30, 2024 and 2023 was $474,192 and $312,314, respectively. The Company has granted stock options to purchase an aggregate of 584,200 shares to certain newly hired employees under the Inducement Plan which options are subject to performance-based conditions. The maximum fair value of $825,353 associated with the performance-based options is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones was not probable as of June 30, 2024. The weighted-average fair value of the options granted under all equity incentive plans during the six months ended June 30, 2024 and 2023 was $1.49 per share and $2.00 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 6.25 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-

align:center;margin:0.05pt 0pt 0.05pt 0pt;">6.25 years </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 101.79% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 81.26% </td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4.17% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3.54% </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 0% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 0% </td></tr></table> | Stock-based compensation expense was classified on the statements of operations as follows for the three and six months ended June 30, 2024 and 2023: | <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> | </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.4%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 229,422 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 683,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"> 467,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> General and administrative expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 871,877 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 628,666 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,715,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,260,915 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,207,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 858,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,399,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,728,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 0.25P90DP10Y1000000026196220.042000000001425762794036 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> AGGEGATE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">REMAINING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> INTRINSIC </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> OUTSTANDING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> EXERCISE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> CONTRACTUAL </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> VALUE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> OPTIONS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PRICE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> TERM (YEARS) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (IN THOUSANDS) </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> 8,273,800 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 5.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> 5,756,875 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 1.85 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> (3,250) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 1.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Options forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (747,095) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 7.39 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,280,330 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 3.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Vested or expected to vest as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,771,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> 4.47 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> 7.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,572,477 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 6.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 4.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr>
</table>82738005.29P6Y3M18D57568751.8532501.667470957.39132803303.68P7Y8M12D50000107710554.47P7Y2M12D55724776.11P4Y10M24D10012044409153985408352
<table style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"> Weighted-Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> Number of Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Underlying RSUs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"> 117,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;background:#cceeff;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"> (58,581) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,581) </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.64%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;background:#ccceff;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.11%;margin:0pt;padding:0pt;"> Unvested at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 48,995 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.2%;margin:0pt;padding:0pt;"> 3.81 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"> </td></tr></table>1171573.81585813.8195813.81489953.81131270P90DP10Y3000000271358 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> WEIGHTED- </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> AGGEGATE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> AVERAGE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> REMAINING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> INTRINSIC </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"> OUTSTANDING </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> EXERCISE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> CONTRACTUAL </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> VALUE </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> OPTIONS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PRICE </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> TERM (YEARS) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (IN THOUSANDS) </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"> 2,590,400 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> .</p></td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 24pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 24pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,850)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Outstanding as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,718,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;background:#cceeff;margin:0pt;padding:0pt;"> Vested or expected to vest as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,134,350 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2.04 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"> 7.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:43.46%;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,177,896 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"> 7.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"> — </td></tr>
</table>25904001.97P8Y1300003.2018503.8527185502.02P7Y6M21343502.04P7Y7M6D11778961.98P7Y2M12D1419532P2Y3M18D00474192312314584200825353 1.492.00 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 6.25 years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 6.25 years </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 101.79% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 81.26% </td></tr><tr><td style="vertical-align:bottom;width:46.48%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4.17% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3.54% </td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 0% </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"> 0% </td></tr></table>P6Y3MP6Y3M1.01790.81260.04170.035400 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.4%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 229,422 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 683,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"> 467,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.4%;margin:0pt;padding:0pt;"> General and administrative expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 871,877 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 628,666 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,715,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,260,915 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,207,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 858,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,399,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,728,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 335445225942268368746735387187762866617157151260915120732285808823994021728268 9. Income Taxes The Company did not record any tax provision or benefit for the six months ended June 30, 2024 or 2023. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at June 30, 2024 and December 31, 2023. 10. License and Collaboration Agreements Apollomics In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company's compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.5pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise use the Products in the Field in the Territory; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:20.5pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. </td></tr></table> In 2020, the Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize any revenue under the clinical supplies agreement during the six months ended June 30, 2024 and 2023. The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $9.0 million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $75.0 million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $105.0 million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to 15%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. The Company did not recognize any milestone revenue under the Agreement for the six months ended June 30, 2024 or 2023. The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has

been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event. 9000000.075000000.0105000000.00.15 11. Subsequent Events In July 2024, the Company's Board of Directors approved a streamlined operating plan that includes the exploration of strategic alternatives focused on maximizing shareholder value. The Company concluded, following feedback from the U.S. Food and Drug Administration, that the regulatory path forward for its lead product candidate uproleselan for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision was not related to any safety or medical issues or negative regulatory feedback related to the Company's programs. In connection with the streamlined operating plan approved by the Board, the Company has undertaken a corporate restructuring that includes a reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction, which costs are expected to be substantially recognized in the third quarter of 2024, with related cash payments expected to be paid out by the end of 2024. These charges will consist primarily of one-time severance payments upon termination and continued benefits for a specified period of time. 260.803600000falsefalsefalsefalse"

@!R/S\CJBF M#.W?_F/;SU!NQNY#8&E!_/SV/-2E M]^]-X=]DGB*0[I ?SI[XPFGN@KH>I% MC?#X/M],Q,8FU"__W3*D